\documentclass[11pt,english,a4paper]{report}

\usepackage{booktabs}
\usepackage[table]{xcolor}
\usepackage{multirow}
\usepackage[hidelinks]{hyperref}
\usepackage{supertabular}

\usepackage[utf8]{inputenc}

\renewcommand{\aboverulesep}{0pt}
\renewcommand{\belowrulesep}{0pt}

\definecolor{blue}{cmyk}{0.99,0.25,0,0}

\makeatletter
\@ifundefined{c@rownum}{%
	\let\c@rownum\rownum
}{}
\@ifundefined{therownum}{%
	\def\therownum{\@arabic\rownum}%
}{}
\makeatother



\begin{document}
\rowcolors{0}{blue!5}{white}

\title{Covid Trial Tracker Report}

\section[Filter Options]{Filter Options}

\begin{table}[h]
	\rowcolors{0}{blue!5}{white}
	\centering
	\fontsize{8pt}{9pt}\selectfont
	\setlength{\extrarowheight}{.75ex}
	\begin{tabular}{p{1cm} p{2cm} p{10cm}}
		
		\toprule
		\multicolumn{2}{ p{3cm} }{\textbf{Option}} & \textbf{Value} \\
		\midrule
		\multicolumn{2}{ p{3cm} }{\textbf{Date of Review}} & 25/09/2020 \\
		\multicolumn{2}{ p{3cm} }{\textbf{Review Options}} & \\
		 & \textbf{Accepted:} & TRUE \\
		 & \textbf{Rejected:} & TRUE \\
		 & \textbf{Unreviewed:} & TRUE \\
		\bottomrule
	\end{tabular}
\end{table}	

\section[Filter Results]{Filter Results}

%\begin{table}[h]
	\rowcolors{0}{blue!5}{white}
	\centering
	\fontsize{8pt}{9pt}\selectfont
	\setlength{\extrarowheight}{.75ex}
	\begin{supertabular}{p{0.5cm} p{1.5cm} p{1.5cm} p{1.5cm} p{1.5cm} p{1.5cm} p{1.5cm} p{1.5cm} p{1.5cm}}
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04470609 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Study Of An Inactivated Sars-Cov-2 Vaccine For Preventing Against Covid-19 In People Aged <U+2A7E>60 Years } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chinese Academy Of Medical Sciences$|$West China Second University Hospital$|$Yunnan Center For Disease Control And Prevention } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 471 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04476680 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reducing Asymptomatic Infection With Vitamin D In Coronavirus Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Royal Centre For Defence Medicine$|$University Of Nottingham$|$Leeds Beckett University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 28/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 4400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection$|$Vitamin D Deficiency$|$Covid19$|$Acute Respiratory Tract Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04471519 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Whole-Virion Inactivated Sars-Cov-2 Vaccine (Bbv152) For Covid-19 In Healthy Volunteers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bharat Biotech International Limited$|$Indian Council Of Medical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 30/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1125 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000034825 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Of Sars-Cov-2 Mrna Vaccine (Bnt162b1) In Chinese Healthy Subjects: A Phase I, Randomised, Placebo-Controlled, Observer-Blind Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Jiangsu Provincial Center For Disease Prevention And Control } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Urine Sample, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026056 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Interventional Study On The Effect Of Arsenicum Album 30 C As A Prophylactic Measure Among High Risk Population Exposed To Covid-19. - Arcov } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026055 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Interventional Study On The Effect Of Asa-20(Ayush Kwath, Samsamani Vati, Anu Taila) As A Prophylaxis Measure Among High Risk Population Exposed To Covid-19 - Asa-20 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04470427 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3, Randomised, Stratified, Observer-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, And Immunogenicity Of Mrna-1273 Sars-Cov-2 Vaccine In Adults Aged 18 Years And Older } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Modernatx, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 30000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026147 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Prophylactic Effect Of Comprehensive Ayurveda And Mindfulness-Based Yoga Regimen Among Quarantined Individuals Exposed To Covid 19 Patients: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Infrastructural Facility Of All India Institute Of Medical Sciences New Delhi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 604 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Exercise + Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026151 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Prophylactic Effect Of Comprehensive Ayurveda And Mindfulness-Based Yoga Regimen Among Health Care Workers (Hcw) Of A Tertiary Care Hospital In Delhi During Covid 19 Pandemic: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Infrastructural Facility Of All India Institute Of Medical Sciences New Delhi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 452 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Exercise + Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202006883882711 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Measles, Mumps And Rubella Vaccine In Health Care Professionals For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dar Al Fouad Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19 $<$Br$>$Respiratory;Covid-19;Respiratory } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04478019 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Shield Study: Using Naso-Oropharyngeal Antiseptic Decolonization To Reduce Covid-19 Viral Shedding } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Wisconsin, Madison } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 94 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026191 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Double Blind, Comparative, Parallel  Group  Study Of Vitamin D3  ( Cholecalciferol )   Vitamin K2-7 \& Magnesium  In Prophylaxis Of   Covid-19 Infection  In  Health Care Professionals - Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Suraksha Pharma Private Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04483635 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preventing Covid-19 With High-Dose Vitamin D Supplements } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Justine's Hospital$|$Canadian Institutes Of Health Research (Cihr)$|$Laboratoire Riva } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 2414 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Labor Absenteeism, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20101020004976N6 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigation Of The Effect Of  Lactocare® Synbiotic On The Prevention Of Covid-19 Infection In The Staff Of Emergency Department } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 21/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026045 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Immune Boosting Ability Of A Homoeopathic Therapeutic Strategy Involving A Nosode Tuberculinum 1m, Followed By Zincum Metallicum 6c, Chininum Arsenicosum 6c And Calc Phos 6x In Asymptomatic Novel Corona Virus Disease (Covid-19 Illness) Vulnerable Risk Group. - Nil } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Father Muller Homoeopathic Medical College } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04475601 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Enzalutamide Treatment In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Andreas Josefsson$|$Umeå University$|$Sahlgrenska University Hospital, Sweden$|$University Hospital, Umeå$|$Uppsala University Hospital$|$Skane University Hospital$|$Jonkoping County Hospital$|$Sundsvall Hospital$|$Helsingborgs Hospital$|$Göteborg University$|$Astellas Pharma Europe Ltd.$|$Norrlands University Hospital$|$Västerbotten County Council } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 08/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hormone therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002106-68 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Favipiravir, Lopinavir/Ritonavir Or Combination Therapy: A Randomised, Double Blind, 2x2 Factorial Placebo-Controlled Trial Of Early Antiviral Therapy In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University College London Comprehensive Clinical Trial Unit } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Lopinavir/ritonavir, Lopinavir/ritonavir + Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Fever, Adverse Events, Bilirubin, Stool Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04483830 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Suloexide In The Treatment Of Early Stages Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Clinedem$|$Alfasigma S.p.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 05/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202006537901307 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label, Multicentre, Randomised, Adaptive Platform Trial Of The Safety And Efficacy Of Several Therapies, Including Antiviral Therapies, Versus Control In Mild/Moderate Cases Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Drug For Neglected Diseases Initiative } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 3000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid 19;Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04476888 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Treatment In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aga Khan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, D-Dimer, Procalcitonin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04472728 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Testing The Efficacy And Safety Of Bio101 For The Prevention Of Respiratory Deterioration In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biophytis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 310 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Angiotensins, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002035-30 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tofacitinib Plus Hydroxycloroquine Vs Hydroxycloroquine In Patients With Early Onset Sars-Cov2 (Covid-19) Interstitial Pneumonia: A Multicenter Randomised Controlled Open Label Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Viral Pneumonitis } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + JAKi } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200705048013N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effects Of Pentoxifylline In Improving The Condition Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karaj University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 20/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Vitamins + Non-invasive respiratory support + Plasma based therapy, Other } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026189 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Double Blind, Parallel Group Study Of Vitamin D3 \& Magnesium In Covid 19 Infection - Covid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Suraksha Pharma Private Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04470544 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Camostat Mesilate Treating Patients With Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Alan Bryce$|$Academic And Community Cancer Research United } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 15/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 264 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026161 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, Parallel Efficacy, Active Control, Multi-Centre Exploratory Drug Trial To Evaluate Efficacy And Safety Of An Ayurvedic Formulation As Adjunct Treatment To Standard Of Care For The Management Of Mild To Moderate Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ayushcsir } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026195 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Individualized Homoeopathy As An Add-On To Standard Treatment Of Covid-19 - A Multicentric, Randomised, Parallel Arm, Single Blind, Placebo, Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Homoeopathy } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04473170 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Evaluating The Safety And Efficacy Of Autologous Non-Hematopoietic Peripheral Blood Stem Cells In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abu Dhabi Stem Cells Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ 20/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 146 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04485169 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } "Plexit - Therapeutic Plasma Exchange (Tpe) For Covid-19 Cytokine Release Storm (Crs), A Retrospective Propensity Matched Control Study" } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Unicef } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 280 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Cytokine Release Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04480593 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Use Of Brazilian Green Propolis Extract (Epp-Af) In Patients Affected By Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ D'or Institute For Research And Education$|$Hospital Sao Rafael } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 15/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Adverse Events, C-Reactive Protein, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04486508 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Intermediate-Dose Vs Standard Prophylactic Anticoagulation And Statin Vs Placebo In ICU Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rajaie Cardiovascular Medical And Research Center$|$Brigham And Women's Hospital$|$Tehran Heart Center$|$Masih Daneshvari Hospital$|$Hazrat Rasool Hospital$|$Modarres Hospital$|$Firuzgar Hospital Affiliated To Iran University Of Medical Sciences$|$Imam Khomeini Hospital$|$Sina Hospital, Iran$|$Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 25/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC, Statins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04483960 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Australasian Covid-19 Trial (Ascot) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Melbourne$|$The Peter Doherty Institute For Infection And Immunity$|$Australasian SOCiety For Infectious Diseases } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 12/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir + Plasma based therapy, Lopinavir/ritonavir, Lopinavir/ritonavir + Plasma based therapy, Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Adverse Events, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026196 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preventing Pulmonary Complications In Surgical Patients At Risk Of Covid-19 - Protect-Surg } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Birmingham } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 6400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: O- Medical And Surgical } & 
				\multicolumn{2}{l}{ Healthy, Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3/ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Lopinavir/ritonavir, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Pneumonia or ARDS, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04479358 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low-Dose Tocilizumab Versus Standard Of Care In Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Chicago } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 332 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202006760881890 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Center, Randomised, Double-Blind, Placebo- Controlled Clinical Trial Of The Safety And Efficacy Of Convalescent Plasma For The Treatment Of Covid-19 In Hospitalized Patients In Lagos State } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lagos State Government } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401579 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Adaptive Covid-19 Treatment Trial 2 (Actt-2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Allergy And Infectious Diseases (Niaid) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 01/08/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1034 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, Remdesivir + JAKi } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, ALT, AST, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04312997 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Use Of Pul-042 Inhalation Solution To Reduce The Severity Of Covid-19 In Adults Positive For Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pulmotect, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334512 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Quintuple Therapy To Treat Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Progenabiome$|$Dscs Cro } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection$|$Coronavirus-19$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04471766 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Locally Produced Cloth Face Mask And Covid-19 Like Illness Prevention } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bandim Health Project$|$University Of Southern Denmark$|$Engineers Without Borders, Denmark (Https://Iug.dk/En) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 66000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Respiratory Illness } & 
				\multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Device, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04470622 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Aprepitant Injectable Emulsion In Patients With Covid-19 (Guards-1) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Heron Therapeutics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001870-32-HU }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 2, Randomised, Controlled, Open Label Multi-Center Study To Assess Efficacy And Safety Of Dfv890 For The Treatment Of Sars-Cov-2 Infected Patients With Covid-19 Pneumonia And Impaired Respiratory Function } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia And Impaired Respiratory Function $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10061986
Term: Sars
System Organ Class: 100000004862
;Therapeutic Area: Diseases [C] - Respiratory Tract Diseases [C08] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026192 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial Investigating The Safety And Efficacy Of C21 In Hospitalised Subjects With Covid-19 Infection Not Requiring Mechanical Ventilation - The Attract Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vicore Pharma Ab } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200516047462N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effectiveness Comparison Of Hyoscyamus Niger Methanolic Extract And Propolis In The Treatment Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kashan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 22/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026123 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii, Open Label, Randomised Controlled Trial To Assess The Safety And Efficacy Of Convalescent Plasma In Severe Covid-19. - Platina Trial. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Sushant Meshram } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 472 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: J128- Other Viral Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20151227025726N20 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Efficacy And Safety Of Intravenous Immunoglobulin (Ivig) In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 09/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir + Immunoglobulins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393038 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Abx464 In Treating Inflammation And Preventing Acute Respiratory Failure In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abivax S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 1034 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, D-Dimer, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026228 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii, Open Label, Randomised Study Of The Efficacy And Safety Of Acalabrutinib With Best Supportive Care Versus Best Supportive Care In Subjects Hospitalized With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Acerta Pharma Bv } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: J960- Acute Respiratory Failure
Health Condition 2: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Acalabrutinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200105046009N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effectiveness Of Dietary Plan For Pulmonary Diseases Based On Persian Medicine In Patients Infected With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Babol University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 20/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Infection Caused By Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04478071 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vadadustat For The Prevention And Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized Patients With Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Texas Health Science Center, Houston$|$Akebia Therapeutics Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/08/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026222 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii Safety And Efficacy Study On Prognosis Of Moderate Pneumonia In Covid-19 Patients With Regular Intravenous Immunoglobulin Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Virchow Biotech Private Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04477993 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ruxolitinib For Acute Respiratory Disorder Syndrome Due To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanderson Geraldo Rocha$|$University Of Sao Paulo General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 17/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome Coronavirus 2$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Ferritin, IL-6, PAI-1, von Wildebrandt Factor, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Troponin, Prothrombin, Fibrinogen, AST, Bilirubin, Glucose, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026190 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Shirashadi Kasai In Adults Hospitalized With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Prof Jaya Chakravarty } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04472494 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Abatacept In The Treatment Of Hospitalized Covid-19 Participants With Respiratory Compromise } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bristol-Myers Squibb } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 13/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 129 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190415043279N6 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Afsantin In The Treatment Of Covid 19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanandaj University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 11/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Heart Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04475991 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Maraviroc And/Or Favipiravir Vs Standard Therapy In Severe Covid-19 Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital General De México Dr. Eduardo Liceaga$|$Ccinshae. Secretaría De Salud. México$|$Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran$|$Centro De Investigación En. Enfermedades Infecciosas, Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants + (hydroxy)chloroquine + Azithromycin + Other, Favipiravir + Anticoagulants + (hydroxy)chloroquine + Azithromycin + Other, Immunomodulators + Anticoagulants + (hydroxy)chloroquine + Azithromycin + Other, Immunomodulators + Favipiravir + Anticoagulants + (hydroxy)chloroquine + Azithromycin + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04477954 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hyperbaric Oxygen As An Adjuvant Treatment For Patients With Covid-19 Severe Hypoxemia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Asociación Argentina De Medicina Hiperbárica E Investigación$|$Hospital De Infecciosas Francisco Javier Muniz$|$Hospital General De Agudos D. F. Santojanni$|$Hospital Central De San Isidro Dr. Melchor Angel Posse } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002632-75 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter, Open-Label, Randomised Trial To Assess The Efficacy And Tolerability Of Poractant Alfa (Porcine Surfactant, Curosurf®) In Hospitalized Patients With Sars-Cov-19 Acute Respiratory Distress Syndrome (ARDS) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chiesi Farmaceutici S.p.a } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 85 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Blood Gas, PaO2-FiO2, Respiratory Rate, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04480424 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Safety And Efficacy Of High Dose Intravenous Immune Globulin (Ivig) Plus Standard Medical Treatment (Smt) Versus Smt Alone In Participants In Intensive Care Unit (ICU) With Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Grifols Therapeutics Llc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PER-013-20 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Use As Treatment For Hospitalized Patients With Covid-19 In Essalud } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Seguro SOCial De Salud, } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 192 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ -B342 Coronavirus Infection, Unspecified Site
 $<$Br$>$Coronavirus Infection, Unspecified Site;B342;Coronavirus Infection, Unspecified Site } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Unspecified } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026193 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Control Study To Evaluate The Therapeutic Effects Of Lithium In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Maulana Azad Medical College } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: B342- Coronavirus Infection, Unspecified } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine  +/- Azithromycin, (hydroxy)chloroquine + Lithium +/- Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04482634 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tele-Rehabilitation Versus Home Exercise Program In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Koç University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/08/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 122 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pulmonary Rehabilitation$|$Covid-19 } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, Rehabilitation } & 
				\multicolumn{3}{p{4.5cm}}{ Dyspnea, 6-Minute Walking Distance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202007606032743 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nebulized Heparin In Patients With Mainly Moderate Coronavirus Disease 2019: Randomised Controlled Trial. Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Tarek Ismail } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid 19;Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026229 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Malla Chandrodaya \& Ashtadashang Ghan Vati In Patients With Mild To Moderate Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Infections: A Prospective Observational Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Namrata Joshi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04482686 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Combination Therapy To Treat Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Progenabiome$|$Topelia Therpeutics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/08/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Covid-19$|$Corona Virus Infection$|$Coronavirus Infection$|$Coronavirus-19$|$Sars-Cov2$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin + Doxycycline + Zinc + Vitamins, Vitamins + Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, C-Reactive Protein, Ferritin, Platelet Count, D-Dimer, Electrolytes } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/026119 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Arsenic Album 30c And 200c Potency In Mild Case Of Covid-19 Positive  Patients: A Randomised Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Swami Vivekaanand Homoeopathic Medical College And Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000034780 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Double Blind, Parallel Placebo Controlled, Phase Iii Clinical Trial To Evaluate The Safety And Protective Efficacy Of Inactivated Sars-Cov-2 Vaccine In Healthy Population Aged 18 Years And Above } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China National Biotec Group Co.ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/07/2020} &
				\multicolumn{2}{l}{ 19/07/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 15/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 15000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000034796 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Heparin In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Prospective, Randomised, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rujin Hospital, Shanghai Jiao Tong University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/01/2020} &
				\multicolumn{2}{l}{ 31/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ D-Dimer, Blood Urea Nitrogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04476940 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Breastfeeding Guideline For African-Americans } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Meharry Medical College } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 01/10/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Exclusive Breastfeeding } & 
				\multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Education } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA, Pregnancy or Birth Outcomes } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04470531 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Role Of Co-Trimoxazole In Severe Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh$|$Anwar Khan Mordern Medical College And Hospital, Dhaka$|$Mugda Medical College And Hospital, Dhaka } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 12/07/2020} &
				\multicolumn{2}{l}{ 12/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 94 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Severe Covid-19 Patients } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antibiotics, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Fever, C-Reactive Protein, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202007611764617 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label Clinical Trial Of Anti-Viral Efficacy And Immune-Boosting Effects Of Oral Treatment With Black Seed Oil In Patients With Corona Virus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lagos State Government } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04485429 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Assessment Of Methylprednisolone And Heparin In Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ D'or Institute For Research And Education } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 268 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, Anticoagulants + Corticosteroids, Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04482699 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rapa-501-Allo Off-The-Shelf Therapy Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rapa Therapeutics Llc$|$Hackensack Meridian Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 30/09/2020} &
				\multicolumn{2}{l}{ 30/09/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 88 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Covid-19 Disease } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04477655 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Positioning In Non-Intubated Patients With Covid-19 Associated Acute Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Civil De Guadalajara } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 03/05/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Patient Positioning } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCT2071200023 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Nelfinavir For Asymptomatic And Mild Covid-19: A Multicenter Open-Label, Blinded Outcome, Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Miyazaki Taiga } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Asymptomatic And Mild Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200503047280N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Laris-Teucrium Polium L.and Laris-Hyssop Combined Herbal Medicine On The Prevention Of Covid-19 Disease In High Risk People Exposed For Corona Virus: A Randomised Controlled Field Trial. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/05/2020} &
				\multicolumn{2}{l}{ 10/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030937 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Gu-Shen Ding-Chuan-Wan Used In The Recovery Phase Of 2019-Ncov Pneumonia(Feipiqixuzheng): A Randomised, Open-Label, Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04433013 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Assessing The Efficacy Of Lianhua Qingwen As An Adjuvant Treatment In Patients With Mild Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nanyang Technological University$|$Ministry Of Health, Singapore } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCTS041190120 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter, Open-Label, Randomised Trial Of Favipiravir In Asymptomatic And Minimally Symptomatic Patients Infected With Sars-Cov2 To Evaluate Viral Load Reduction } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Doi Yohei } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection $<$Br$>$Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347226 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Interleukin-8 (Anti-Il-8) For Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Matthew Dallos$|$Bristol-Myers Squibb$|$Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 01/09/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 138 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Solid Tumor$|$Sars-Cov2$|$Hematological Malignancy } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ RPCEC00000306 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Control Clinical Trial Of Cigb 2020 In Contacts And Sars-Cov-2 Infection Suspects (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center For Genetic Engineering And Biotechnology (Cigb), In Havana } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Contacts And Sars-Cov-2 Infection Suspects $<$Br$>$Suspected Of Sars-Cov-2 Infection;Coronavirus Infections;Suspected Of Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 02-Jan } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Prothrombin, Triglycerides, ALT, Albumin, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029461 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Integrated Traditional Chinese Medicine And Western Medicine In The Treatment Of Common Type Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 1. Xinhua Affiliated Hospital, Hubei University Of Chinese Medicine; 2. Hubei Provincial Hospital Of Integrated Chinese And Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Adverse Events, 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04332094 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Combined Use Of Hydroxychloroquine, Azithromycin, And Tocilizumab For The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau$|$Instituto De Salud Carlos Iii } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 276 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, Tocilizumab + Azithromycin + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030043 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Shen-Fu Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (Covid-19): A Multicenter, Randomised, Open-Label, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University Third Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04278963 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Adaptive, Randomised, Single-Blind, Three-Arm Parallel Controlled Clinical Trial Of Yinhu Qingwen Decoction In The Treatment Of Mild / Common Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China Academy Of Chinese Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Chinese Medicine } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029381 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Comparative Study For Xue-Bi-Jing Injection In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, ALT, Albumin, Bilirubin, IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354831 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Evaluating The Efficacy And Safety Of High-Titer Anti-Sars-Cov-2 Plasma In Hospitalized Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Medical College Of Wisconsin$|$Froedtert Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 01/05/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 131 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382625 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine In Sars-Cov-2 (Covid-19) Pneumonia Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kootenai Health$|$Washington State University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/01/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Pneumonia$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04261426 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Controlled, Single-Center Study To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Patients With Severe 2019- Ncov Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking Union Medical College Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029621 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter, Randomised, Open-Label, Controlled Trial For The Efficacy And Safety Of Arbidol Hydrochloride Tablets In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ruijin Hospital, Shanghai Jiao Tong University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 380 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04385095 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Inhaled Anti-Viral (Sng001) For Sars-Cov-2 (Covid-19) Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Synairgen Research Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Adverse Events, Blood Pressure, Heart Rate, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029941 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Traditional Chinese Medicine In The Treatment For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Longhua Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed And Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031089 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Research On Treatment Of Covid-19 (Mild And Moderate Cases) With Toujiequwen Granules } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangzhou Eighth People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ 13/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029550 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Recommendations For Diagnosis And Treatment Of Influenza Patients In The Hospital Of Chengdu University Of Traditional Chinese Medicine Under The Raging Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 29/01/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Influenza } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, Creatinine Phosphokinase, Troponin, Procalcitonin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030039 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For Infusing Convalescent Plasma To Treat Patients With New Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Affiliated Hospital Of Xuzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ 01/02/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, C-Reactive Protein, IL-6, LDH, Respiratory Rate, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030255 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Jing-Yin Granule In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) Wind-Heat Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04349592 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine With Or Without Azithromycin For Virologic Cure Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamad Medical Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 14/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 456 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030987 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Favipiravir Tablets Combine With Chloroquine Phosphate In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Chao-Yang Hospital, Capital Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 05/03/2020} &
				\multicolumn{2}{l}{ 25/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Favipiravir + (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Cough, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04376034 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Collection And Treatment In Pediatrics And Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ West Virginia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 30/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Coronavirus Infection$|$Coronavirus$|$Virus Diseases$|$Rna Virus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04268537 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Immunoregulatory Therapy For 2019-Ncov-Induced Severe Pneumonia Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Southeast University, China } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019 Ncov, Pd-1 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Procalcitonin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ DRKS00021238 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Randomised, Double Blinded Placebo-Controlled Trial To Evaluate The Efficacy And Safety Of Tocilizumab In Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universitätsklinikum Freiburg } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Emergency Use Of U07.1 (U07.1) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029638 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Controlled Trial For Recombinant Super-Compound Interferon (Rsifn-Co) In The Treatment Of Novel Coronavirus (2019-Ncov) Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ West China Hospital, Sichuan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus (2019-Ncov) Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, Hemoglobin, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, Myoglobin, Troponin, Procalcitonin, Coagulation Test, Urine Sample, Blood Pressure, Heart Rate, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04331899 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Single-Blind Study Of A Single Dose Of Peginterferon Lambda-1a Compared With Placebo In Outpatients With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stanford University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 31/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029947 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Qingyi No. 4 Compound In The Treatment Of Convalescence Patients Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Longhua Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029960 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Study For Integrate Chinese And Conventional Medicine The The Treatment Of Novel Coronavirus Pneumonia (Covid-19) In Hu'nan Province } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Hu'nan University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 28/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04299724 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunity Of Covid-19 Aapc Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shenzhen Geno-Immune Medical Institute$|$Shenzhen Third People's Hospital$|$Shenzhen Second People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 31/07/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed, Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Treat And Prevent Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed And Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029460 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Shadowboxing For Pulmonary Function And Quality Of Life In Patients With Novel Coronavirus Pneumonia (Covid-19) In Rehabilitation Period } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 1. Xinhua Affiliated Hospital, Hubei University Of Chinese Medicine; 2. Hubei Provincial Hospital Of Integrated Chinese And Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04315298 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Efficacy And Safety Of Sarilumab In Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Regeneron Pharmaceuticals$|$Sanofi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 24/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1912 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, C-Reactive Protein, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Respiratory Rate, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347538 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Nasal Saline Irrigations On Viral Load In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanderbilt University Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20140428017469N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Short-Term Protection For Covid-19 By Oral Polio Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Petroleum Industry Health Organization } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/06/2020} &
				\multicolumn{2}{l}{ 14/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 130000 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445311 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Ivermectin As A Therapeutic Option For Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zagazig University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04429867 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Use In Hospitalized Patients With Covid-19: Impact On Progression To Severe Or Critical Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wellstar Health System } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 07/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 700 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392128 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Evaluating The Efficacy Of Hydroxychloroquine And Azithromycine In Patients With Covid-19 And Hematological Malignancies (Hyacinthe) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institut De Cancerologie Strasbourg Europe } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 114 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Hematologic Malignancy } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04379518 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rintatolimod And Ifn Alpha-2b For The Treatment Of Mild Or Moderate Covid-19 Infection In Cancer Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Roswell Park Cancer Institute$|$National Cancer Institute (Nci)$|$Aim Immunotech Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 06/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Malignant Neoplasm$|$Sars Coronavirus 2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon + Rintatolimod } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04369365 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Single-Blinded, Randomised, Placebo Controlled Phase Ii Trial Of Prophylactic Treatment With Oral Azithromycin Versus Placebo In Cancer Patients Undergoing Antineoplastic Treatment During The Corona Virus Disease 19 (Covid-19) Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Prof. Dr. Matthias Preusser$|$Medical University Of Vienna } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 27/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381988 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii Randomised Double-Blind Placebo-Controlled Clinical Trial Of Hydroxychloroquine For Prophylaxis Against Covid-19 In Patients Receiving Radiotherapy (Covid) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Memorial Sloan Kettering Cancer Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 132 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Cancer } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Radiation therapy, Radiation therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04326790 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Greek Study In The Effects Of Colchicine In Covid-19 Complications Prevention } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National And Kapodistrian University Of Athens } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease 19 (Covid 19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), C-Reactive Protein, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029989 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Therapeutic Efficacy Of Recombinant Human Interferon Alpha 1b Eye Drops In The Treatment Of Elderly With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chinese Pla General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025178 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Immuno- Stimulatory Potential (Shareera Bala) Of An Ayurveda Management Protocol In Cohort Of Quarantined Delhi Police Under Covid-19 Care Centers- An Exploratory Clinical Study - Apcovida } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ All India Institute Of Ayurveda } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347239 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Efficacy And Safety Of Leronlimab For Patients With Severe Or Critical Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cytodyn, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 390 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04394117 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Controlled Evaluation Of Angiotensin Receptor Blockers For Covid-19 Respiratory Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The George Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 30/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 605 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030855 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For The Effect Of External Diaphragmatic Pacing Assisted Invasive Ventilation And Weaning In Patients With Severe New Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Critical Care Medicine, The Third Affiliated Hospital Of Zunyi Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030479 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For The Effectiveness And Safety Of Yi-Qi Hua-Shi Jie-Du-Fang In The Treatment Of The Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Affiliated Hospital Of Traditional Chinese And Western Medicine Nanjing University Of Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 25/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Procalcitonin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029780 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open, Controlled Trial For The Efficacy And Safety Of Shen-Qi Fu-Zheng Injection In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Union Hospital Affiliated To Tongji Medical College Of Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 09/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029742 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Parallel Controlled Trial For The Efficacy And Safety Of Sodium Aescinate Injection In The Treatment Of Patients With Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital,Tongji Medical College, Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04323800 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma To Stem Coronavirus (Cssc-001) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Johns Hopkins University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ 31/12/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Convalescence } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04397328 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Pep- High-Risk Individuals In Long-Term And Specialized Care - Canada } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lawson Health Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed, Hospital } & 
				\multicolumn{2}{l}{ 336 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04323527 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine Diphosphate For The Treatment Of Severe Acute Respiratory Syndrome Secondary To Sars-Cov2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundação De Medicina Tropical Dr. Heitor Vieira Dourado$|$Marcus Vinícius Guimarães De Lacerda$|$Mayla Gabriela Silva Borba$|$Wuelton Marcelo Monteiro$|$Gisely Cardoso De Melo$|$Fernando Fonseca De Almeida E Val$|$Felipe Gomes Naveca$|$Maria Paula Gomes Mourão$|$Ludmila Abrahão Hajjar$|$Jorge Souza Mendonça } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 07/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 278 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection$|$Severe Acute Respiratory Syndrome (Sars) Pneumonia } & 
				\multicolumn{2}{l}{ Mixed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Creatinine Phosphokinase, CK-MB, Troponin, AST, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322565 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine Counteracting Inflammation In Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero-Universitaria Di Parma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 310 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections$|$Pneumonia, Viral } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389359 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prophylaxis For Patients At Risk Of Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge University Hospitals Nhs Foundation Trust$|$University Of Cambridge } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 01/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20160313027033N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Oral Intermediate Chain Triglyceride On Prognosis And Course Of Disease In Suspected Outpatients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kerman University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 03/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001469-35 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Open, Randomised, Non-Commercial Study To Evaluate The Efficacy And Safety Of Chloroquine Phosphate In The Outpatient Treatment Of Covid-19 In Combination With Telemedicine Care For Patients With Sars-Cov-2 Infection With The Risk Of Developing Complications To Reduce The Risk Of Covid-19-Related Hospitalization And Death. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wroclaw Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Heart Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370834 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tocilizumab For Patients With Cancer And Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Cancer Institute (Nci) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 01/11/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 217 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hematopoietic And Lymphoid Cell Neoplasm$|$Malignant Solid Neoplasm$|$Pneumonia$|$Pneumonitis$|$Severe Acute Respiratory Distress Syndrome$|$Symptomatic Covid-19 Infection Laboratory-Confirmed } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04276896 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Immunity And Safety Of Covid-19 Synthetic Minigene Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shenzhen Geno-Immune Medical Institute$|$Shenzhen Third People's Hospital$|$Shenzhen Second People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 31/07/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pathogen Infection Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030720 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prognosis Investigation And Intervention Study On Patients With Novel Coronavirus Pneumonia (Covid-19) In Recovery Period Based On Community Health Management } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Provincial Hospital Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 12/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Recovering } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Fever, Antibodies, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364802 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19: Povidone-Iodine Intranasal Prophylaxis In Front-Line Healthcare Personnel And Inpatients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Alexandra Kejner$|$University Of Kentucky } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Hospital } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002287-31 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Covid19 Infection With Hydroxychloroquine In Institutionalized Older People And Nursing Home Staff. An Open, Randomised Controlled Stepped-Wedge Clinical Trial By Clusters. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fimabis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1930 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04400019 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Covid19 Infection In Nursing Homes By Chemoprophylaxis With Hydroxychloroquine (Previcharm) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Malaga$|$Instituto De Investigacion Biomedica De Malaga$|$Carlos Iii Health Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1930 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Coronavirus Infection$|$Prevention \& Control$|$Nursing Home$|$Hydroxychloroquine } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04394169 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Care Program For The Management Of Post-ICU Syndrome And Chronic Pain After Covid-19 Infection. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Clinic Of Barcelona } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 25/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 102 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Post ICU Syndrome$|$Chronic Pain$|$Covid-19 } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Rehabilitation, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347941 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Awake Prone Positioning To Reduce Invasive Ventilation In Covid-19 Induced Acute Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University College Hospital Galway } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ARDS, Human;Mechanical Ventilation Complication;Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Respiratory Rate, Patient Positioning } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343248 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial To Evaluate The Efficacy And Safety Of Nitazoxanide (Ntz) For Post-Exposure Prophylaxis Of Covid-19 And Other Viral Respiratory Illnesses In Elderly Residents Of Long-Term Care Facilities (Ltcf) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Romark Laboratories L.c. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Viral Respiratory Illnesses } & 
				\multicolumn{2}{l}{ Not Specified } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389801 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Desferal For Prevention Of ARDS In Hospitalised Cases Documented With Covid 19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hesham Al-Inany$|$Cairo University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8633 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Compared To Standard Plasma For Treatment Of Hospitalized Non-ICU Patients With Covid-19 Infections } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Leiden University Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 430 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04303507 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine/ Hydroxychloroquine Prevention Of Coronavirus Disease (Covid-19) In The Healthcare Setting } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 40000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Coronavirus$|$Acute Respiratory Illnesses } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029978 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For The Efficacy Of Dao-Yin In The Prevention And Controlling Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yueyang Hospital Of Integrated Traditional Chinese And Western Medicine, Shanghai University Of Traditional Chinese Medicine, } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, Fever, Dyspnea, PD-1, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, ALT, CD4, CD8, Respiratory Rate, Radiographic Findings, Depression, Anxiety, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-UMIN000040602 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Homeopathy For Covid-19 In Primary Care: Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Clinical Trial - Homeopathy For Covid-19 In Primary Care: Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Clinical Trial 
(Covid-Simile Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sao Carlos Federal University - School Health Unit (Use) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Mild Cases Of Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04275388 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Xiyanping Injection For The Treatment Of New Coronavirus Infected Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Jiangxi Qingfeng Pharmaceutical Co. Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 14/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 348 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019 Novel Coronavirus Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Interferon, Lopinavir/ritonavir + Interferon + Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04438850 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covidivermectin: Ivermectin For Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Irccs Sacro Cuore Don Calabria Di Negrar$|$Istituto Di Ricerche Farmacologiche Mario Negri } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Outpatient, Unclear } & 
				\multicolumn{2}{l}{ 102 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-000936-23 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Centre, Adaptive, Randomised Trial Of The Safety And Efficacy Of Treatments Of Covid-19 In Hospitalized Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inserm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 3100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Remdesivir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000566932 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Beat Covid-19: A Bayesian Adaptive Randomised Controlled Trial Platform To Evaluate The Efficacy Of Interventions For High Risk Older Patients With Covid-19 In Reducing The Risk Of Hospital Admission Or Death. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sydney } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Coronary (Ischaemic) Heart Disease;Hypertension;Asthma;Chronic Obstructive Pulmonary Disease (Copd);Diabetes
;Previous Stroke;Active Cancer; Immunosuppression; $<$Br$>$Covid-19 $<$Br$>$Coronary (Ischaemic) Heart Disease $<$Br$>$Hypertension $<$Br$>$Asthma $<$Br$>$Chronic Obstructive Pulmonary Disease (Copd) $<$Br$>$Diabetes$<$Br$>$ $<$Br$>$Previous Stroke $<$Br$>$Active Cancer $<$Br$>$ Immunosuppression;Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases;Cardiovascular - Coronary Heart Disease;Cardiovascular - Hypertension;Respiratory - Asthma;Respiratory - Chronic Obstructive Pulmonary Disease;Metabolic And Endocrine - Diabetes;Stroke - Haemorrhagic;Stroke - Ischaemic;Cancer - Any Cancer } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04428008 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Thymosin Alpha 1 To Prevent Covid-19 Infection In Elderly Renal Dialysis Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inova Health System$|$Nephrology Associates Of Northern Virginia, Inc.$|$Davita Clinical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Lymphocyte Count, CD4, CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04324073 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cohort Multiple Randomised Controlled Trials Open-Label Of Immune Modulatory Drugs And Other Treatments In Covid-19 Patients - Sarilumab Trial - Corimuno-19 - Sari } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 27/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 239 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04331808 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corimuno-19 - Tocilizumab Trial - Toci (Corimuno-Toci) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 228 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, PaO2-FiO2, Radiographic Findings, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374019 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Multi-Arm Phase Ii Trial Of Novel Agents For Treatment Of High-Risk Covid-19 Positive Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Susanne Arnold } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Ivermectin, Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333914 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Controlled, Randomised, Multicenter Study To Compare The Efficacy Of A Chloroquine Analog (Gns561), An Anti-Pd-1 (Nivolumab), An Anti-Nkg2a (Monalizumab), An Anti-Interleukine-6 Receptor (Tocilizumab) And An Anti-C5ar (Avdoralimab) Versus Standard Of Care In Patients With Advanced Or Metastatic Cancer And Sars-Cov-2 (Covid-19) Infection. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Leon Berard } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 384 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 (Covid-19) Infection;Advanced Or Metastatic Hematological Or Solid Tumor } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, mAb, SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Neutrophils, Hemoglobin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001673-75-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2/3, Randomised, Double Blind, Placebo-Controlled Study To Evaluate The
Efficacy And The Safety Of Abx464 In Treating Inflammation And Preventing Covid-19
Associated Acute Respiratory Failure In Patients Aged = 65 And Patients Aged =18 With
At Least One Additional Risk Factor Who Are Infected With Sars-Cov-2. (The Mir-Age
Study). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abivax } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1034 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infection With Sars-Cov-2 Virus, Covid-19 Infection;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030084 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter Study For Efficacy Of Intelligent Psychosomatic Adjustment System Intervention In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) Patients With Mild To Moderate Anxiety And Depression } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Hospital Of Shanxi Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 01/02/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) With Mild To Moderate Anxiety And Depression } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04279197 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Placebo-Controlled, Multi-Center Study On The Efficacy And Safety Of Fuzheng Huayu On Pulmonary Fibrosis Due To 2019-Ncov } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shuguang Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 136 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pulmonary Fibrosis Due To 2019-Ncov } & 
				\multicolumn{2}{l}{ Negative(?) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Dyspnea, 6-Minute Walking Distance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322773 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Il6 Treatment Of Serious Covid-19 Disease With Threatening Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Marius Henriksen$|$Lars Erik Kristensen$|$Frederiksberg University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346667 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Post-Exposure Prophylaxis For Asymptomatic Sars-Cov-2 Covid-19 Patients With Choloroquine Compounds } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Government Of Punjab, Specialized Healthcare And Medical Education Department$|$Mayo Hospital Lahore$|$Services Institute Of Medical Sciences, Pakistan$|$Pakistan Kidney And Liver Institute$|$Forman Christian College$|$Harvard School Of Public Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Coronavirus Infection$|$Asymptomatic Condition$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN86534580 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Platform Randomised Trial Of Interventions Against Covid-19 In Older People (Principle) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 3000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations $<$Br$>$Coronavirus Infection, Unspecified Site } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Iii } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001448-24-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preventing Pulmonary Complications In Surgical Patients At Risk Of Covid-19
 - Covidsurgrct\_v1.0\_20200330 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Birmingham } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 6400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Preventing Pulmonary Complications In Surgical Patients At Risk Of Covid-19 $<$Br$>$Meddra Version: 20.0
Level: Pt
Classification Code 10035664
Term: Pneumonia
System Organ Class: 10021881 - Infections And Infestations
 $<$Br$>$Meddra Version: 21.1
Level: Llt
Classification Code 10003083
Term: ARDS
System Organ Class: 100000004855
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Healthy, Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333628 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine For Mild Symptomatic And Asymptomatic Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Haemek Medical Center, Israel$|$T May Biopharma Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/03/024402 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxy Chloroquine, In Open Labelled, Randomised Intervention For Prevention Of New Infection And Adverse Outcomes Following Covid-19 Infection- A Tertiary Hospital Based Study - Corona Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Remesh Bhasi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04264533 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vitamin C Infusion For The Treatment Of Severe 2019-Ncov Infected Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhiyong Peng$|$Zhongnan Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 10/03/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Vitamin C$|$Pneumonia, Viral$|$Pneumonia, Ventilator-Associated } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), PaO2-FiO2, Respiratory Rate, Hypoxia, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8609 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Enhancing The Bcg-Induced Trained Immunity Response By Addition Of Bisphosphonate Or Mmr Vaccine: A Possible Preventive Approach Against Covid-19 (Bcg-Plus) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboudumc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19, Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine, Vaccine + Bisphosphonate, Vaccine + Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Monocyte Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024833 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Bcg-Denmark (Green Signal) On Prevention Of Covid 19 Infection In Health Care Workers Â?? A Double Blind Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Narayanan Parameswaran } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1826 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Antibodies, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN88057279 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prophylaxis For Patients At Risk Of Covid-19 Infection (Protect) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge University Hospitals Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) In Dialysis, Vasculitis, And Kidney Transplant Patients $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii/Iii } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025171 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Immuno-Stimulatory(Shareera Bala) Potential Of Ayurveda Management Protocol In Cohort Of Delhi Police - An Exploratory Clinical Study - Ebamd } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ All India Institute Of Ayurveda } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed } & 
				\multicolumn{2}{l}{ 50000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025069 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Ayurvedic Interventions In Prevention Of Covid-19 Infection In Containment Areas Of Delhi- A Community Based Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Ayurvedic Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1324 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3/ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025088 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Observational Study Of Guduchi Tablet Intake As A Preventive Measure In Pandemic Of Covid-19 Â?? An Open Label, Randomised, Controlled, Prospective, Interventional, Community-Based Clinical Study On Healthy Subjects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Rsearch In Ayurvedic Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025093 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Observational Study Of Yashtimadhu Tablet Intake As A Preventive Measure In Pandemic Of Covid-19 Â?? An Open Label, Randomised, Controlled, Prospective, Interventional, Community-Based Cclinical Study On Healthy Subjects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412356 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Timing Of Tracheotomy In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sahlgrenska University Hospital, Sweden } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$ARDS$|$Tracheostomy Complication$|$Respiratory Insufficiency$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Procedure } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025067 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Of Hydroxychloroquine Prophylaxis For Healthcare Workers Exposed To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ George Institute For Global Health India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 6950 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04422275 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Coronavirus Smell Therapy For Anosmia Recovery } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Washington University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} &
				\multicolumn{2}{l}{ 01/06/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Anosmia } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids + Other, Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029806 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Optimization Of Treatment And Diagnosis Plan For Critically Ill Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 31/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ mAb, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04326075 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ec-Covid-Rct. Early Cpap In Covid Patients With Respiratory Failure. A Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mario Negri Institute For Pharmacological Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Cpap Ventilation;Covid-19;Emergency Departments } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029992 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Randomised Controlled Trial For Chloroquine Phosphate And Hydroxychloroquine Sulfate In The Treatment Of Severe Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongshan Hospital Affiliated To Xiamen University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 20/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Viral Load or Clearance, Fever, Serious Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029855 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open And Controlled Clinical Trial For Traditional Chinese Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Medical College Of Zhejiang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04286503 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Clinical Study Of Carrimycin On Treatment Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Youan Hospital$|$Shenyang Tonglian Group Co., Ltd.$|$Institute Of Medicine And Biotechnology, Chinese Academy Of Medical Sciences$|$Huangshi Central Hospital$|$Shenyang Pharmaceutical University$|$First Affiliated Hospital Of Chongqing Medical University$|$The Second Affiliated Hospital Of Harbin Medical University$|$No.2 People's Hospital Of Fuyang City$|$First Affiliated Hospital Bengbu Medical College$|$Renmin Hospital Of Wuhan University$|$The Sixth People's Hospital Of Shenyang$|$Nanyang Central Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 28/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital, ICU } & 
				\multicolumn{2}{l}{ 520 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Infectious Disease (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine or Lopinavir/ritonavir or Umifenovir, Carrimycin } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029867 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Carrimycin Treatment In Patients With Novel Coronavirus Pneumonia (Covid-19): A Multicenter, Randomised, Open-Label, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing You'an Hospital, Capital Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 28/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital, ICU } & 
				\multicolumn{2}{l}{ 520 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Carrimycin, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024749 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Phase Iii, Double-Blind, Randomised, Placebo-Controlled Study To Evaluate The Efficacy Of Recombinant Bcg Vpm1002 In Reducing Infection Incidence And Disease Severity Of Sars-Cov-2/Covid-19 Among High-Risk Subjects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Serum Institute Of India Pvt Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 5946 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: Z23- Encounter For Immunization } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025166 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Observational Study Of Ashwagandha Tablet Intake As A Preventive Measure In Pandemic Of Covid-19 Â?? An Open Label, Randomised, Controlled, Prospective, Interventional, Community-Based Clinical Study On Healthy Subjects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush Government Of India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202004893013257 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protect-Surg } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Birgit Whitman } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 6400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19;Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Lopinavir/ritonavir, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425837 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness And Safety Of Convalescent Plasma In Patients With High-Risk Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundación Santa Fe De Bogota } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 236 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Troponin, Procalcitonin, LDH, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030923 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Treatment And Diagnosis Plan Of Integrated Traditional Chinese And Western Medicine For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Affiliated Hospital Of Shaanxi University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 16/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04313023 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Use Pul-042 To Reduce The Infection Rate And Progression To Covid-19 In Adults Exposed To Sars-Cov-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pulmotect, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04467918 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cannabidiol For Covid-19 Patients With Mild To Moderate Symptoms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sao Paulo$|$Conselho Nacional De Desenvolvimento Científico E Tecnológico$|$Fundação De Amparo À Pesquisa Do Estado De São Paulo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04383548 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For Efficacy Of Anti-Corona Vs2 Immunoglobulins Prepared From Covid19 Convalescent Plasma Prepared By Vips Mini-Pool Ivig Medical Devices In Prevention Of Sars-Cov-2 Infection In High Risk Groups As Well As Treatment Of Early Cases Of Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assiut University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed, Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202005622389003 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Hydroxychloroquine, Azythromycine And Zinc For The Treatment Of Patients With Sars-Cov2 Infection In Senegal: A Dose Ranging Randomised Trial. Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Faculty Of Medicine University Cheikh Anta Diop Of Dakar Senegal. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 384 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Respiratory;Respiratory } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04443881 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of The Use Of Anakinra In Cytokine Storm Syndrome Secondary To Covid-19 (Ana-Covid-Geas) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Miguel Servet } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pnemonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025803 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Convalescent Plasma Therapy In Patients With Covid-19: A Randomised Control Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institute Of Liver And Biliary Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425707 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ivermectin In Treatment Of Covid 19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Health And Population, Egypt } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333589 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative To Positive } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University First Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04409509 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment With Csl312 In Adults With Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Csl Behring } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 124 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04325893 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Versus Placebo In Covid-19 Patients At Risk For Severe Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Angers } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, CK-MB, Procalcitonin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04406064 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Viral Specific T-Cells (Vsts) For Treatment Of Sars-Cov-2/Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Children's Hospital Medical Center, Cincinnati } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Viral Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030117 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open, Parallel Controlled Trial For The Evaluation Of The Effectiveness And Safety Of Xiyanping Injection In The Treatment Of Common Type Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Public Health Clinical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 14/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 348 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Interferon, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024904 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial To Compare Efficacy Of  Hydroxychloroquine Alone And In Combination With Azithromycin  In Treatment Of Covid-19
 - Hazes } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Director General Armed Forces Medical Services } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: B338- Other Specified Viral Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412486 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Convalescent Plasma (Ccp) Transfusion } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gailen D. Marshall Jr., Md Phd$|$University Of Mississippi Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/05/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), IgG, IgM or IgA, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04273529 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Thalidomide In The Adjuvant Treatment Of Moderate New Coronavirus (Covid-19) Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ First Affiliated Hospital Of Wenzhou Medical University$|$Second Affiliated Hospital Of Wenzhou Medical University$|$Wenzhou Central Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Thalidomide } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425772 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Trial For Azvudine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Henan Sincere Biotech Co., Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 12/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 342 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Non-invasive Ventilation, Cough, Other Mild Symptoms, Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030484 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Humscs And Exosomes Treating Patients With Lung Injury Following Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Shiyan Taihe Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 31/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Lung Injury } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04427501 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Ly3819253 (Ly-Cov555) In Participants With Mild To Moderate Covid-19 Illness } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Eli Lilly And Company$|$Abcellera Biologics Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 05/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAB, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001206-35-AT }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Stopping Ace-Inhibitors In Covid-19 - A Randomised, Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Medizinische Universität Innsbruck } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 798 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ The Study Will Investigate Infections With The New Sars-Cov2 Virus. Current Studies Show That The Sars-Cov2 Virus Penetrates Human Cells Via The Angiotensin Converting Enzyme Ii (Ace2) Receptor 2. Experimental Studies Show That Ace Inhibitors (Acei) And Angiotensin Receptor Blockers (Arb) Can Increase The Expression Of Ace2 And Thus Could Facilitate Virus Uptake. This Study Will Investigate The Effect Of Stopping Chronic Acei Or Arb Therapy In Patients With Proven Sars-Cov2 Infection.;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): Yes } &
				\multicolumn{3}{p{4.5cm}}{ ACEi + ARBs, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Angiotensins, ACE, ACE-II, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466241 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Combination Therapies To Reduce Carriage Of Sars-Cov-2 And Improve Outcome Of Covid-19 In Ivory Coast: A Phase Randomised Iib Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ French National Institute For Health And Medical Research-French National Agency For Research On Aids And Viral Hepatitis (Inserm-Anrs)$|$Université De Bordeaux$|$Programme Pacci } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 20/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 294 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Covid-19 Drug Treatment$|$Severe Acute Respiratory Syndrome Coronavirus 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + ARBs + Statins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, Fibrinogen, IgG, IgM or IgA, CD4, CD8, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCTS061200002 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial Of Teprenone For Preventing Aggravation Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ichihara Eiki } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Fever, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030535 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Center Clinical Study On The Treatment Of Patients With Novel Coronavirus Pneumonia (Covid-19) By Ebastine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Red Cross Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 30/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Interferon, Lopinavir/ritonavir + Interferon + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04388514 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Blood Ozonization In Patients With Sars-Cov-2 Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Sanitaria-Universitaria Integrata Di Udine$|$Fondazione Toscana Gabriele Monasterio$|$Policlinico Militare, Roma - Italy$|$Ospedale San Liberatore Di Atri$|$Ospedale Umberto I Di Torino$|$Università Di Siena$|$Ospedale Civile Di Lucca$|$Ospedale Di Siracusa$|$Azienda Sanitaria Locale Di Vercelli } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 08/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Respiratory Failure } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04383535 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Double-Blind, Placebo-Controlled Clinical Trial Of Convalescent Plasma For The Treatment Of Covid-19 Pneumonia With Severity Criteria } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Italiano De Buenos Aires } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 333 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars Virus;Sars-Cov-2;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Ferritin, D-Dimer, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392141 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine Plus Phenolic Monoterpenes To Treat Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kermanshah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine + Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, C-Reactive Protein, IL-6, Lymphocyte Count, Erythrocyte Sedimentation Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04398004 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Inflammatory Clarithromycin For Improving Covid-19 Infection Early } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hellenic Institute For The Study Of Sepsis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 06/05/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Virus Diseases$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antibiotics } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Monocyte Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401527 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Lung Injury From Covid-19 Infection With Intravenous Sodium Nitrite: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hope Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Acute Respiratory Distress Syndrome;Acute Respiratory Failure } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032915 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For The Efficacy And Safety Of Artemisinin-Pipequine Tablets In The Treatment Of The Mild And Common Type Novel Coronavirus Pneumonia (Covid-19) Patients Whose Ncov Nucleic Acid Did Not Turn Negative After Treated By Hydroxychloroquine And Abidor } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hongqi Hospital Affiliated To Mudangjiang Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Urine Sample, Blood Pressure, ECG, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425915 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Convalescent Plasma Therapy In Patients With Covid-19: A Randomised Control Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institute Of Liver And Biliary Sciences, India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351919 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of Efficacy And Safety Of Hcq And Antibiotics Administrated To Patients Covid19(+), Intunisia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abderrahmane Mami Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients With Covid19;Patients With Covid19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025022 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Label Randomised  Controlled Trial To Assess The Efficacy Of Hydroxychloroquine In Patients With Mild Covid -19  Illness With Risk Factors For Severe Disease. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aiims Department Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 166 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001736-95 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Accord 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study To Assess The Efficacy And Safety Of Multiple Candidate Agents For The Treatment Of Covid 19 In Hospitalised Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Southampton Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 825 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Blood Pressure, Heart Rate, Respiratory Rate, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04403685 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Tocilizumab In Moderate To Severe Covid-19 And Increased Inflammatory Markers: A Phase Iii Randomised Clinical Trial (Covid-19 Coalition Brazil Vi) (Tocibras) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beneficência Portuguesa De São Paulo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Sars Pneumonia;Cytokine Release Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ KCT0005105 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Ciclesonide In Adults With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Koera University Guro Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 141 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ;Certain Infectious And Parasitic Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Corticosteroids, Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ DRKS00021447 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cytoresc - Cytosorb Rescue For Covid-19 Cytokine Storm } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Charité Campus Virchow-Klinikum } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Emergency Use Of U07.1 (U07.1) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Iib } &
				\multicolumn{3}{p{4.5cm}}{ Cytokine removal, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04429711 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ivermectin Vs. Placebo For The Treatment Of Patients With Mild To Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sheba Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338698 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine, Oseltamivir And Azithromycin For The Treatment Of Covid-19 Infection: An Rct } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shehnoor Azhar$|$University Of Health Sciences Lahore } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025336 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase-Iii, Open Label, Randomised Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Asymptomatic Or Mildly Symptomatic Patients With Sars-Cov-2 Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tata Memorial Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04327401 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19-Associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil Iii } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Sirio-Libanes$|$Hospital Israelita Albert Einstein$|$Hospital Do Coracao$|$Brazilian Research In Intensive Care Network$|$Ache Laboratorios Farmaceuticos S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Pneumonia, Viral$|$Acute Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Dexamethasone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334265 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Anluohuaxian In The Treatment Of Rehabilitation Patients With Corona Virus Disease 2019 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University First Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 750 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04384588 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigational- Compassionate Use Of Convalescent Plasma From Covid-19 Donors In Oncological And Non-Oncological Patients With Severity Criteria: Falp 001-2020 Trial (Falp-Covid) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Arturo Lopez Perez } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection;Cancer Patients;General Population } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04255017 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open, Prospective/Retrospective, Randomised Controlled Cohort Study To Compare The Efficacy Of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir And Lopinavir/Ritonavir) In The Treatment Of 2019-Ncov Pneumonia. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Oseltamivir, SOC, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030225 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Reseach Of Acupuncture In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yueyang Hospital Of Integrated Traditional Chinese And Western Medicine, Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032769 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised,Double Blinded, Parallel  Controlled Clinical Trial For Azvudine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Ditan Hospital Affiliated To Capital Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/05/2020} &
				\multicolumn{2}{l}{ 09/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 342 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ DAA, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031204 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Single-Blind, Randomised Controlled Clinical Trial For Chloroquine Phosphate In The Treatment Of 2019 Novel Coronavirus-Infected Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing You'an Hospital, Capital Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 30/01/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031271 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Metabolic Abnormalities And Rearrangement Reversal Treatment Of Patient With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Third Affiliated Hospital Of Sun Yat-Sen University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031196 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Efficacy Of Novel Coronavirus Infection Treated By Combination Of Interferon Regimen And Ritonavir Tablets } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Diagnosis, Treatment And Research Center For Infectious Diseases, The Fifth Medical Center Of The Pla } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 10/01/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Retrospective Study } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029869 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Controlled Trial For Integrated Chinese And Western Medicine In The Treatment Of Ordinary Novel Coronavirus Pneumonia (Covid-19) Based On The ' Internal And External Relieving -Truncated Torsion' Strategy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Huangshi Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Pneumonia or ARDS, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405843 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Ivermectin In Adult Patients With Early Stages Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centro De Estudios En Infectogía Pediatrica } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04254874 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open, Prospective/Retrospective, Randomised Controlled Cohort Study To Compare The Efficacy Of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)In The Treatment Of 2019-Ncov Pneumonia. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Umifenovir, Umifenovir + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030490 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } To Evaluate The Efficacy And Safety Of Diammonium Glycyrrhizinate Enteric-Coated Capsules Combined With Hydrogen-Rich Water In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Huo-Shen-Shan Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 31/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025849 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, 2-Treatment Groups Clinical Trial Evaluating The Safety And Efficacy Of A Combination Of Nitazoxanide And Hydroxychloroquine Versus Hydroxychloroquine Alone In The Acute Treatment Of Moderate Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Reddys Laboratories Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/12/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 158 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024948 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine, Ciclesonide And Ivermectin In Treatment Of Moderate Covid-19 Illness: An Open-Label Randomised Controlled Study - Ehyciver-Covid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lady Hardinge Medical College } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: B338- Other Specified Viral Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Corticosteroids, Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20171105037262N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Adalimumab Effect On Clinical Symptoms Including Respiratory Distress, Oxygen Saturation And Lung Involvement Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + mAb } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04449588 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Study Of Bdb-001 In Severe Covid-19 With Ali/ARDS } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Staidson (Beijing) Biopharmaceuticals Co., Ltd$|$Beijing Defengrui Biotechnology Co. Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 07/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 368 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435587 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Efficacy Of Ivermectin Versus Combination Of Hydroxychloroquine Plus Darunavir/ Ritonavir For Shortening Duration Of Sars-Cov2 Detection From Respiratory Secretion Among Asymptomatic Or Afebrile Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mahidol University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Asymptomatic Infections;Sars-Cov2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, Ivermectin } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04414098 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ruxolitinib In The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Marcelo Iastrebner$|$Novartis$|$Clinica Zabala } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 15/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04459325 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tigerase® Efficacy And Safety As Part Of Complex Therapy In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ao Generium } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 20/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus Disease 2019 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Lymphocyte Count, D-Dimer, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029819 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For The Pharmacodynamics And Mechanism Of Traditional Chinese Medicine In The Treatment Of Novel Coronavirus Infection (Covid-19) Based On Inflammatory Factor Network } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sir Run Run Shaw Hospital, School Of Medicine, Zhejiang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 11/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025273 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Indian Traditional Ayurvedic Treatment Regime For Ncov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Patanjali Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: J969- Respiratory Failure, Unspecified } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001310-38-DE }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Prospective, Open Label Clinical Trial On The Use Of Convalescent Plasma Compared To Best Supportive Care In Patients With Severe Covid-19 - Convalescent Plasma Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Drk-Bluspendedienst Baden-Württemberg - Hessen Ggmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients With Sars-Cov-2 Infection And:
1.	Age = 18 Years And = 75 Years
2.	Sars-Cov-2 Infection Confirmed By Pcr (Bal, Sputum, Nasal And/Or Pharyngeal 
                    Swap)
3.	Severe Disease Defined By At Least One Of The Following:
  A.	Respiratory Rate = 30 Breaths / Minute Under Ambient Air
  B.	Requirement Of Any Type Of Ventilation Support
  C.	Needs ICU Treatment
 $<$Br$>$Meddra Version: 20.1
Level: Llt
Classification Code 10047475
Term: Viral Pneumonia, Unspecified
System Organ Class: 100000004862
 $<$Br$>$Meddra Version: 23.0
Level: Llt
Classification Code 10070267
Term: Sars Virus Test Positive
System Organ Class: 100000004848
 $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10021433
Term: Immunization
System Organ Class: 100000004865
 $<$Br$>$Meddra Version: 21.1
Level: Llt
Classification Code 10054540
Term: Passive Immunization
System Organ Class: 100000004865
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029868 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Treating Novel Coronavirus Pneumonia (Covid-19): A Randomised Controlled, Open Label, Multicenter Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ruijin Hospital, Shanghai Jiaotong University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 360 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04263402 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open, Prospective/Retrospective, Randomised Controlled Cohort Study To Compare The Efficacy Of Different Hormone Doses In The Treatment Of 2019-Ncov Severe Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov Severe Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032205 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter Randomised, Double-Blind, Placebo-Controlled Trial For Sheng-Mai-Yin For Improvement Of The Pulmonary Heart Function Related Symptoms Of Convalescence Patients Of New Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Hospital Of Traditional Chinese And Western Medicine (Wuhan 1st Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCTS031200026 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter, Single Blinded Randomised Controlled, Comparative Study To Evaluate The Efficacy And Safety Of Favipiravir And Nafamostat Mesilate In Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kyoji Moriya } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19) $<$Br$>$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, Favipiravir } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Prothrombin, Coagulation Test, ALT, Bilirubin, Glucose, SpO2, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04421508 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Assess Pulsed Inhaled Nitric Oxide Vs Placebo In Subjects With Mild Or Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bellerophon Pulse Technologies$|$Bellerophon } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 12/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04387760 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Favipiravir Vs Hydroxychloroquine In Covid -19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Royal College Of Surgeons In Ireland - Medical University Of Bahrain$|$Bahrain Defence Force Royal Medical Services, Military Hospital$|$Ebrahim Khalil Kanoo Community Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Ferritin, Lymphocyte Count, D-Dimer, Procalcitonin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04379479 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Effect Of Dialyzable Leukocyte Extract In Suspected Or Confirmed Cases Of Covid-19 (Future-T) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Polytechnic Institute, Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 562 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200408046987N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dose-Finding Study Of Ivermectin Treatment On Patients Infected With Covid-19:A Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chistasazan Notash Fartak Company Limited. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 04/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 125 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363840 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Lead Covid-19 Trial: Low-Risk, Early Aspirin And Vitamin D To Reduce Covid-19 Hospitalizations } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Louisiana State University Health Sciences Center In New Orleans } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1080 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Vitamin D Deficiency;Coagulopathy;Disseminated Intravascular Coagulation } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, Antihypertensive + Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032400 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of High Dose Intravenous Vitamin C In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Prospective, Randomize, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rujin Hospital, Shanghai Jiao Tong University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 01/01/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ New Treatment Measure Clinical Study } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein, Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer, Bilirubin, LDH, Urine Sample, CD4, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395768 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } International Alliance Study Of Therapies To Prevent Progression Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Integrative Medicine, Australia$|$Catholic Health Initiatives } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 31/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Zinc + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200410047009N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Role Of Naproxen As Adjunctive Therapy With Standard Therapies And Its Efficacy In The Early Improvement And Reduced Mortality Rate Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Iran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 15/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 101 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ NSAIDs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20160131026298N3 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Iranian Medicine Product, Algro, On The Symptoms Of Patients With Covid-19 (Coronavirus 19 Disease) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 19/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Dyspnea, Radiographic Findings, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/024962 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Topical Povidone Iodine (Pvp-I) Oropharyngeal And Intranasal Application During The Current Coronavirus Pandemic Amongst Covid-19 Positive Patients In Andhra Pradesh, India } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Win Medicare Pvtltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032399 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Xiaoyao Capsule Improves Covid-19 Convalescence Sleep Mood Disorder In A Randomised, Double-Blind, Placebo-Controlled, Multicenter Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Xiaogan Traditional Chinese Medicine Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19); Mental Health } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029605 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Blank-Controlled, Multicenter Trial For Shuang-Huang-Lian Oral Solution In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital, Tongji Medical College, Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 05/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001882-36-GR }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Inflammatory Clarithromycin To Improve Sars-Cov-2 (Covid-19) Infection Early: The Achieve Open-Label Non-Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hellenic Institute For The Study Of Sepsis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Management Of Infection By Sars-Cov-2 (Covid-19) $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10035738
Term: Pneumonia Viral Nos
System Organ Class: 100000004862
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Unspecified } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Antibiotics } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Cough, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025049 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Proving The Efficacy Of Homoeopathic Treatment In Prevention And Cure Of Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sai Nidan Homoeopathy Clinic } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445935 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anticoagulation In Patients Suffering From Covid-19 Disease The Anti-Co Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamad Medical Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ 28/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Anticoagulation In Covid-19 ARDS } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ PaO2-FiO2, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351347 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Evaluating The Efficacy Of Ivermectin And Nitazoxanide In Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Antivirals, Ivermectin } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04324996 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase I/Ii Study Of Universal Off-The-Shelf Nkg2d-Ace2 Car-Nk Cells For Therapy Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chongqing Public Health Medical Center$|$Chongqing Sidemu Biotechnology Technology Co.,Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 21/03/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Natural Killer Cells } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382846 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Novel Regimens In Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 01/12/2030} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals + Azithromycin, Ivermectin + (hydroxy)chloroquine, Ivermectin + Antivirals, Ivermectin + Antivirals + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04409873 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Antiseptic Mouthwash / Pre-Procedural Rinse On Sars-Cov-2 Load (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of California, San Francisco } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov 2$|$Severe Acute Respiratory Syndrome Coronavirus 2$|$Virus Disease$|$Coronavirus Infections$|$Pharyngeal Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030750 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Study For Effectiveness And Safety Evaluation For Recombinant Chimeric Covid-19 Epitope Dc Vaccine In The Treatment Of Novel Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shenzhen Third People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/03/2020} &
				\multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 28/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1-2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein, IL-17, Lymphocyte Count, Blood Gas } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029778 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For Traditional Chinese Medicine Combined With Western Medicine In Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai University Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 13/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466670 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hemostasis In Covid-19: An Adaptive Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sao Paulo General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 310 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, Antihypertensive } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025575 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Antiviral Combination Therapy In Symptomatic Patients Of Covid-19 Infection - A Randomised Control Trial - Sev-Covid Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aiims Rishikesh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 175 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3/ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, Lopinavir/ritonavir + antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381871 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Potential Role Of Gum Arabic As Immunomodulatory Agent Among Covid 19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Al-Neelain University$|$University Of Khartoum } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025800 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Comparative Clinical Study To Involving Ayurvedic Drug Intervention In The Management Of Covid 19 Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Health Mission Uttar Pradesh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04319900 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Favipiravir Tablets Combine With Chloroquine Phosphate In The Treatment Of Novel Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Chao Yang Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 05/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pnuemonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Favipiravir, Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029559 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Therapeutic Effect Of Hydroxychloroquine On Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 31/01/2020} &
				\multicolumn{2}{l}{ 29/02/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Completed w. Results } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, CD4, CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04421534 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Utility Of Lactoferrin As An Adjunct Therapeutic Agent For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cairo University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04252885 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy Of Lopinavir Plus Ritonavir And Arbidol Against Novel Coronavirus Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangzhou 8th People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 28/01/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Completed w. Results } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, SOC, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, ALT, Bilirubin, Blood Pressure, Heart Rate, PaO2-FiO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030034 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Traditional Chinese Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Multicentre, Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongde Hospital Of Zhejiang Province } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 132 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04310228 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Favipiravir Combined With Tocilizumab In The Treatment Of Corona Virus Disease 2019 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University First Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 08/03/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Favipiravir + Tocilizumab, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04447534 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Does Zinc Supplementation Enhance The Clinical Efficacy Of Chloroquine/Hydroxychloroquine In Treatment Of Covid-19? } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029939 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Single-Blind, Randomised, Controlled Clinical Trial For Chloroquine Phosphate In The Treatment Of Novel Coronavirus Pneumonia 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hwamei Hospital, University Of Chinese Academy Of Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 06/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Fever, Serious Adverse Events, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), ALT, Bilirubin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04459702 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Combination Therapies To Treat Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Progenabiome$|$Big Corona Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Covid-19$|$Corona Virus Infection$|$Coronavirus Infection$|$Coronavirus Sars-Associated As Cause Of Disease Classified Elsewhere$|$Coronavirus-19$|$Sars-Cov 2$|$Sars Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Azithromycin + Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Platelet Count, ALT, AST, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389411 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Covid-19 Symptom Montelukast Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mcgill University$|$Lady Davis Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030262 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Novel Coronavirus (Sars-Cov-2) Infection Treated With Aerosol Inhalation (Ifn-? Plus Anti-Inflammatory Factor Tff2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Public Health Clinical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025856 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Clincal Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid 19 - A Randomised Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Directorate Of Indian Medicine And Homeopathy } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Vitamins + Azithromycin + Zinc + Other, Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029468 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Early Use Of Lopinavir/Litonavir (Lpv/R) And Emtritabine (Ftc)/ Tenofovir Alafenamide Fumarate Tablets (Taf) Regimen In The Treatment Of The Novel Coronavirus Pneumonia (Covid-19): A Real-World Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institute Of Emergency Medicine And Disaster Medicine Sichuan People's Hospital, Sichuan Academy Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20131129015584N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Herbal Oral Product (Thyme Syrup) In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mazandaran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ 19/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 152 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ARDS. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Azithromycin, Lopinavir/ritonavir + Azithromycin + Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04251871 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment And Prevention Of Traditional Chinese Medicines (Tcms) On Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing 302 Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 22/01/2020} &
				\multicolumn{2}{l}{ 22/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia Caused By Human Coronavirus (Disorder) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir + Interferon + Traditional Chinese Medicine + Non-invasive respiratory support, Lopinavir/ritonavir + Non-invasive respiratory support + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030218 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined With Xiyanping Injection For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fifth People's Hospital Of Ganzhou } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ 22/01/2020} &
				\multicolumn{2}{l}{ 25/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Lopinavir/ritonavir + Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ RPCEC00000307 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect And Safety Of Heberferon Versus Heberon Alfa In Patients Infected With The Sars-Cov-2 Coronavirus (Covid-19). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center For Genetic Engineering And Biotechnology (Cigb), In Havana } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients Infected With The Sars-Cov-2 Coronavirus. $<$Br$>$Covid-19;Coronavirus Infections;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025766 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Oronasopharyngeal 254 Nm Ultraviolet C Therapy For Asymptomatic To Mild Cases Of Corona Virus Disease-2019: A Randomised Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Jagdeep Kakadia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029994 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Liu-Zi-Jue Qigong And Acupressure Therapy For Pulmonary Function And Quality Of Life In Patient With Severe Novel Coronavirus Pneumonia (Covid-19): A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai University Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Natural Killer Cell Count, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025557 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, Parallel Efficacy, Active Control, Multi-Centre Exploratory Drug Trial To Evaluate Efficacy And Safety Of An Ayurvedic Formulation As Adjunct Treatment To Standard Of Care For The Management Of Mild To Moderate Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 420 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04320277 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Baricitinib Combined With Antiviral Therapy In Symptomatic Patients Infected By Covid-19: An Open-Label, Pilot Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Prato } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pharmacological Action } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025796 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Aragwadhadi Kwath Mentioned In Bhavprakash Jwarachikitsa 1/155 In Mild  Covid-19 Patients: A Randomised Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vaidhyatushar Trivedi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: J100- Influenza Due To Other Identifiedinfluenza Virus With Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Novel Coronavirus Pneumonia (Covid-19) Emergency Research Project Tackled By Shanghai University Of Traditional Chinese Medicine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 19/02/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, Radiographic Findings, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04464408 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Favipiravir Therapy In Adults With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ King Abdullah International Medical Research Center$|$Ministry Of Health, Saudi Arabia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 576 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ TCTR20200514001 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Investigation Of The Efficacy And Safety Of Favipiravir In Covid-19 Patients Without Pneumonia Â?? An Open-Label Randomised Controlled Study Â?? } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Faculty Of Medicine, Siriraj Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/12/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 $<$Br$>$Covid-19 Patients Without Pneumonia$<$Br$>$Sars-Cov-2;Covid-19 Patients Without Pneumonia$<$Br$>$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, SpO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025799 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, Prospective, Comparative, Parallel Group,
Multicentre Study To Evaluate Efficacy And Safety Of Favipiravir With
Supportive Care Versus Supportive Care Alone In Subjects With Mild To
Moderate Coronavirus Disease (Covid-19).
 - Na } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cipla Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 156 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025996 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Evalution Of The Combination Giloy Gomutra Capsules, Asthi Churna And Kamdhenu Asava In The Management Of The Pandemic- Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bansi Gir Gaushala } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452799 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hesperidin And Diosmin For Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, IL-1, Tumor Necrosis Factor (Any), Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/024969 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Adjuvant Homoeopathy With Standard Treatment Protocol In Management Of Covid-19: A Randomised, Open Label, Placebo Controlled, Parallel  Group Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Naiminath Homoeopathic Medical College Hospital And Research Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030988 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Chinese Herb Medicine Hua-Shi Bai-Du Granules In Patients With Novel Coronavirus Pneumonia (Covid-19) In Wuhan, China: A Prospective, Randomised, Controlled, Open-Label Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangdong Provincial Hospital Of Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 204 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Pneumonia or ARDS, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330495 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Controlled, Double-Blind Clinical Trial Comparing The Efficacy And Safety Of Chemoprophylaxis With Hydroxychloroquine In Patients Under Biological Treatment And / Or Jak Inhibitors In The Prevention Of Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Investigación Marqués De Valdecilla } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19;Immunomediated Inflammatory Disease In Treatment With Biological Agents And / Or Jak Inhibitors } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374552 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rct In Asymptomatic Volunteers With Covid-19 Comparing Azithromycin And Hydroxychloroquine Vs. Hydroxychloroquine Alone Vs Standard Of Care Without Antibiotics } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rutgers, The State University Of New Jersey } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection;Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04443725 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Anti Hcv Drugs In The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cairo University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412395 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Assessment Of Oral Lactoferrin As A Safe Antiviral And Immunoregulatory In Treating Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Research Center, Egypt$|$Egyptian Military Medical Services } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 516 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Middle East Respiratory Syndrome (Mers)$|$Acute Respiratory Distress Syndrome$|$Coronavirus Infection$|$Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, IL-10, Tumor Necrosis Factor (Any), Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, Prothrombin, ALT, AST, Albumin, Bilirubin, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030058 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Double-Blind, Controlled Clinical Trial For Leflunomide In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 10/03/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ DMARD, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029434 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Blank-Controlled Trial For Lian-Hua Qing-Wen Capsule /Granule In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hebei Yiling Hospital, Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032919 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Double-Blind, Placebo-Controlled Trial For Lu-Dang-Shen Oral Liquid In The Treatment Of Reduced Digestion Function Of Convalescent New Coronavirus Pneumonia (Covid-19) Patient } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Third Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 08/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms, Stool Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030418 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Application Of Rehabilitation Lung Exercise Eight-Segment Exercise In Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Fujian Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ IL-6, Quality of Life, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04323345 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Natural Honey Treatment In Patients With Novel Coronavirus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Misr University For Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Fever, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04407390 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effects Of Nicotinamide Riboside On The Clinical Outcome Of Covid-19 In The Elderly. A Randomised Double-Blind, Placebo-Controlled Trial Of Nicotinamide Riboside Nr-Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Copenhagen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04463264 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Study Of Nitazoxanide (Ntx) In The Treatment Of Patients With Sars-Cov-2 Virus Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Laboratorios Roemmers S.a.i.c.f. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 15/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 135 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392427 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } New Antiviral Drugs For Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mansoura University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Drug Effect } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin + Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200326046868N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Propolis Supplementation On Clinical Manifestations And Inflammatory Biomarkers In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abadan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 21/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 88 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Platelet Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030480 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Open, Blank Controlled Trial For The Efficacy And Safety Of Recombinant Human Interferon Alpha 1beta In The Treatment Of Wuhan Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Respiratory And Critical Care Medicine, Tongji Hospital Of Tongji Medical College, Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 328 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030007 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter Randomised Controlled Trial For Rhg-Csf In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 28/02/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 10/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000033320 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For Traditional Chinese Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Pulmonology, Shuguang Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 21/01/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030188 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study On Syndrome Differentiation Of Tcm In Treating Severe And Critical Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangdong Provincial Hospital Of Chinese Medicine - Zhuhai Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 30/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030810 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Observation And Evaluation Of Traditional Chinese Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) In Hubei 672 Orthopaedics Hospital Of Integrated Chinese&Western Medicine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei 672 Orthopaedics Hospital Of Integrated Chinese&Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 30/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Creatinine Phosphokinase, CK-MB, ALT, Blood Urea Nitrogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029790 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For The Integration Of Traditional Chinese And Western Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Pulmonary Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029747 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Evaluation And Prognosis Of Chinese Medicine Based On Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Anhui University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 10/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029436 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Evaluation Of Integrated Traditional Chinese And Western Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Hospital Of He'nan University Of Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030836 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Novel Covid-19 Pneumonia Combined With Chinese And Western Medicine Based On ''Internal And External Relieving -Truncated Torsion'' Strategy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Longhua Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Interferon (Any), eGFR, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025320 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Naturopathy And Yoga In The Management Of Covid19
A Multi-Center Controlled Clinical Trial - Yonac Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Government Yoga And Naturopathy Medical College Chennai } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 658 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3/ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Exercise + Nutrition + Hygiene + Alternative therapy + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030288 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study On Prevention And Treatment Of Novel Coronavirus Pneumonia (Covid-19) With Traditional Chinese Medicine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China Academy Of Chinese Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 204 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029756 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Nebulized Xiyanping Injection In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 15/02/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 238 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Blood Pressure, Heart Rate, Surfactant Factor Protein, PaO2-FiO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20110726007117N11 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of  Vitamin D Supplementation In Diagnosed Cases Of  2019 Novel Coronavirus; A Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/06/2020} &
				\multicolumn{2}{l}{ 20/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029935 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Single-Arm Clinical Trial For Chloroquine Phosphate In The Treatment Of Novel Coronavirus Pneumonia 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hwamei Hospital, University Of Chinese Academy Of Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 06/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Serious Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025762 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label Randomised Controlled, Proof-Of-Concept (Poc) Study To
Evaluate The Safety And Efficacy Of Selected Siddha Formulations In Patients
Diagnosed With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Siddha } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025768 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Label Randomised Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Selected Siddha Formulations In Patients Diagnosed With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Siddha } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B342- Coronavirus Infection, Unspecified } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030219 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For Evaluation Of Integrated Traditional Chinese And Western Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ First Teaching Hospital Of Tianjin University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 29/02/2020} &
				\multicolumn{2}{l}{ 21/01/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ New Treatment Measure Clinical Study } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029578 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chinese Medicine Prevention And Treatment Program For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhejiang Chinese Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04407286 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vitamin D Testing And Treatment For Adults With Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Arizona State University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19;Vitamin D Deficiency } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04447235 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Treatment With Ivermectin And Losartan For Cancer Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Do Cancer Do Estado De São Paulo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 176 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Cancer$|$Covid$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin + ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025214 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, Parallel Efficacy, Active Control, Exploratory Clinical Trial To Evaluate Efficacy And Safety Of An Ayurvedic Formulation (Ayush 64) As Adjunct Treatment To Standard Of Care For The Management Of Mild To Moderate Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Ayurvedic Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04443673 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Glycine Supplement For Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Enfermedades Respiratorias } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 28/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 82 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov Infection$|$Sars (Severe Acute Respiratory Syndrome)$|$Sars Pneumonia$|$ARDS, Human$|$Pneumonia, Viral } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, IL-17, Tumor Necrosis Factor (Any), PAI-1, Granulocyte Stimulaiting Factor, MCP-1, MIP-1, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, AST, Bilirubin, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ DRKS00021626 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Controlled, Open Label, Multicentre Clinical Trial To Explore Safety And Efficacy Of Hyperbaric Oxygen For Preventing
ICU Admission, Morbidity And Mortality In Adult Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karolinska Institutet, Departement Physiology Und Pharmacology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025625 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Multicenter, Randomised, Open-Label, Proof-Of-Concept (Poc) Study To Evaluate The Efficacy And Safety Of Siddha Treatment In Patients With Novel Coronavirus Infectious Disease (Covid-19) - Start (Siddha Treatment Accelerating Recovery From Sars-Cov-2 Test) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Eminentlabs Business Solutions Pvt Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029549 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Recommendations Of Integrated Traditional Chinese And Western Medicine For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360356 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ivermectin And Nitazoxanide Combination Therapy For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin + Antivirals, Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Ferritin, IL-6, Tumor Necrosis Factor (Any), Platelet Count, Prothrombin, INR, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029558 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Recommendations Of Integrated Traditional Chinese And Western Medicine For Diagnosis And Treatment Of Novel Coronavirus Pneumonia (Covid-19) In Sichuan Province } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 29/01/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, C-Reactive Protein, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Troponin, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04446104 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Preventive Treatment For Migrant Workers At High-Risk Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National University Hospital, Singapore } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Hygeine, Ivermectin, Vitamins, Vitamins + Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04428801 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Autologous Adipose-Derived Stem Cells (Admscs) For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Celltex Therapeutics Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 31/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, C-Reactive Protein, IL-1, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, D-Dimer, Procalcitonin, Bilirubin, Stool Sample, IgG, IgM or IgA, Antibodies, Blood Gas } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025854 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Effectiveness Of Bcg Vaccine In Reducing Morbidity And Mortality In Elderly Individuals In Covid-19 Hotspots In India - Bcg For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Indian Council Of Medical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1450 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029433 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Blank-Controlled Trial For Lian-Hua Qing-Wen Capsule/Granule In The Treatment Of Suspected Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hebei Yiling Hospital<U+3001>Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Suspected Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029517 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chinese Medicine Prevention And Treatment Program For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhejiang Chinese Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025248 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Covid-19 Telephonic Counseling Model For Addressing Mental Health Concerns In Different Populations During Corona Outbreak In India: A Hospital Based Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Rahul Taneja } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 128 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001367-88-DK }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Novel Treatment Options For Adults With Covid-19 Pneumonia. A Double-Blinded, Randomised, Multi-Stage, 6-Armed Placebo-Controlled Trial In The Framework Of An Adaptive Trial Platform - Ccap-Rct } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Infectious Diseases } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, JAKi, Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031781 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blinded, Placebo-Controlled Phase Ii Clinical Trial For Recombinant Novel Coronavirus (2019-Ncov) Vaccine (Adenovirus Vector) In Healthy Adults Aged Above 18 Years } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Jiangsu Provincial Center For Disease Control And Prevention } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361422 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Isotretinoin In Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341493 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Vs Nitazoxanide In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hugo Mendieta Zeron$|$Materno-Perinatal Hospital Of The State Of Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365309 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protective Effect Of Aspirin On Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Xijing Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 01/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 128 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia$|$Aspirin$|$Treatment } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352959 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19: Nasal And Salivary Detection Of The Sars-Cov-2 Virus After Antiviral Mouthrinses: Double-Blind, Randomised, Placebo-Controlled Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Claude Bernard University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 178 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Mouthwash;Saliva } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361474 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Evaluating The Efficacy Of Local Budesonide Therapy In The Management Of Hyposmia In Covid-19 Patients Without Signs Of Severity } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fondation Ophtalmologique Adolphe De Rothschild } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Budesonide;Olfaction Disorders;Sars-Cov-2;Anosmia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Blood Pressure, Heart Rate, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355143 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine To Reduce Cardiac Injury In Covid-19 (Colheart-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of California, Los Angeles } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 25/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, D-Dimer, Troponin, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200404046934N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigation Of The Effect Of Zufa Syrup On Clinical Symptoms In The With Suspected  Corona(Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Deouty Of Research \& Technology Qom University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/03/2020} &
				\multicolumn{2}{l}{ 19/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 130 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, Blood Pressure, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032242 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open, Controlled Trial For The Efficacy And Safety Of Oral Kolimycin In The Treatment Of Patients With New Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mudanjiang Kang'an Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, C-Reactive Protein, White Blood Cell Count, Coagulation Test, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361643 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low-Dose Lenalidomide For Non-Severe Covid-19 Treatment Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitario Getafe } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 27/10/2020} &
				\multicolumn{2}{l}{ 31/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Neutrophils } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032214 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled, Multicentre Clinical Study On The Improvement Of Novel Coronavirus Pneumonia (Covid-19) Convalescent Sleep Mood Disorder With Shumian Capsule } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Provincial Hospital Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 10/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20180520039738N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison Of The Effectiveness Of Standard Treatment With Stand Treatment Plus Vitamin A In Treatment In Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Saveh University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 07/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease 2019 (Covid-19). } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, LDH, Respiratory Rate, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032237 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Double-Blind, Placebo-Controlled Trial For Xiang-Sha-Liu-Jun Pill In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) Decline In Digestive Function During Convalescence } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ezhou Hospital Of Traditional Chinese Medicine In Hubei Province } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001466-11-GR }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Supar-Guided Anakinra Treatment For Validation Of The Risk And Early Management Of Severe Respiratory Failure By Covid-19: The Save Open-Label, Non-Randomised Single-Arm Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hellenic Institute For The Study Of Sepsis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Lower Respiratory Tract Infection By Covid-19 At High Risk For Development Of Severe Respiratory Failure $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10035738
Term: Pneumonia Viral Nos
System Organ Class: 100000004862
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra + Cotrimoxazole } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353336 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacay Of Chloroquine In Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 23/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032098 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For Danggui Shaoyao Powder In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Union Hospital Of Tongji Medical College, Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/01/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20191125045492N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison Of The Effectiveness Of Ozone Therapy With Conventional Therapy In Improving Patient Outcomes In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 21/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20150303021315N17 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Safety And Efficacy Of Tocilizumab (Aryogen <U+200E>Pharmed Co., Iran) In Patients With Severe Covid-19<U+200E> } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aryogen Pharmed } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 21/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 85 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04410562 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Efficacy And Safety In Preventing Sars-Cov-2 Infection And Covid-19 Disease Severity During Pregnancy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Barcelona Institute For Global Health$|$Hospital Clinic Of Barcelona$|$Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau$|$University Hospital Of Torrejon$|$Fundación De Investigación Hm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 13/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 714 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pregnancy Related$|$Covid$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Hemoglobin, Pregnancy or Birth Outcomes } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355936 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Telmisartan For Treatment Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Laboratorio Elea Phoenix S.a.$|$Carlos R. Rojo, Md } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Drug Treatment } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Troponin, LDH, Urine Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343729 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Methylprednisolone In The Treatment Of Patients With Signs Of Severe Acute Respiratory Syndrome In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundação De Medicina Tropical Dr. Heitor Vieira Dourado } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 16/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 416 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection$|$Severe Acute Respiratory Syndrome (Sars) Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344041 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 And Vitamin D Supplementation: A Multicenter Randomised Controlled Trial Of High Dose Versus Standard Dose Vitamin D3 In High-Risk Covid-19 Patients (Covittrial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Angers$|$Mylan Laboratories } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 260 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342650 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine Diphosphate In The Prevention Of Sars In Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundação De Medicina Tropical Dr. Heitor Vieira Dourado } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 14/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 152 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov Infection$|$Severe Acute Respiratory Syndrome (Sars) Pneumonia$|$Clinical Trial } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Natural Killer Cell Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031888 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Research On Treatment Of Novel Coronavirus Pneumonia  With ''Guangdong Pneumonia No.1'' } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangzhou Eighth People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, CD4, CD8, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345419 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Results Of Covid 19 Treatment: A Real-Life Experience On Patients With Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000033284 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For The Improvement Of The Quality Of Life Of Severe Patients Of Novel Coronavirus Pneumonia (Covid-19) By The Integrated Chinese Medicine And Western Medicine Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangzhou Women And Children's Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/05/2025} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Other, Traditional Chinese Medicine + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Dyspnea, Weight, Height or BMI } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030433 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Application Of Rehabilitation And Lung Eight-Segment Exercise In  Home Rehabilitation Of Survivors From Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Fujian Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov Pneumonia } & 
				\multicolumn{2}{l}{ Recovered } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032573 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Controlled Trial For Bu-Fei-Huo-Xue Capsule In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) Convalescence Patient With ''Fei-Pi-Qi-Xu Zhen'' } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ State Key Laboratory Of Respiratory Disease, Guangzhou Institute Of Respiratory Diseases, The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, Guangdong, China } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/05/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 02/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Recovery } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030920 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Taking Tricholoma Matsutake, Cannabis Sativa Capsule And Dendrobium Candidum To Nutrition Intervention Of Patients With Novel Coronavirus Pneumonia (Covid-19) During Convalescence. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hwamei Hospital, University Of Chinese Academy Of Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Secondary CoViD-19 Re-infection, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030933 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of ''Liu-Zi-Jue'' Combined With Respiratory Muscle Training For Respiratory Function In Covid-19 Patients: A Demonstration Study For The Key Techniques } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Nanchang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 108 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, Exercise + Respiratory support, Respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029495 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Traditional Chinese Medicine, Psychological Intervention And Investigation Of Mental Health For Patients With Novel Coronavirus Pneumonia (Covid-19) In Convalescent Period } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 1. Xinhua Affiliated Hospital, Hubei University Of Chinese Medicine; 2. Hubei Provincial Hospital Of Integrated Chinese And Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy, Traditional Chinese Medicine, Traditional Chinese Medicine + Psychological therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374487 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assess The Safety And Efficacy Of Convalescent Plasma To Limit Covid-19 Associated Complications } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Max Healthcare Insititute Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 09/05/2020} &
				\multicolumn{2}{l}{ 09/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029459 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pulmonary Rehabilitation To Improve Pulmonary Function And Quality Of Life In Patients With Novel Coronavirus Pneumonia (Covid-19) In Rehabilitation Period } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 1.Xinhua Affiliated Hospital, Hubei University Of Chinese Medicine; 2. Hubei Provincial Hospital Of Integrated Chinese And Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ New Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029956 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chinese Medicine Promotes Rehabilitation Recommendations After 2019 Novel Coronavirus Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029789 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial For Tcm Syndrome Differentiation Treatment Impacting Quality Of Life Of Post-Discharge Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of He'nan University Of Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 30/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department, Pneumonia or ARDS, Radiographic Findings, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029493 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Traditional Chinese Medicine For Pulmonary Fibrosis, Pulmonary Function And Quality Of Life In Patients With Novel Coronavirus Pneumonia (Covid-19) In Convalescent Period: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 1. Xinhua Affiliated Hospital, Hubei University Of Chinese Medicine; 2. Hubei Provincial Hospital Of Integrated Chinese And Western Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Resolved } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04368845 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Telerehabilitation In Patients With Covid-19 After Hospitalization. The Athlos Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Clinical Exercise Physiology And Rehabilitation Reasearch Laboratory$|$University Of Athens$|$University Of Ioannina$|$University Of Thessaly } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Resolved Discharged } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Comorbidities And Coexisting Conditions } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04260594 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Arbidol Hydrochloride Tablets In The Treatment Of Pneumonia Caused By Novel Coronavirus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Jieming Qu$|$Ruijin Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 380 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381923 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covidnoche Trial (Hfno Versus Cpap Helmet) In Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Pennsylvania } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 15/08/2020} &
				\multicolumn{2}{l}{ 15/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome Coronavirus 2$|$Hypoxemic Respiratory Failure$|$Pneumonia, Viral$|$Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Dyspnea, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363853 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Serious And Critical Patients With Covid-19 With Tocilizumab } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Cancerologia De Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, White Blood Cell Count, Hemoglobin, Glucose, Blood Urea Nitrogen, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348305 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low-Dose Hydrocortisone In Patients With Covid-19 And Severe Hypoxia - The Covid Steroid Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Scandinavian Critical Care Trials Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Hypoxia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04350281 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label Randomised Controlled Trial On Interferon Ss-1b And Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, As Treatment For Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Hong Kong } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030333 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label Study To Evaluate The Efficacy And Safety Of Pirfenidone In Patients With Severe And Critical Novel Coronavirus Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital Of Tongji Medical College; Huazhong Science And Technology University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/02/2020} &
				\multicolumn{2}{l}{ 29/02/2020} &
				\multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ 07/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 292 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Cough, Dyspnea, IL-8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330638 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Covid-19 Patients With Anti-Interleukin Drugs } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Ghent$|$Belgium Health Care Knowledge Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 342 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra, Anakinra + Siltuximab, Anakinra + Tocilizumab, Siltuximab, SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, Radiographic Findings, Hypoxia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445272 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Evaluate The Effectiveness And Safety Of Tocilizumab For Treating Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Seimc-Gesida$|$Roche Pharma Ag$|$Dynamic Science S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 22/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04468646 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } To Determine The Efficacy Of Neurokinin 1 Receptor Antagonist As A Therapeutic Tool Against Cytokine Storm And Respiratory Failure In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Prof. Dr. Fridoon Jawad Ahmad$|$University Of Lahore$|$Bahria International Hospital$|$University Of Health Sciences Lahore } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Neurokinin 1 Receptor, Substance P, Respiratory Illness, Inflammation, Covid-19, Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200414047072N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Experimental Use Of Covid-19 Convalescent Plasma For The Purpose Of Passive Immunization In Current Covid-19 Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hilton Pharma Pvt. Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 357 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377997 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label Trial Of Therapeutic Anticoagulation In Covid-19 Patients With An Elevated D-Dimer } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Cardiovascular Diseases;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Deep Vein Thrombosis or Pulmonary Embolism, Shock, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321616 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy Of Different Anti-Viral Drugs In Covid 19 Infected Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Oslo University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 700 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection$|$Covid 19$|$Acute Respiratory Distress Syndrome ARDS } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374461 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of N-Acetylcysteine In Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Memorial Sloan Kettering Cancer Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04411602 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Feasibility Study Of Anti-Sars-Cov-2 Plasma Transfusions In Covid-19 Patients With Srd } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ascension South East Michigan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome$|$Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322123 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Hydroxychloroquine Associated With Azithromycin In Sars-Cov-2 Virus (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Do Coracao$|$Hospital Israelita Albert Einstein$|$Hospital Sirio-Libanes$|$Brazilian Research In Intensive Care Network$|$Ems } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 630 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04373707 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Weight-Adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses To Prevent Venous Thromboembolism In Covid-2019. The Multicenter Randomised Controlled Open-Label Trial Covi-Dose } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Hospital, Nancy, France } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 602 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Thrombosis;Pulmonary Embolism;Deep Vein Thrombosis } & 
				\multicolumn{2}{l}{ Confirmed, Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345848 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preventing Covid-19-Associated Thrombosis, Coagulopathy And Mortality With Low- And High-Dose Anticoagulation: A Randomised, Open-Label Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Geneva } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Sars-Cov2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04433910 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Trial Of Convalescent Plasma Compared To Best Supportive Care For Treatment Of Patients With Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Deutsches Rotes Kreuz Drk-Blutspendedienst Baden-Wurttemberg-Hessen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 106 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346797 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corimuno19-Ecu: Trial Evaluating Efficacy And Safety Of Eculizumab (Soliris) In Patients With Covid-19 Infection, Nested In The Corimuno-19 Cohort } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344756 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Evaluating Efficacy And Safety Of Anticoagulation In Patients With Covid-19 Infection, Nested In The Corimmuno-19 Cohort } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 808 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Coagulation Test, Bicarbonates, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361253 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Randomised, Double-Masked, Placebo-Controlled Trial Of High-Titer Covid-19 Convalescent Plasma (Ht-Ccp) For The Treatment Of Hospitalized Patients With Covid-19 Of Moderate Severity } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Brigham And Women's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 220 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Infectious Disease } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352751 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Experimental Use Of Convalescent Plasma For Passive Immunization In Current Covid-19 Pandemic In Pakistan In 2020 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hilton Pharma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital, ICU } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381338 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rehabilitation For People With Covid-19 In ICU } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Padova$|$Prof. S Masiero, University Of Padova, Italy$|$Dr. A. Venturin, General Hosipital, Padova, Italy$|$Dr. I. Tiberio, General Hospital, Padova, Italy$|$Dr. D. Zampieri, University Of Padova, Italy$|$Dr.ssa M Cattelan, University Of Padova, Italy$|$Prof. P. Zanatta, University Hosiptal, Verona, Italy$|$Dr.ssa C. Carollo, General Hospital, Padova, Italy$|$Prof. E. Polati, University Hospital, Verona, Italy$|$Prof. K. Donadello, University Hospital, Verona, Italy } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 10/05/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 92 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease 19 (Covid-19)$|$Covid$|$Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)$|$Critical Illness } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Rehabilitation, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04424056 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Using Anakinra, Tocilizumab Alone Or In Association With Ruxolitinib In Severe Stage 2b And 3 Of Covid19-Associated Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique Hopitaux De Marseille } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 30/09/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 216 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra + Ruxolitinib, SOC, Tocilizumab + Ruxolitinib } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04384900 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Accelerated Prone Position Ventilation Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nordsjaellands Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001722-66-ES }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Plasma Turnover In Patients With Covid-19 Disease And Invasive Mechanical Ventilation: A Randomised Study - Rep-Covid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundació Clínic Per A La Recerca Biomèdica } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus (Covid-19) Infection With Respiratory Failure Requiring Mechanical Ventilation. $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
 $<$Br$>$Meddra Version: 21.1
Level: Pt
Classification Code 10067221
Term: Mechanical Ventilation
System Organ Class: 10042613 - Surgical And Medical Procedures
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04350580 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Value Of Early Treatment With Polyvalent Immunoglobulin In The Management Of Acute Respiratory Distress Syndrome Associated With Sars-Cov-2 Infections } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Hospitalier St Anne } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 138 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome;Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, C-Reactive Protein, Procalcitonin, PaO2-FiO2, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04406389 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anticoagulation In Critically Ill Patients With Covid-19 (The Impact Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Weill Medical College Of Cornell University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341285 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Versus Late Ecmo Therapy In Covid-19 Induced ARDS (Ecmo-Vid) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Tuebingen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ARDS, Human;Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ ECMO } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04415060 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Sedating With Volatile Anesthetics Critically Ill Covid-19 Patients In ICU: Effects On Ventilatory Parameters And Survival } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sunnybrook Health Sciences Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 15/06/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 752 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anesthetic, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04311697 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Intravenous Aviptadil For Critical Covid-19 With Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Neurorx, Inc.$|$Lavin Consulting, Llc$|$International Business Machines (Ibm) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Critical Covid-19 With Respiratory Failure$|$Acute Respiratory Distress Syndrome (ARDS)$|$Corona Virus Infection$|$Acute Lung Injury } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Inhaled solution, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04420741 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Infusion Of Prostacyclin (Iloprost) Vs Placebo For 72-Hours In Covid-19 Patients With Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pär Johansson$|$Rigshospitalet, Denmark } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 31/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Respiratory Failure } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20120215009014N354 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Effect Of Intravenous Hydrocortisone, Methylprednisolone, And Dexamethasone In Treatment Of Patients With Moderate To Severe Acute Respiratory Distress Syndrome Caused By Covid-19: A Double Blind Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamedan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 05/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, Dexamethasone } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348461 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Two-Treatment,Randomised, Controlled, Multicenter Clinical Trial To Assess The Safety And Efficacy Of Intravenous Administration Of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells In Critically Ill Patients Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Investigación Sanitaria De La Fundación Jiménez Díaz } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04394416 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Imatinib For Hospitalized Adults With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Maryland, Baltimore } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 01/06/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 204 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Imatinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381858 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Vs Human Immunoglobulin To Treat Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centenario Hospital Miguel Hidalgo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030540 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Research For The Mechanism Of Improvement Of Novel Coronavirus Pneumonia (Covid-19) Patients' Pulmonary Exudation By Continuous Renal Replacement Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital Affiliated To Tongji Medical College Of Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 07/03/2020} &
				\multicolumn{2}{l}{ 08/03/2020} &
				\multicolumn{2}{l}{ 08/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 152 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04244591 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Glucocorticoid Therapy For Covid-19 Critically Ill Patients With Severe Acute Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking Union Medical College Hospital$|$Zhongda Hospital$|$Zhongnan Hospital$|$Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/01/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 26/01/2020} &
				\multicolumn{2}{l}{ 13/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341038 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Open Randomised Single Centre Clinical Trial To Evaluate Methylprednisolone Pulses And Tacrolimus In Patients With Severe Lung Injury Secondary To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitari De Bellvitge } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Lung Injury } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04325906 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Pp With Hfnc Versus Hfnc In Covid-19 Induced Moderate To Severe ARDS } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rush University Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 346 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Prone Positioning$|$High Flow Nasal Cannula$|$Acute Respiratory Distress Syndrome$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, Positioning + Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04306393 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nitric Oxide Gas Inhalation In Severe Acute Respiratory Syndrome In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital$|$Xijing Hospital$|$Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico$|$Niguarda Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/03/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 21/03/2020} &
				\multicolumn{2}{l}{ 21/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars (Severe Acute Respiratory Syndrome)$|$Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04380519 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of The Efficacy And Safety Of A Single Administration Of Olokizumab And Rph-104 With Standard Therapy In Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ R-Pharm International, Llc$|$Data Management 365 Llc$|$K-Research, Llc$|$R-Pharm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 15/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 372 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425031 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Handling Oxygenation Targets In Covid-19 Patients With Acute Hypoxaemic Respiratory Failure In The Intensive Care Unit: A Randomised Clinical Trial Of A Lower Versus A Higher Oxygenation Target } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aalborg University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 780 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hypoxemic Respiratory Failure;Oxygen Toxicity } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374539 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Plasma Exchange In Patients With Covid-19 Disease And Invasive Mechanical Ventilation: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Clinic Per A La Recerca Biomédica } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 05/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04385771 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cytokine Adsorption In Patients With Severe Covid-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr. Alexander Supady$|$Klinikum Ibbenbüren$|$Ludwig-Maximilians - University Of Munich$|$University Hospital, Saarland$|$Klinikum Ludwigsburg$|$University Of Ulm$|$Slk-Kliniken Heilbronn$|$Martin-Luther-Universität Halle-Wittenberg$|$University Hospital Freiburg } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Covid$|$Sars-Cov 2$|$Respiratory Failure$|$Cytokine Storm$|$Extracorporeal Membrane Oxygenation } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ ECMO, ECMO + Cytokine removal } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389580 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Combination Therapy With Isotretinoin And Tamoxifen Expected To Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kafrelsheikh University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hormone therapy, Hormone therapy + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, C-Reactive Protein, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Erythrocyte Sedimentation Rate, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04432051 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Significance Of Lung Ultrasonography In The Follow-Up And Treatment Of Covid-19 Patients With Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gaziosmanpasa Taksim Research And Education Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Ultrasonography } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Monitoring, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04391101 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For The Treatment Of Severe Sars-Cov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital San Vicente Fundación$|$Clínica León Xiii$|$Grupo De Inmunodeficiencias Primarias Universidad De Antioquia$|$Clínica Universitaria Bolivariana$|$Hospital Pablo Tobón Uribe$|$Clínica Rosario El Tesoro$|$Clínica Las Américas$|$Clínica Cardiovid } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 231 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Fever, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8578 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Alkaline Phosphatase For Reducing Systemic Inflammatory Response Syndrome (Sirs) In Patients With Sars-Cov-2 Infection And Acute Respiratory Insufficiency (Covid 19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rode Kruis Ziekenhuis Beverwijk } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 124 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed, Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04409834 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised-Controlled Trial To Evaluate The Efficacy And Safety Of Antithrombotic Therapy For Prevention Of Arterial And Venous Thrombotic Complications In Critically-Ill Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Timi Study Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 750 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Venous Thromboembolism;Arterial Thrombosis } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, Anticoagulants + Antiplatelets } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377620 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of Efficacy And Safety Of Ruxolitinib In Participants With Covid-19-Associated ARDS Who Require Mechanical Ventilation (Ruxcovid-Devent) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Incyte Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ 29/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Organ Failure or Dysfunction (SOFA), Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001644-25 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2, Open-Label, Randomised Study Of The Efficacy And Safety Of Acalabrutinib With Best Supportive Care Versus Best Supportive Care In Subjects Hospitalized With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Acerta Pharma B.v. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Acalabrutinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04404426 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cacolac : Randomised Trial Of Citrulline Administration In The Hospital Patient In Intensive Care For Covid-19 Acute Respiratory Distress Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rennes University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ARDS Secondary To Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377750 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Use Of Tocilizumab In The Management Of Patients Who Have Severe Covid-19 With Suspected Pulmonary Hyperinflammation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hadassah Medical Organization$|$Sheba Medical Center$|$Wolfson Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200510047383N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Tocilizumab On Outcomes Of The Severe Covid-19, Determining Indications Within The Paradigm Of Host-Directed Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Arak University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 22/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389710 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Thomas Jefferson University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 14/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Hospital Discharge, Adverse Events, C-Reactive Protein, Platelet Count, D-Dimer, Prothrombin, Fibrinogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344730 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dexamethasone And Oxygen Support Strategies In ICU Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 550 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Hypoxemic Respiratory Failure$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Dexamethasone, Dexamethasone + Non-invasive respiratory support, Mechanical ventilation + Dexamethasone, Non-invasive respiratory support, Non-invasive respiratory support + Dexamethasone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Hypoxemia, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343989 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Placebo-Controlled Safety And Dose-Finding Study For The Use Of The Il-6 Inhibitor Clazakizumab In Patients With Life-Threatening Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353180 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment The Activity Value Of Isotretinoin (13- Cis-Retinoic Acid ) In The Treatment Of Covid-19 (Randomised) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kafrelsheikh University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Anti SARS-COV-2 Titers, C-Reactive Protein, IL-1, IL-6, Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04367831 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Intermediate Or Prophylactic-Dose Anticoagulation For Venous Or Arterial Thromboembolism In Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 02/05/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Venous Thromboses$|$Arterial Thrombosis } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366115 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating Avm0703 For Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Avm Biotechnology Llc$|$Medpace, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/06/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 126 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, Dexamethasone + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04371367 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Double-Blind, Randomised Study Versus Placebo Of Avdoralimab (Iph5401), An Anti-C5ar Antibody, In Patients With Covid-19 Severe Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique Hopitaux De Marseille } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 108 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200324046851N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effects Of Nano Curcumin Supplementation On The Reduction Of Inflammation And Mortality In Patients With Coronavirus 2019 Admitted To ICU Ward Of Imam Reza Hospital In Tabriz } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ 29/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-2019. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355364 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Aerosolized Intra-Tracheal Dornase Alfa Administration In Patients With Covid19-Induced Acute Respiratory Distress Syndrome (ARDS) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fondation Ophtalmologique Adolphe De Rothschild } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Acute Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Inhaled solution, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ TCTR20200409006 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Ha330 Hemoperfusion In Critically Ill Patients With Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Excellence Center For Critical Care Nephrology, King Chulalongkorn Memorial Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 206 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19
ARDS $<$Br$>$Covid-19$<$Br$>$ARDS$<$Br$>$Pneumonia$<$Br$>$Hemoadsorption$<$Br$>$Il-6;Covid-19$<$Br$>$ARDS$<$Br$>$Pneumonia$<$Br$>$Hemoadsorption$<$Br$>$Il-6 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hemoperfusion, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Non-invasive Ventilation, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04371393 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Mesenchymal Stem Cells For The Treatment Of Moderate To Severe Covid-19 Acute Respiratory Distress Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Icahn School Of Medicine At Mount Sinai } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Mesenchymal Stromal Cells;Remestemcel-L;Acute Respiratory Distress Syndrome;Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04369469 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3 Open-Label, Randomised, Controlled Study To Evaluate The Efficacy And Safety Of Intravenously Administered Ravulizumab Compared With Best Supportive Care In Patients With Covid-19 Severe Pneumonia, Acute Lung Injury, Or Acute Respiratory Distress Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Alexion Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 270 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Severe Pneumonia, Acute Lung Injury, Or Acute Respiratory Distress Syndrome;Pneumonia, Viral } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361032 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of Efficacy And Safety Of Tocilizumab Compared To Deferoxamine, Associated With Standards Treatments In Covid-19 (+) Patients Hospitalized In Intensive Care In Tunisia. Multicentric, Comparative, Randomised Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abderrahmane Mami Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 260 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Intensive Care Unit;Covid19;Intensive Care Unit } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab + mAb } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001329-30 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inhaled Nitric Oxide Gas Therapy In Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachussetts General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04358003 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Plasma Adsorption In Patients With Confirmed Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Marker Therapeutics Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Respiratory Failure;ARDS } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04339816 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Azithromycin Added To Hydrochloroquine In Patients Admitted To Intensive Care With Covid-19: Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Frantisek Duska, Md, Phd$|$Masaryk Hospital Usti Nad Labem$|$University Hospital Pilsen$|$The Faculty Hospital Na Bulovce$|$St. Anne's University Hospital Brno, Czech Republic$|$University Hospital, Motol$|$General University Hospital, Prague$|$University Hospital Olomouc$|$Charles University, Czech Republic } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ ICU } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Respiratory Failure } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329923 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Patch Trial (Prevention And Treatment Of Covid-19 With Hydroxychloroquine) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ravi Amaravadi, Md$|$University Of Pennsylvania } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed And Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Hospital Discharge, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025861 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Scientific Evaluation Of Immuno-Modulatory Effects Of Ayush Interventions On Normal Healthy And High-Risk Individuals In Context With Covid-19 Pandemic: An Open Level, Multi Centric, Non-Randomised, Comparative, Interventional Community Based Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Ayush Uttarakhand } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed, Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy, Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390191 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Cpap In Covid-19 Confirmed Or Suspected Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Icahn School Of Medicine At Mount Sinai$|$Itamar Medical Ltd$|$Community Surgical Supply Of Toms River, Inc$|$Philips Healthcare } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Covid$|$Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Household Members with CoViD-19, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001498-63 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Adaptive Design Phase 2 To 3, Randomised, Double- Blind, Multicenter, To Evaluate The Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Bio101 In The Prevention Of The Respiratory Deterioration In Hospitalized Patients With Covid-19 Pneumonia (Severe Stage) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biophytis S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 465 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Viral Infections Nec$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Angiotensins, ACE, ECG, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029954 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Honeysuckle Oral Liquid In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Multicenter, Randomised, Controlled, Open Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 10/02/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04391179 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dipyridamole To Prevent Coronavirus Exacerbation Of Respiratory Status (Dicer) In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Michigan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Corona Virus Infection$|$Covid-19$|$Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000033318 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rqesearch On The Application Of Traditional Chinese Medicine Traditional Techniques To Prevent And Control New Coronary Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yueyang Integrated Traditional Chinese And Western Medicine Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 104 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04336332 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Comparison Of Combination Azithromycin And Hydroxychloroquine Vs. Hydroxychloroquine Alone For The Treatment Of Confirmed Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rutgers, The State University Of New Jersey } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04336904 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study To Evaluate The Performance And Safety Of Favipiravir In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Giuliano Rizzardini$|$Asst Fatebenefratelli Sacco } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04419025 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of N-Acetylcysteine (Nac) In Preventing Covid-19 From Progressing To Severe Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge Health Alliance } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 15/08/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Sars-Cov2$|$Sars-Associated Coronavirus As Cause Of Disease Classified Elsewhere$|$Oxidative Stress } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Invasive Mechanical Ventilation or ECMO, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338828 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nitric Oxide Inhalation Therapy For Covid-19 Infections In The Ed } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital$|$Department Of Anesthesia, Mgh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 260 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001860-27 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Agile: Seamless Phase I/Iia Platform For The Rapid Evaluation Of Candidates For Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Liverpool } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Platelet Count, Hemoglobin, ALT, SpO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190810044500N5 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigation Of The Efficacy And Safety Of Colchicine In Combination With Standard Treatment On Covid-19 Patients: A Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yazd University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ 04/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Colchicine, Colchicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Cough, Fever, Dyspnea, C-Reactive Protein, Ferritin, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, LDH, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030215 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For The Efficacy Of Kangguan No. 1-3 Prescription In The Treatment Of Novel Coronavirus Pneumonia (Covid19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Nanchang University, Ten Layers Pulse Research Institute Of Traditional Chinese Medicine, Nanchang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, CD4, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04295551 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter Clinical Study On The Efficacy And Safety Of Xiyanping Injection In The Treatment Of New Coronavirus Infection Pneumonia (General And Severe) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Jiangxi Qingfeng Pharmaceutical Co. Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ 14/03/2020} &
				\multicolumn{2}{l}{ 14/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Lopinavir/ritonavir + Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030471 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Lipoic Acid Injection In Reducing The Risk Of Progression In Common Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Maoming People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 08/03/2020} &
				\multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 394 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Erythrocyte Sedimentation Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029974 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Multicenter, Open-Label, Randomised, Parallel-Controlled Trial For Probiotics To Evaluate Efficacy And Safety In Patients Infected With 2019 Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Qingdao East Sea Pharmaceutical Co., Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 09/02/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious or Seconday Infections, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025855 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Ayurveda Intervention (Ayush 64) As Add-On Therapy In Covid 19 Patients - An Open Label Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ipgt And Ra } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04324463 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Coronavirus Therapies To Prevent Progression Of Coronavirus Disease 2019 (Covid-19) Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Population Health Research Institute$|$Bayer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445467 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Adaptive Randomised Placebo Controlled Phase Ii Trial Of Antivirals For Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bayside Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 190 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20160625028622N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of  Noscovid On Pulmonary \& Other Clinical Manifestations Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Qazvin University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 17/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 125 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Cronavirus Disease (Covid-19). } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030102 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter Randomised Controlled Trial For Ozone Autohemotherapy In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tianjin Huanhu Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 23/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Blood Gas, SpO2, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04416048 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Anticoagulation Therapy On Clinical Outcomes In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Charite University, Berlin, Germany$|$Deutsches Zentrum Für Herz-Kreislauf-Forschung (Dzhk)$|$Bayer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Coagulation Test } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029518 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Randomised Double-Blind Placebo-Controlled Study Of Traditional Chinese Medicine Staging Regimen In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhejiang Chinese Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025763 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Clinical Trial To Determine The Complementary Effect Of Selected Siddha Formulations In Facilitating The Possibility Of Accelerated Recovery In Covid 19 Patients. - Sidcovid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Siddha } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030481 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Clinical Value Of Corticosteroid Therapy Timing In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Prospective Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377308 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Fluoxetine To Reduce Intubation And Death After Covid19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Toledo Health Science Campus } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Cytokine Storm } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, SSRIs } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030936 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hospital Of Chengdu University Of Traditional Chinese Medicine Jointly Launched A Real-World Study On The Clinical Efficacy Evaluation Of The Inner Hospital Preparation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 10/03/2020} &
				\multicolumn{2}{l}{ 10/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 2840 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354259 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Interferon Lambda For Immediate Antiviral Therapy At Diagnosis In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Health Network, Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Serious Adverse Events, Interferon (Any), Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029573 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open, Controlled Clinical Study To Evaluate The Efficacy And Safety Of Recombinant Cytokine Gene-Derived Protein Injection In Combination With Standard Therapy In Patients With Novel Coronavirus Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Medical College Of Zhejiang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient, Hospital } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335552 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pragmatic Factorial Trial Of Hydroxychloroquine, Azithromycin, Or Both For Treatment Of Severe Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Duke University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Presumed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362813 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Efficacy And Safety Of Canakinumab Treatment For Crs In Participants With Covid-19-Induced Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharmaceuticals$|$Novartis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 28/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia And Cytokine Release Syndrome (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Adverse Events, C-Reactive Protein, Ferritin, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389840 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dociparstat For The Treatment Of Severe Covid-19 In Adults At High Risk Of Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chimerix } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 524 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Acute Lung Injury$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363736 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Investigate Intravenous Tocilizumab In Participants With Moderate To Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hoffmann-La Roche } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 03/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200325046859N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effects Of The 2-Drug Diet (Hydroxychloroquine + Umifenovir(Arbidol)) Compared With Hydroxy Chlorquine On The Of Mortality Rate In Patients With Moderate Symptoms Of Covid-19 Infections: A  Randomised Interventional Study In Imam Reza Hospital, Mashhad. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 23/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, C-Reactive Protein, White Blood Cell Count, LDH, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04315987 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nestacell® Mesenchymal Stem Cell To Treat Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azidus Brasil$|$Cellavita Pesquisa Científica Ltda$|$Hospital Vera Cruz } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Platelet Count, CD4, CD8, PaO2-FiO2, Respiratory Rate, Hypoxia, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347980 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dexamethasone Treatment For Severe Acute Respiratory Distress Syndrome Induced By Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Chirurgical Marie Lannelongue } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 122 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Respiratory Distress Syndrome, Adult$|$Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Dexamethasone + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Patient Positioning } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344782 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Evaluating Efficacy And Safety Of Bevacizumab (Avastin®/Zeribev®) In Patients With Covid-19 Infection, Nested In The Corimmuno-19 Cohort } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 130 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 Pneumonia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04432272 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Antibody-Level Based Analysis Of Covid-19 Convalescent Serum (Abaccus) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ William Beaumont Hospitals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Severe Acute Respiratory Syndrome (Sars)$|$Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, IgG, IgM or IgA, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024947 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Drug Proving \& Checking Its Effectiveness In Treatment Of Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Priti Katre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04378920 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Trans Crocetin In Patients With Acute Respiratory Distress Syndrome Due To Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institut De Cancerologie Strasbourg Europe } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Acute Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04383613 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Positioning For Patients On General Medical Wards With Covid19: A Multicenter Pragmatic Randomised Trial [Covid-Prone] } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Michael's Hospital, Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;ARDS } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029990 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trials Of Mesenchymal Stem Cells For The Treatment Of Pneumonitis Caused By Novel Coronavirus (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 30/01/2020} &
				\multicolumn{2}{l}{ 31/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonitis Caused By Novel Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1-2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04320056 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Closed-Loop Oxygen To Verify That Healthcare Workers Interventions Decrease During Sars-Cov-2 Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Laval University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 30/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 216 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Pneumonia$|$Oxygen Toxicity } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029777 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Controlled Trial For Integrated Chinese And Western Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) Based On The 'Truncated Torsion' Strategy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Huangshi Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Coagulation Test, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04305106 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bevacizumab In Severe Or Critically Severe Patients With Covid-19 Pneumonia-Rct } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Qilu Hospital Of Shandong University$|$Renmin Hospital Of Wuhan University$|$Ialy Moriggia Pelascini Gravedona Hospital S.p.a$|$Wuhan University$|$Jiangbei Union Hospital Of Huazhong University Of Science And Technology$|$Shandong Provincial Chest Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/03/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395105 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } High Versus Low Dose Dexamethasone For The Treatment Of Covid-19 Related ARDS: A Multicenter And Randomised Open-Label Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centro De Educación Medica E Investigaciones Clínicas Norberto Quirno } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 284 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Respiratory Distress Syndrome, Adult;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Dexamethasone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435353 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of The Effectiveness Of Vibroacoustic Therapy For Respiratory Failure Caused By Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Astana Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Respiratory Distress Syndrome;Hypoxemia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04468087 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Antiviral Agents Against Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Do Coracao } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 17/08/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 189 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antiretroviral, DAA, Favipiravir, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04414631 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Conestat Alfa In The Prevention Of Severe Sars-Cov-2 Infection In Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Basel, Switzerland$|$Pharming Technologies B.v. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Non-invasive Ventilation, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04410510 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } P2et Extract In The Symptomatic Treatment Of Subjects With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitario San Ignacio$|$Pontificia Universidad Javeriana } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Coronavirus Infection$|$Sars-Cov 2$|$Covid19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir + Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001449-38-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Of Early Intervention In Patients Hospitalised With Covid-19: Favipiravir Verses Hydroxycholorquine \& Azithromycin \& Zinc Verses Standard Care - Pioneer } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chelsea And Westminster Hospital Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 100000004862
;Therapeutic Area: Diseases [C] - Respiratory Tract Diseases [C08] } & 
				\multicolumn{2}{l}{ Confirmed, Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Zinc, Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029739 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Parallel Controlled Clinical Study Of Hydrogen-Oxygen Nebulizer To Improve The Symptoms Of Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 31/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 440 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, ALT, Albumin, Bilirubin, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321993 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Moderate To Severe Coronavirus Disease (Covid-19) In Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lisa Barrett$|$Nova Scotia Health Authority$|$Dalhousie University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/02/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, JAKi, Lopinavir/ritonavir, Sarilumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, SpO2, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04280705 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Adaptive Covid-19 Treatment Trial (Actt) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Allergy And Infectious Diseases (Niaid) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1062 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04408040 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Convalescent Plasma Collected From Donors Recovered From Covid-19 Virus Disease For Transfusion, As An Empirical And Preemptive Treatment During Viral Pandemic Outbreak } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Northside Hospital, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 700 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001052-18 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Adaptive, Randomised Blinded Controlled Trial Of The Safety And Efficacy Of Investigational Therapeutics For The Treatment Of Covid-19 In Hospitalized Adults - Version For European Union/United Kingdom Sites } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Regents Of The University Of Minnesota } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 440 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Influenza Viral Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001643-13 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Double-Blind Placebo-Controlled Trial Of Brensocatib (Ins1007) In Patients With Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Dundee } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ DPP1 inhibitor, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04380961 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Efficacy And Safety Of Sirukumab In Confirmed Severe Or Critical Confirmed Coronavirus Disease (Covid)-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Janssen Pharmaceutica N.v., Belgium } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 15/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 270 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Or Critical Confirmed Coronavirus Disease (Covid)-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, ALT, Bilirubin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04315948 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Treatments For Covid-19 In Hospitalized Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institut National De La Santé Et De La Recherche Médicale, France } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ 01/03/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 3100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Lopinavir/ritonavir + Interferon, Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04420247 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Chloroquine Or Hydroxychloroquine In Treating Pneumonia Caused By Sars-Cov-2 - Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centro De Estudos E Pesquisa Em Emergencias Medicas E Terapia Intensiva } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Covid-19$|$Sars-Cov 2$|$Coronavirus$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030522 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Ma-Xing-Gan-Shi Decoction In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Affiliated Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 09/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, White Blood Cell Count, Erythrocyte Sedimentation Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04323592 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prolonged Low Doses Of Methylprednisolone For Patients With Covid-19 Severe Acute Respiratory Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Trieste } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 104 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome (Sars) Pneumonia;Coronavirus Infections;ARDS, Human } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20180425039414N3 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Vitamin C And E In The Treatment And Clinical Course Of Patients With Sars-Cov2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Esfahan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 21/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2(Covid-19). } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20180425039414N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Zinc On The Treatment And Clinical Course Of Patients With Sars-Cov2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Esfahan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 21/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2(Covid-19). } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, Fever, Dyspnea, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341116 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Tj003234 (Anti-Gm-Csf Monoclonal Antibody) In Subjects With Severe Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ I-Mab Biopharma Co. Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200518047497N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Laris - Hyssop Combined Herbal Distilled On The Improving Clinical And Paraclinical Symptoms In Patients With Covid-19: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 20/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, SpO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412057 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Clinical Trial To Evaluate The Efficacy And Safety Of Cerc-002 In Adults With Covid 19 Pneumonia And Acute Lung Injury } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aevi Genomic Medicine, Llc, A Cerecor Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 82 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia;Acute Lung Injury;ARDS } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001411-25-AT }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2 Randomised Single-Blind Study To Evaluate The Activity And Safety Of Low Dose Oral Selinexor (Kpt-330) In Patients With Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karyopharm Therapeutics Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Covid-19 Infection $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04424797 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Positioning On Admission For Hospitalized Covid-19 Pneumonia Protocol } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Poudre Valley Health System } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, SpO2, Patient Positioning } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372979 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Convalescent Plasma Therapy In The Early Care Of Covid-19 Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Direction Centrale Du Service De Santé Des Armées$|$University Hospital, Grenoble } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Anti SARS-COV-2 Titers, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04424134 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bromhexine And Spironolactone For Coron<U+0430>virus Infection Requiring Hospitalization } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lomonosov Moscow State University Medical Research And Educational Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ 18/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200506047319N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Therapeutic Effect Of Thyme Essence In Corona Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zanjan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ 21/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ New Corona Virus Infection. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425460 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Center,Randomised,Double-Blind,Placebo-Controlled,Phase 3 Study Evaluating Favipiravir In Treatment Of Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhejiang Hisun Pharmaceutical Co. Ltd.$|$Opera Cro, A Tigermed Group Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 256 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Pneumonia or ARDS, Non-invasive Ventilation, Cough, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390061 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tofacitinib Plus Hydroxycloroquine Vs Hydroxycloroquine In Patients With Early Onset Sars-Cov2 (Covid-19) Interstitial Pneumonia:a Multicenter Randomised Controlled Open Label Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Università Politecnica Delle Marche } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonitis, Interstitial;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + JAKi } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024883 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Single Blinded Prospective Multi Centre Clinical Trial To
Investigate The Safety And Efficacy Of Zingivir-H As An Adjuvant Therapy In Hospitalized Adults
Diagnosed With Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pankajakasthuri Herbal Research Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 112 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393311 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ulinastatin For The Treatment Of Covid-19 In Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stanford University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435015 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Utility Of Camostat Mesylate In Patients With Covid-19 Associated Coagulopathy (Cac) And Cardiovascular Complications } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yale University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coagulopathy;Cardiovascular Complication;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04378712 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydrogen/Oxygen Mixed Gas Inhalation For Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Guangzhou Institute Of Respiratory Disease } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 21/01/2020} &
				\multicolumn{2}{l}{ 23/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Hydrogen/Oxygen Mixed Gas$|$Dyspnea } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Cough, Dyspnea, SpO2, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200525047562N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Immediate Uses Of Convalescent Covid-19 Plasma In The Treatment Of New Infected Patients At The First Day Of Hospitalization In A Clinical Trail } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ High Educational And Research Institute Of Transfusion Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 26/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Hospital Discharge } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04421027 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Baricitinib (Ly3009104) In Participants With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Eli Lilly And Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04396106 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of At-527 In Subjects With Moderate Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Atea Pharmaceuticals, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 190 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04469114 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tofacitinib In Hospitalized Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Israelita Albert Einstein$|$Pfizer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 07/08/2020} &
				\multicolumn{2}{l}{ 07/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 260 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351763 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Amiodarone Or Verapamil In Covid-19 Hospitalized Patients With Symptoms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nicolaus Copernicus University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 02/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 804 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ CCB, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Fever, PaO2-FiO2, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393415 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Prp And Cord Blood In Improving The Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aljazeera Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Virus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001411-25-DE }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2 Randomised Single-Blind Study To Evaluate The Activity And Safety Of Low Dose Oral Selinexor (Kpt-330) In Patients With Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karyopharm Therapeutics Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Covid-19 Infection $<$Br$>$Meddra Version: 20.0
Level: Llt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 100000004862
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Labor Absenteeism, Fever, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04376684 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating Otilimab In Patients With Severe Pulmonary Covid-19 Related Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Glaxosmithkline } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 21/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393727 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Transfusion Of Convalescent Plasma For The Early Treatment Of Pneumonia Due To Sarscov2: A Multicenter Open Label Randomised Control Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero, Universitaria Pisana } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 126 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04426695 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety, Tolerability, And Efficacy Of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies For Hospitalized Adult Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Regeneron Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ 29/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2580 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ mAB } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001370-30-DE }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Multicenter, Randomised, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Canakinumab On Cytokine Release Syndrome In Patients With Covid-19-Induced Pneumonia (Can-Covid). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19-Induced Pneumonia (Can-Covid) $<$Br$>$Meddra Version: 20.1
Level: Pt
Classification Code 10053983
Term: Corona Virus Infection
System Organ Class: 10021881 - Infections And Infestations } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001904-41 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Glasgow Early Treatment Arm Favipiravir<U+F063> : A Randomised Controlled Study Of Favipiravir As An Early Treatment Arm In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nhs Greater Glasgow And Clyde$|$The University Of Glasgow } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 302 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001370-30-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Multicenter, Randomised, Double-Blind, Placebo-Controlled Study To Assess The Efficacy And Safety Of Canakinumab On Cytokine Release Syndrome In Patients With Covid-19-Induced Pneumonia (Can-Covid). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19-Induced Pneumonia (Can-Covid) $<$Br$>$Meddra Version: 20.1
Level: Pt
Classification Code 10053983
Term: Corona Virus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Respiratory Tract Diseases [C08] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382651 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Efficacy And Safety Of Mas825 In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharmaceuticals$|$Novartis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 02/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia, Impaired Respiratory Function } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382053 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Efficacy And Safety Of Dv890 In Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharmaceuticals$|$Novartis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 Pneumonia, Impaired Respiratory Function } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001786-36 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Recombinant Interleukin-7 (Cyt107) To Improve Clinical Outcomes In Lymphopenic Patients With Covid-19 Infection “Iliad 7 Trial” } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Revimmune Sas France } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, C-Reactive Protein, Ferritin, Monocyte Count, Lymphocyte Count, D-Dimer, CD4, CD8, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN54917435 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Awake Prone Positioning With High Flow Nasal Cannula In Critically Ill Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Uppsala County Council } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Respiratory Function In Patients With Respiratory Failure Due To Covid-19 Infection $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04415073 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2 Study To Evaluate Axatilimab For Hospitalized Patients With Respiratory Involvement Secondary To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Syndax Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Covid$|$ARDS$|$Cytokine Storm$|$Cytokine Release Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04432766 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 1 Study To Assess Bat2020 In Hospitalized Patients Infected With Sars-Cov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bio-Thera Solutions } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 03/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 174 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04429854 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Adaptive, Proof-Of-Concept Clinical Trial Of Donated Antibodies Working Against With Covid-19: Dawn-Plasma } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universitaire Ziekenhuizen Leuven } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 02/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 483 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029656 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label Study To Evaluate The Efficacy And Safety Of Low-Dose Corticosteroids In Hospitalized Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Pulmonary Hosptial } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 14/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029308 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Controlled Open-Label Trial To Evaluate The Efficacy And Safety Of Lopinavir-Ritonavir In Hospitalized Patients With 2019-Ncov Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/01/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 10/01/2020} &
				\multicolumn{2}{l}{ 10/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Completed w. Results } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200506047323N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effects Of Ginger On Clinical Manifestations And Paraclinical Features Of Patients With Covid-19: A Randomised Double-Blind Placebo-Control Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bandare-Abbas University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 22/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Alternative therapy + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, Serious Adverse Events, C-Reactive Protein, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025369 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Center, Randomised Controlled, Phase Iii Study To Evaluate The Clinical Outcomes And Safety Of Tocilizumab Along With
Standard Of Care In Patients With Cytokine Release Syndrome Associated With Covid-19 Infection
 - None } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Medanta Institute Of Education And Research Mier } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04323514 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Ascorbic Acid In Patients With Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Palermo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 13/03/2020} &
				\multicolumn{2}{l}{ 13/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hospitalized Patients With Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Peak RRadiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04325061 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Dexamethasone Treatment For Patients With ARDS Caused By Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr. Negrin University Hospital$|$Li Ka Shing Knowledge Institute$|$Consorcio Centro De Investigación Biomédica En Red, M.p. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome Caused By Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Dexamethasone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329650 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Siltuximab Vs. Corticosteroids In Hospitalized Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Judit Pich Martínez$|$Fundacion Clinic Per A La Recerca Biomédica } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 20/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, Siltuximab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, Lymphocyte Count, Platelet Count, Hemoglobin, D-Dimer, ALT, Bilirubin, LDH, SpO2, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04441385 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Efficacy And Safety Of Maraviroc In Sars-Cov-2 Infection (Covid-19). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitario Infanta Leonor$|$Hospital Clínic De Barcelona$|$Viiv Healthcare } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, ECG } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04389450 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase Ii Study To Evaluate The Efficacy And Safety Of Intramuscular Injections Of Plx Pad For The Treatment Of Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pluristem Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;ARDS } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20120215009014N355 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Effect Of Intravenous N-Acetyl Cysteine Versus Placebo In The Treatment Of Patients With Mild And Moderate Acute Respiratory Distress Syndrome Caused By Covid-19: A Double-Blind Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamedan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 05/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 92 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032367 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rqesearch On The Application Of Traditional Chinese Medicine Traditional Techniques To Prevent And Control New Coronary Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yueyang Integrated Traditional Chinese And Western Medicine Hospital Affiliated To Shanghai University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024806 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Imatinib In Mild Sars Cov2 Infection: A Randomised Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ All India Institute Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Imatinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348383 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Defibrotide As Prevention And Treatment Of Respiratory Distress And Cytokine Release Syndrome Of Covid 19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 08/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antithrombotics, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, C-Reactive Protein, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04350320 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial To Study The Benefit Of Colchicine In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacion Para La Formacion E Investigacion Sanitarias De La Region De Murcia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 20/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 102 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, Ferritin, IL-1, IL-6, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, D-Dimer, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCT2031190264 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Adaptive, Randomised Blinded Controlled Trial Of The Safety And Efficacy Of Investigational Therapeutics For The Treatment Of Covid-19 In Hospitalized Adults - Adaptive Covid-19 Treatment Trial (Actt) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ohmagari Norio } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Infectious Disease (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344535 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma To Reduce Complications Associated With Covid-19 Infection: A Randomised Trial Comparing The Efficacy And Safety Of High-Titer Anti-Sars-Cov-2 Plasma Vs. Standard Plasma In Hospitalized Patients With Covid- 19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stony Brook University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Mixed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20160310026998N11 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Metformin In Covid-19 Mortality Rate And Symptom Improvement } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 18/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Or Covid-19. } & 
				\multicolumn{2}{l}{ Mixed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351724 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Austrian Coronavirus Adaptive Clinical Trial (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Medical University Of Vienna$|$Kaiser Franz Josef Hospital$|$Smz-Ost Donauspital$|$Otto Wagner Hospital$|$Hospital Hietzing$|$Wilhelminenspital Vienna$|$Medical University Innsbruck } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Anticoagulants, Lopinavir/ritonavir, mAb, RAS blockade, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392973 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Favipiravir And Hydroxychloroquine Combination In Adults Hospitalized With Moderate And Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ King Abdullah International Medical Research Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 520 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04379271 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Efficacy, Safety And Tolerability Of Imu-838 As Addition To Investigator's Choice Of Standard Of Care Therapy, In Patients With Coronavirus Disease 19 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Immunic Ag$|$Fgk Clinical Research Gmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), D-Dimer, Weight, Height or BMI, Troponin, Procalcitonin, LDH, IgG, IgM or IgA, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024775 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii, Open Label, Randomised Controlled Trial To Assess The Safety And Efficacy Of Convalescent Plasma To Limit Covid-19 Associated Complications In Moderate Disease. - Placid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Indian Council Of Medical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 452 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04373044 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Baricitinib, Placebo And Antiviral Therapy For The Treatment Of Patients With Moderate And Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Southern California$|$National Cancer Institute (Nci) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Symptomatic Covid-19 Infection Laboratory-Confirmed } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi + Antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Hemoglobin, Blood Pressure, Respiratory Rate, Radiographic Findings, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04434248 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Adaptive Study Of Favipiravir Compared To Standard Of Care In Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chromis Llc$|$Chemical Diversity Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 330 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001805-21 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prospective, Randomised, Parallel-Group, Open-Label Study To Evaluate The Efficacy And Safety Of Imu-838, In Combination With Oseltamivir, In Adults With Coronavirus Disease Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Coventry \& Warwickshire } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Oseltamivir, Oseltamivir + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04424901 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label Study Of The Vascular And Microbiologic Efficacy Of Dipyridamole Plus Standard Care Vs. Standard Care In Hospitalized Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Uconn Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 03/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia;Vascular Complications } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Coagulation Test } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ RPCEC00000311 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Patients With Severe Sars-Cov-2 Pneumonia With The Anti-Cd6 Monoclonal Antibody Itolizumab. (Covid-19) - Victoria } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center Of Molecular Immunology (Cim) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/12/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Sars-Cov-2 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ mAb } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04402879 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corona (Covid Prone Hypoxemia): Prone Positioning For Hypoxemic Covid-19 Patients With Do-Not-Intubate Goals } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Calgary$|$Alberta Health Services } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 596 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome Coronavirus 2$|$Covid-19$|$Acute Respiratory Distress Syndrome$|$ARDS$|$Hypoxemic Respiratory Failure } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001265-36 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicentre, Prospective, Randomised Trial Comparing Standard Of Care (SOC) Alone, SOC Plus Hydroxychloroquine Monotherapy Or SOC Plus A Combination Of Hydroxychloroquine And Azithromycin In The Treatment Of Non-Critical, Sars-Cov-2 Pcr-Positive Population Not Requiring Immediate Resuscitation Or Ventilation But Who Have Evidence Of Clinical Decline. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University College Dublin } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 267 } & 
				\multicolumn{2}{l}{ Status Unclear } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Test Positive } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04312009 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Losartan For Patients With Covid-19 Requiring Hospitalization } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Minnesota$|$Bill And Melinda Gates Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Acute Respiratory Distress Syndrome$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04276688 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Lopinavir/ Ritonavir, Ribavirin And Ifn-Beta Combination For Ncov Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Hong Kong$|$Hospital Authority, Hong Kong } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 30/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 127 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Lopinavir/ritonavir + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, IL-6, Tumor Necrosis Factor (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04317040 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cd24fc As A Non-Antiviral Immunomodulator In Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Oncoimmune, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Coronavirus Disease (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351152 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Study To Evaluate Efficacy And Safety Of Lenzilumab In Hospitalized Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Humanigen, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 238 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19) Pneumonia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000445976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Australasian Covid-19 Trial (Ascot). A Multi-Centre Randomised Clinical Trial To Assess Clinical, Virological And Immunological Outcomes In Patients With Sars-Cov-2 Infection (Covid-19) Treated With Lopinavir/Ritonavir And/Or Hydroxychloroquine Compared To Standard Of Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Melbourne } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2); $<$Br$>$Covid-19 (Sars-Cov-2);Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Lopinavir/ritonavir + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JAPICCTI-205238 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multicenter, Adaptive, Randomised, Placebo-Controlled, Comparative Study To Evaluate The Efficacy And Safety Of Favipiravir In Patients With Covid-19 Non-Severe Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fujifilm Toyama Chemical Co., Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients With Covid-19 Non-Severe Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381936 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Evaluation Of Covid-19 Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford$|$Uk Research And Innovation$|$National Institute For Health Research, United Kingdom$|$Wellcome$|$Bill And Melinda Gates Foundation$|$Department For International Development, United Kingdom$|$Health Data Research Uk$|$Medical Research Council Population Health Research Unit$|$Nihr Clinical Trials Unit Support Funding } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 01/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 15000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8490 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Label Randomised Controlled Trial Of Chloroquine, Hydroxychloroquine Or Only Supportive Care In Patients Admitted With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Umc Utrecht } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/12/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 950 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348071 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Ruxolitinib For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Colorado, Denver } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Hemoglobin, Creatinine Phosphokinase, Prothrombin, ALT, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329572 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Hydroxychloroquine And Azithromycin For The Treatment Of Hospitalized Patients With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azidus Brasil } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04448756 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } M5049 Study In Participants With Coronavirus Disease 2019 (Covid-19) Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Emd Serono Research \& Development Institute, Inc.$|$Merck Kgaa, Darmstadt, Germany$|$Emd Serono } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 13/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, ECG, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04336462 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydrogen-Oxygen Generator With Nebulizer In The Improvement Of Symptoms In Patients Infected With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Asclepius Meditec Inc.$|$Shanghai Public Health Clinical Center$|$Henan Provincial People's Hospital$|$Shenzhen Third People's Hospital$|$The First People's Hospital Of Yunnan$|$Shanghai General Hospital, Shanghai Jiao Tong University School Of Medicine$|$Shanghai 6th People's Hospital$|$Guangdong Provincial Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, Neutrophils, Hemoglobin, Urine Sample, IgG, IgM or IgA, Blood Urea Nitrogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363814 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Impact Of Bactek-R In Subject With Mild Pneumonia Due To Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inmunotek S.l.$|$Bioclever 2005 S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Blood Pressure, Heart Rate, SpO2, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04420299 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial On The Efficacy And Safety Of Bemiparin In Patients Hospitalized Because Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundación De Investigación Hm$|$Syntax For Science, S.l } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Ferritin, D-Dimer, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330690 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatments For Covid-19: Canadian Arm Of The Solidarity Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sunnybrook Health Sciences Centre$|$Abbvie$|$Apotex Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 18/03/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335786 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Valsartan For Prevention Of Acute Respiratory Distress Syndrome In Hospitalized Patients With Sars-Cov-2 (Covid-19) Infection Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboud University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 651 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome$|$Sars-Cov-2$|$Covid$|$Covid-19$|$Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335136 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Recombinant Human Angiotensin-Converting Enzyme 2 (Rhace2) As A Treatment For Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Apeiron Biologics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342182 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma As Therapy For Covid-19 Severe Sars-Cov-2 Disease (Concovid Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Erasmus Medical Center$|$Sanquin Plasma Products Bv } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 426 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338802 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Nintedanib Ethanesulfonate Soft Capsule In The Treatment Of Pulmonary Fibrosis In Patients With Moderate To Severe Covid-9(Covid 19) : A Single-Center, Randomised, Placebo-Controlled Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Huilan Zhang } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Nintedanib;Safety;Effect Of Drugs } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334460 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 2, Randomised, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Antiviral Activity Of Bld-2660 In Hospitalized Subjects With Recently Diagnosed Covid-19 Compared To Standard Of Care Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Blade Therapeutics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343001 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Coronavirus Response - Active Support For Hospitalised Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ London School Of Hygiene And Tropical Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 10000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Presumed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, ARBs + Statins, NSAIDs, NSAIDs + ARBs, NSAIDs + ARBs + Statins, NSAIDs + Statins, Statins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Lung Inflamation, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346147 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Evaluate Efficacy Of 3 Types Of Treatment In Patients With Pneumonia By Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitario De Fuenlabrada$|$Centro Nacional De Investigaciones Oncologicas Carlos Iii } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 165 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Imatinib, (hydroxy)chloroquine + JAKi, (hydroxy)chloroquine + Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343092 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Ivermectin As Add On Therapy In Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Baghdad } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Azithromycin + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348695 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Ruxolitinib Plus Simvastatin In The Prevention And Treatment Of Respiratory Failure Of Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundación De Investigación Hm$|$Apices Soluciones S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ 13/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 94 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi + Statins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04349098 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Activity And Safety Of Oral Selinexor In Participants With Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karyopharm Therapeutics Inc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04440007 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of The Efficacy And Safety Of Sti-5656 (Abivertinib Maleate) With SOC Versus SOC In Subjects With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sorrento Therapeutics, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346615 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Trial Of Zavegepant* Intranasal For Hospitalized Patients With Covid-19 Requiring Supplemental Oxygen } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biohaven Pharmaceuticals, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 25/04/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351490 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Zinc And Vitamin D3 Supplementation On The Survival Of Institutionalized Aged Patients Infected With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Lille } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 3140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Zinc + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04325633 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Addition Of Naproxen In The Treatment Of Critically Ill Patients Hospitalized For Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 13/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 584 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NSAIDs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031430 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of  The Safety And Efficacy For Human Umbilical Cord Mesenchymal Stem Cells In Covid-19 Induced Pulmonary Fibrosis } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Fifth Medical Center Of Pla General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), C-Reactive Protein, Ferritin, IL-6, Interferon (Any), Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, ALT, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas, ECG, SpO2, 6-Minute Walking Distance, Radiographic Findings, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001270-29 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Adaptive Phase 2/3, Randomised, Open-Label Study Assessing Efficacy And Safety Of Hydroxychloroquine For Hospitalized Patients With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanofi-Aventis Recherche \& Développement } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Status Unclear } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04455243 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inflammatory Regulation Effect Of Nac On Covid-19 Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr. Tariq Alhawassi$|$King Saud University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 30/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1180 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8538 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Sleep Position Related To Hospital Length Of Stay In Admitted Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ None. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 342 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200624047908N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Sofosbuvir/Daclatasvir  In Covid-19 Patients: A Randomised Double-Blind Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abadan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 08/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ DAA, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025209 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Label Randomised 
Control Trial On Passive Immunization With Convalescent Plasma In Severe Covid-19 Disease - Picp19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Council Of Scientific And Industrial Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025346 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii, Open Label, Randomised Controlled Trial To Assess The Safety And Efficacy Of Convalescent Plasma In Severe Covid-19 Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Government Of Tamilnadu } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412772 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Rct - Safety \& Efficacy Of Tocilizumab - Tx Of Severe Covid-19: Architects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Queen's Medical Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025328 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } To Assess The Safety And Efficacy Of Convalescent Plasma On Outcome Of Covid-19 Associated Complications - Covid Plasma Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Apollo Hospitals Enterprise Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04451174 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Use Of Corticosteroids In Hospitalized Patients With Moderate Covid19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Chile } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 184 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381377 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Polyoxidonium® In Hospitalized Patients With Coronavirus Disease Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Npo Petrovax } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 394 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infections, Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Immunomodulators, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025804 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Awake Self Proning Strategy In Covid-19: An Open-Labelled Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aiims Jodhpur } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200325046860N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Convalescent Plasma As A Potential Therapy For Covid-19 Infected Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Darmanara .Co } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 20/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346199 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care In Subjects Hospitalized With Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Astrazeneca$|$Acerta Pharma B.v. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 26/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Acalabrutinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Serious Adverse Events, C-Reactive Protein, Ferritin, Lymphocyte Count, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04411446 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cholecalciferol To Improve The Outcomes Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vitamin D Study Group$|$Ag Nac Promoción De La Investigación, El Desarrollo Tecnológico Y La Innovación } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1265 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04317092 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tocilizumab In Covid-19 Pneumonia (Tocivid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Cancer Institute, Naples } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 19/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04375202 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine In Covid-19: A Pilot Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Perugia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 308 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Organ Failure or Dysfunction (SOFA), Ferritin, White Blood Cell Count, ALT } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04326426 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Odyssey: A Study To Investigate The Efficacy Of Tradipitant In Treating Severe Or Critical Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanda Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04444700 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Pragmatic Randomised Controlled Trial Of Therapeutic Anticoagulation Versus Standard Care As A Rapid Response To Covid-19 Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sao Paulo General Hospital$|$St. Michael's Hospital, Toronto$|$University Of Vermont Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 462 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Coronavirus Infection$|$Severe Acute Respiratory Syndrome$|$Thromboembolism, Venous$|$Anticoagulants And Bleeding Disorders } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Platelet Count, Prothrombin, Fibrinogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363372 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study For Efficacy And Safety Of Live Biotherapeutic Mrx4dp0004 To Treat Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ 4d Pharma Plc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04458948 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Open Label Non-Comparative Trial Of The Combination Of Hydroxychloroquine And Azithromycin In The Treatment Of Hospitalized Patients With Moderate Or Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of New Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 10000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363463 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Prone Position In Patients Under Spontaneous Breathing On Intubation Or Non-Invasive Ventilation Or Death Incidence During Covid-19 Acute Respiratory Distress } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Hospitalier Régional D'orléans } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Oxygen Therapy;Prone Position;Spontaneous Ventilation;Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401423 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Txa Covid-19 Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, IL-6, Shock, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04310865 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Adaptive, Randomised, Double-Blind, Parallel-Controlled Clinical Trial Of Yinhu Qingwen Granula For The Treatment Of Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhong Wang } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Severe Pneumonia;Chinese Medicine } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412291 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study In Patients With Covid-19 And Respiratory Distress Not Requiring Mechanical Ventilation, To Compare Standard-Of-Care With Anakinra And Tocilizumab Treatment The Immunomodulation-Cov Assessment (Immcova) Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karolinska University Hospital$|$Karolinska Institutet } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra + Non-invasive respiratory support + Anticoagulants + Antibiotics + Other, Non-invasive respiratory support + Anticoagulants + Antibiotics + Other, Tocilizumab + Non-invasive respiratory support + Anticoagulants + Antibiotics + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000517976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Of Nebulised Heparin In Critically Ill Mechanically Ventilated Patients With Covid-19 To Assess The Effect On  The  Duration Of Mechanical Ventilation. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St Vincents Hospital Melbourne } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 172 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Respiratory Failure ; $<$Br$>$Covid-19 Respiratory Failure ;Respiratory - Other Respiratory Disorders / Diseases;Infection - Other Infectious Diseases } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346355 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Early Administration Of Tocilizumab In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Unità Sanitaria Locale Reggio Emilia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 06/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 126 } & 
				\multicolumn{2}{l}{ Status Unclear } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, IL-6, Lymphocyte Count, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335032 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Study Of Eicosapentaenoic Acid (Epa-Ffa) Gastro-Resistant Capsules To Treat Hospitalized Subjects With Confirmed Sars-Cov-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ S.l.a. Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374526 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Transfusion Of Convalescent Plasma In Elderly Covid-19 Patients. To Prevent Disease Progression. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fondazione Policlinico Universitario Agostino Gemelli Irccs } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 182 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 )Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001759-42 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled, Study Evaluating The Efficacy And Safety Of Otilimab Iv In Patients With Severe Pulmonary Covid-19 Related Disease. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Glaxosmithkline Research \& Development Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001696-32-ES }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open-Label Parallel Group Pilot Study To Evaluate Safety And Efficacy Of High Dose Intravenous Immune Globulin (Ivig) Plus Standard Medical Treatment (Smt) Versus Smt Alone In Hospitalized Subjects With Covid-19 - Study To Evaluate The Safety And Efficacy Of High Dose Ivig In Patients With Mild/Moderate Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Grifols, S.a } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients With Mild To Moderate Coronavirus Disease (Covid-19) $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
 $<$Br$>$Meddra Version: 23.0
Level: Llt
Classification Code 10053983
Term: Corona Virus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04432324 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Safety And Efficacy Of High Dose Ivig In Hospitalized Participants With Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Grifols, S.a.$|$Grifols Therapeutics Llc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Immunoglobulins } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334629 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Liberate Trial In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ King's College London$|$Guy's \& St Thomas Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 25/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Respiratory Distress Syndrome$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ NSAIDs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04459676 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Prospective, Randomised, Double-Blind, Placebo-Controlled Phase 2 Study To Assess Safety And Efficacy Of Ang- 3777 In Patients Hospitalized With Confirmed Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Angion Biomedica Corp } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04391140 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Positioning And High-Flow Nasal Cannula In Covid-19 Induced ARDS } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitari Vall D'hebron Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 248 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$ARDS$|$Acute Respiratory Distress Syndrome$|$Acute Respiratory Failure$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning + Respiratory support, Respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04292730 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Safety And Antiviral Activity Of Remdesivir (Gs-5734™) In Participants With Moderate Coronavirus Disease (Covid-19) Compared To Standard Of Care Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gilead Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 29/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1113 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04413838 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficiency And Security Of Nivolumab Therapy In Obese Individuals With Covid-19(Corona Virus Disease) Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospices Civils De Lyon } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 15/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Obesity, Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Adverse Events, IL-1, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), PD-1, Lymphocyte Count, CD4, CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025161 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised And Comparative Study To Assess Safety And Efficacy Of Supplemental Treatment Of A Herbal Formulation - Aayudh Advance Comprising Essential Oils In Patients With Corona Virus 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ms Shukla Ashar Impex Pvt Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025114 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Favipiravir Combined With Standard  Supportive Care In Adult Indian Patients With Mild To Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Glenmark Pharmaceuticals Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/12/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04495101 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Safety And Efficacy Of Prolastin In Hospitalized Participants With Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Grifols, S.a.$|$Grifols Therapeutics Llc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190418043307N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Effectiveness Of Selenium On Recovery Of Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Deputy Dean Of Research And Technology, Ilam University Of Medical Science } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 27/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, C-Reactive Protein, Ferritin, White Blood Cell Count, Platelet Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466657 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Antioxidant Therapy For Covid-19 Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Obafemi Awolowo University$|$Borno State Ministry Of Health$|$Ogun State Ministry Of Health$|$Abia State Ministry Of Health$|$Sokoto State Ministry Of Health$|$Benue State Minsitry Of Health$|$University Of Calabar Teaching Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04386850 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Oral 25-Hydroxyvitamin D3 And Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences$|$Boston University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335071 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tocilizumab In The Treatment Of Coronavirus Induced Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Inselspital, Berne$|$Roche Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04386616 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Safety And Efficacy Of Mstt1041a (Astegolimab) Or Uttr1147a In Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Genentech, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 24/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Antibodies, Blood Pressure, Heart Rate, ECG, SpO2, Respiratory Rate, Radiographic Findings, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025434 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised, Double-Blind, Placebo-Controlled
Prospective Multicenter Trial To Validate The
Safety And Efficacy Of An Antiviral Drug
Zingivir-H, In Adults With Asymptomatic, Mild Or
Moderate Ncovid-19 Infection. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pankajakasthuri Herbal Research Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 135 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04397562 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Trial Of The Efficacy And Safety Of Levilimab (Bcd-089) In Patients With Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biocad } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 204 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333420 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Open-Label, Randomised Study Of Ifx-1 In Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inflarx Gmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 130 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030179 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Experimental Study Of Novel Coronavirus Pneumonia Rehabilitation Plasma Therapy Severe Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Nanchang University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 24/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ New Treatment Measure Clinical Study } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04293887 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Ifn-<U+0391>2ß In The Treatment Of Novel Coronavirus Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 328 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Recombinant Human Interferon <U+0391>1ß } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030167 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial For Recombinant Human Interleukin-2 In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, C-Reactive Protein, Natural Killer Cell Count, CD4, CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029765 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised Controlled Trial For The Efficacy And Safety Of Tocilizumab In The Treatment Of New Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of University Of Science And Technology Of China (Anhui Provincial Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 10/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 188 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ New Coronavirus Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200421047150N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of Safety, Efficacy And Effective Dose Determination Of Human Umbilical Cord Wharton’s Jelly Mesenchymal Stem Cell Transplantation On Treatment Of Covid-19 (Coronavirus)  Pneumonia And Complications In Humans } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dey Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 16/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412252 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing The Safety And Efficacy Of Tofacitinib In Hospitalized Participants With Covid-19 Pneumonia Who Are Receiving Standard Of Care Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pfizer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025337 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase-Ii, Open Label, Randomised Controlled Trial Of Resveretrol-Copper Plus Standard Treatment Or Sodium-Copper-Chlorophyllin Plus Standard Treatment Versus Standard Treatment In Hospitalized Patients With Pneumonia Due To Sars-Cov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tata Memorial Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029781 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Randomised, Open And Controlled Trial For The Efficacy And Safety Of Kang-Bing-Du Granules In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Union Hospital Affiliated To Tongji Medical College Of Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04288102 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment With Human Umbilical Cord-Derived Mesenchymal Stem Cells For Severe Corona Virus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing 302 Hospital$|$Huoshenshan Hospital$|$Maternal And Child Health Hospital Of Hubei Province$|$General Hospital Of Central Theater Command, Wuhan, China$|$Vcanbio Cell \& Gene Engineering Corp.,Ltd, China } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/02/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 05/03/2020} &
				\multicolumn{2}{l}{ 12/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease 2019(Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ KCT0005003 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Effect Of Nafamostat Mesilate In Patients With Covid-19 Pneumonia: Open Labelled Randomised Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gyeongsang National University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ;Certain Infectious And Parasitic Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase2 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342897 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Ly3127804 In Participants With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Eli Lilly And Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04326920 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Sargramostim In Patients With Acute Hypoxic Respiratory Failure Due To Covid-19 (Sarpac) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Ghent$|$Flanders Institute Of Biotechnology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382755 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Zilucoplan® In Improving Oxygenation And Short- And Long-Term Outcome Of Covid-19 Patients With Acute Hypoxic Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Ghent$|$Ucb Pharma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer, PaO2-FiO2, Radiographic Findings, Hypoxia, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04415086 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Patients With Covid-19 With Convalescent Plasma } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sao Paulo General Hospital$|$Ministério Da Ciência, Tecnologia, Inovações E Comunicações$|$Faculty Of Medicine Of Ribeirão Preto (Fmrp-Usp)$|$Hospital De Clínicas, Faculdade De Medicina Universidade Estadual De Campinas$|$Hospital Sirio-Libanes$|$Hospital Israelita Albert Einstein } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 20/04/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma-based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any), Adverse Events, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405310 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Of Covid-19 To Treat Sars-Cov-2 A Randomised Doble Blind 2 Center Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Grupo Mexicano Para El Estudio De La Medicina Intensiva$|$Hospital General Naval De Alta Especialidad - Escuela Medico Naval$|$National Institute Of Pediatrics, Mexico$|$Instituto Nacional De Enfermedades Respiratorias } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 20/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, Plasma based therapy + (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321278 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Hydroxychloroquine Associated With Azithromycin In Sars-Cov2 Virus (Coalition Covid-19 Brasil Ii) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Israelita Albert Einstein$|$Ems$|$Hospital Do Coracao$|$Hospital Sirio-Libanes$|$Brazilian Research In Intensive Care Network } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ 14/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 440 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections$|$Pneumonia, Viral } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200418047126N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Therapeutic Effect Of Colchicine Plus Chloroquine In Comparison With Chloroquine In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ardabil University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 20/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pulmonary Infection Of Covd19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Colchicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365985 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Immunomodulation Using Naltrexone And Ketamine For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ William Beaumont Hospitals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Acute Respiratory Distress Syndrome$|$Severe Acute Respiratory Syndrome (Sars)$|$Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Opiate antagonists, Opiate antagonists + Anesthetic, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04447469 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Mavrilimumab (Kpl-301) In Participants Hospitalized With Severe Corona Virus Disease 2019 (Covid-19) Pneumonia And Hyper-Inflammation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kiniksa Pharmaceuticals, Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 573 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348656 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For Hospitalized Adults With Covid-19 Respiratory Illness (Concor-1) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamilton Health Sciences Corporation$|$Canadian Blood Services$|$Héma-Québec$|$University Of Toronto$|$Université De Montréal$|$Weill Cornell Medicine/New York-Presbyterian$|$New York Blood Centre$|$Mcmaster University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04433546 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pb1046, A Long-Acting, Sustained Release Human Vip Analogue, Intended To Provide Clinical Improvement To Hospitalized Covid-19 Patients At High Risk For Rapid Clinical Deterioration And Acute Respiratory Distress Syndrome (ARDS). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Phasebio Pharmaceuticals Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 18/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome$|$Coronavirus$|$Hypoxic Respiratory Failure$|$Hypoxemic Respiratory Failure$|$Respiratory Complication$|$Respiratory Insufficiency$|$Cardiac Dysfunction$|$Pneumonia$|$Pulmonary Edema$|$Pulmonary Inflammation$|$Respiratory Failure$|$Cytokine Storm$|$Covid 19$|$Sars-Cov-2$|$Cardiac Event$|$Cardiac Complication$|$Cardiac Failure$|$Cardiac Infarct } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any), Troponin, Antibodies, ECG, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04418518 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Convalescent Plasma For Hospitalized Adults With Acute Covid-19 Respiratory Illness } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Weill Medical College Of Cornell University$|$Hamilton Health Sciences Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma-based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04457817 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Compensatory Reserve Index (Cri) For Management Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Colorado, Denver$|$Children's Hospital Colorado } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Blood Pressure, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401293 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin In High Risk Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Northwell Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 22/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 308 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Pneumonia or ARDS, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381364 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inhalation Of Ciclesonide For Patients With Covid-19: A Randomised Open Treatment Study (Halt Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ola Blennow, Md, Phd$|$Karolinska University Hospital$|$Danderyd Hospital$|$Centrallasarettet Västerås$|$St Goran's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 446 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Pneumonia, Viral$|$ARDS$|$ARDS, Human$|$Sars-Cov2$|$Coronavirus Infection$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04409262 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Efficacy And Safety Of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo In Hospitalized Participants With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hoffmann-La Roche$|$Gilead Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, Remdesivir + Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04453384 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Phase 2 (2a And 2b) Study To Evaluate The Safety And Efficacy Of Xav-19 In Patients With Covid-19 Induced Moderate Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nantes University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 368 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars Virus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347889 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preventing Covid-19 In Healthcare Workers With Hcq: A Rct } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stony Brook University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1212 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Negative } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401475 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Eb05 + SOC Vs. Placebo + SOC In Adult Hospitalized Patients With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Edesa Biotech Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 865 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;ARDS } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04460183 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Assess Efficacy And Safety Of Resp301 Plus Standard Of Care (SOC) Compared To SOC Alone In Hospitalized Participants With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Thirty Respiratory Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 27/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002120-37 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label, Adaptive Randomised, Controlled Multicenter Study To Evaluate The Efficacy And Safety Of Resp301 Plus Standard Of Care (SOC) Compared To SOC Alone In Hospitalized Participants With Covid-19 Requiring Supplemental Oxygen (Nocov2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Thirty Respiratory Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382924 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Open Label Phase 2b/3 Study Of The Safety And Efficacy Of Np-120 (Ifenprodil) For The Treatment Of Hospitalized Patient With Confirmed Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Algernon Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 682 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382729 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Neuromuscular Electrical Stimulation In Patients With Covid19 Associated Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Turin, Italy$|$San Luigi Gonzaga Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Exercise, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Other Mild Symptoms, 6-Minute Walking Distance, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04386447 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase Ii Rct To Assess Efficacy Of Intravenous Administration Of Oxytocin In Patients Affected By Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero-Universitaria Di Parma$|$University Of Parma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 145 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hormone therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04432298 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of The Efficacy And Safety Of Intravenous Pamrevlumab, In Hospitalized Patients With Acute Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fibrogen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 130 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345614 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Auxora In Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Calcimedica, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, IL-17, Tumor Necrosis Factor (Any), Procalcitonin, PaO2-FiO2, SpO2, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200501047258N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigation Of The Effects Of Covid-19 Convalescent Plasma In Acute Respiratory Distress Syndrome Due To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Oroumia University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 05/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04428021 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Standard Or Convalescent Plasma In Patients With Recent Onset Of Covid-19 Respiratory Failure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliera Città Della Salute E Della Scienza Di Torino } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 15/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392232 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Covid 19 Convalescent Plasma In High Risk Patients With Covid 19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Trihealth Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Covid-19$|$Convalescent Plasma } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001662-11-DE }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Randomised, Double-Blind, Placebo-Controlled, Multi-Center Study To Assess The Efficacy And Safety Of Ruxolitinib In Patients With Covid-19 Associated Cytokine Storm (Ruxcovid) - Ruxcovid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharma Ag } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 402 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Associated Cytokine Storm;Therapeutic Area: Diseases [C] - Respiratory Tract Diseases [C08] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04411433 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Hydroxychloroquine And Favipiravir In The Treatment Of Mild To Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Health, Turkey$|$Hacettepe University, Faculty Of Medicine$|$Prof. Dr. Cemil Tascioglu Education And Research Hospital Organization$|$Umraniye Education And Research Hospital$|$Sb Istanbul Education And Research Hospital$|$Sultan Abdulhamid Han Training And Research Hospital, Istanbul, Turkey$|$Tepecik Training And Research Hospital$|$Istanbul University-Cerrahpasa, Cerrahpasa Faculty Of Medicine$|$Ankara University$|$Ankara City Hospital Bilkent$|$Ankara Training And Research Hospital$|$Ege University Hospital (Application And Research Center)$|$Kocaeli Derince Education And Research Hospital$|$Istanbul University, Istanbul Faculty Of Medicine$|$Kayseri City Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 30/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Favipiravir, Favipiravir, Favipiravir + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Viral Load or Clearance, Fever, Adverse Events, C-Reactive Protein, D-Dimer, Prothrombin, ALT, AST, Blood Pressure, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025957 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Open-Label Study To Evaluate The Efficacy And Safety Of Favipiravir And Umifenovir As Compared To Favipiravir Alone In Moderate Hospitalized Adult Indian Covid-19 Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Glenmark Pharmaceuticals Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 158 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Favipiravir + Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04252664 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Remdesivir In Adults With Mild And Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Capital Medical University$|$Chinese Academy Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 10/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 308 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04449718 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vitamin D Supplementation In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Sao Paulo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001411-25-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2 Randomised Single-Blind Study To Evaluate The Activity And Safety Of Low Dose Oral Selinexor (Kpt-330) In Patients With Severe Covid-19 Infection - Low Dose Oral Selinexor In Patients With Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karyopharm Therapeutics Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Covid-19 Infection $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04407182 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Viusid And Asbrip In Hospitalized Patients In Teodoro Maldonado Carbo Specialty's Hospital Infected And Diagnosed By Sars-Cov-2 With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Catalysis Sl } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Sars-Cov2;Diabete Mellitus;Cardiopathy;Pulmonary Disease;Renal Disease;Liver Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029988 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Chloroquine Phosphate In The Treatment Of Severe Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04408235 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial Comparing High Versus Low Lmwh Dosages In Hospitalized Patients With Severe Covid-19 Pneumonia And Coagulopathy Not Requiring Invasive Mechanical Ventilation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero-Universitaria Di Modena } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Pneumonia, Viral;Coagulation Disorder } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04400058 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Octagam 10\% Therapy In Covid-19 Patients With Severe Disease Progression } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Octapharma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 208 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Ferritin, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Troponin, Fibrinogen, INR, ALT, AST, Albumin, Bilirubin, Glucose, LDH, IgG, IgM or IgA, Blood Urea Nitrogen, Blood Pressure, SpO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04315896 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Treatment For Severe Covid-19 Pulmonary Infection (Hydra Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Respiratory Diseases, Mexico$|$Sanofi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001236-10 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Counter-Covid - Oral Imatinib To Prevent Pulmonary Vascular Leak In Covid-19 – A Randomised, Single-Blind, Placebo Controlled, Clinical Trial In Patients With Severe Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Amsterdam Umc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 304 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, Albumin, Bilirubin, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8491 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Countering Lung Damage In Covid-19 Infection (Countercovid) Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Amsterdam Umc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 386 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 Positive Pneumonitis With Need For Hospital Admission } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Albumin, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04257656 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3 Randomised, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Remdesivir In Hospitalized Adult Patients With Severe Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Capital Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 237 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Remdesivir;Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328480 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Ecla Phri Colcovid Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Estudios Clínicos Latino América } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393051 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Baricivid-19 Study: Multicentre, Randomised, Phase Iia Clinical Trial Evaluating Efficacy And Tolerability Of Baricitinib As Add-On Treatment Of In-Patients With Covid-19 Compared To Standard Therapy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliero, Universitaria Pisana } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 126 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Sars-Cov 2;Sars Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ DRKS00021248 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cytokine Adsorption In Patients With Severe Covid-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation – Randomised, Controlled, Open-Label Intervention, Multi-Center Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universitätsklinikum Freiburgklinik Für Innere Medizin Iii } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Emergency Use Of U07.1 (U07.1) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ ECMO, ECMO + Cytokine removal } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, IL-6, D-Dimer, Urine Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395456 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2 Clinical Trial To Assess The Safety And Efficacy Of Complement 3 Inhibitor, Amy-101, In Patients With Acute Respiratory Distress Syndrome Due To Covid-19 (Save) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Amyndas Pharmaceuticals S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 144 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome Due To Sars-Cov-2 Infection (Severe Covid19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030010 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Parallel-Controlled, Trial To Evaluate The Efficacy And Safety Of Anti-Sars-Cov-2 Virus Inactivated Plasma In The Treatment Of Severe Novel Coronavirus Pneumonia Patients (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029757 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For The Treatment Of Severe And Critical Novel Coronavirus Pneumonia (Covid-19): A Prospective Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China-Japan Friendship Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 09/03/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 05/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001497-30 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3 Open-Label, Randomised, Controlled Study To Evaluate The Efficacy And Safety Of Intravenously Administered Ravulizumab Compared With Best Supportive Care In Patients With Covid-19 Severe Pneumonia, Acute Lung Injury, Or Acute Respiratory Distress Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Alexion Pharmaceuticals, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 270 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Lung Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04396067 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Combination With Inhibitor Of Neutrophil Elastase (All-Trans Retinoic Acid ) And Isotretinoin May Enhances Neutralizing Antibodies In Covid -19 Infected Patients Better Than Covid-19 Inactivated Vaccines } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kafrelsheikh University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 360 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid -19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04292899 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Safety And Antiviral Activity Of Remdesivir (Gs-5734™) In Participants With Severe Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gilead Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/03/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 09/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 4891 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04397757 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Convalescent Plasma For The Treatment Of Hospitalized Patients With Pneumonia Caused By Sars-Cov-2. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Pennsylvania } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 13/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04397718 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hormonal Intervention For The Treatment In Veterans With Covid-19 Requiring Hospitalization } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Va Office Of Research And Development } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 06/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 198 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Hormone therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04459286 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Nitazoxanide Plus Atazanavir For Covid-19 Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Obafemi Awolowo University$|$University Of Liverpool$|$African Centre Of Excellence For Genomics Of Infectious Diseases$|$Oyo State Ministry Of Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 98 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04463420 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Phr 160 Spray On The Outcomes Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Baqiyatallah Medical Sciences University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 224 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other + (hydroxy)chloroquine + NSAIDs + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395144 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19: Awake Proning And High-Flow Nasal Cannula In Respiratory Distress } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hôpital De Verdun } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 346 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Covid$|$Severe Acute Respiratory Syndrome$|$Respiratory Failure$|$Respiratory Insufficiency$|$Respiratory Distress Syndrome$|$ARDS$|$Lung Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452435 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of C21 In Subjects With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vicore Pharma Ab$|$Orphan Reach } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338958 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ruxolitinib In Covid-19 Patients With Defined Hyperinflammation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Jena } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 31/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20171122037571N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Single-Arm Multicenter Clinical Trial To Evaluate The Safety And Efficacy Of Remdesivir In Covid-19 Patients With Progressive Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 19/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Remdesivir + Chloroqines + Lopinavir/ritonavir or Atazanavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Cough, Fever, Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452474 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of The Efficacy And Safety Of A Single Administration Of Olokizumab Vs. Placebo In Addition To Standard Treatment In Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Infection (Covid-19). } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ R-Pharm$|$Cromos Pharma, Llc$|$Covance } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 16/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 376 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04320615 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Safety And Efficacy Of Tocilizumab In Patients With Severe Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hoffmann-La Roche } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 28/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04394442 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Samah Lutfy$|$Zagazig University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 21/03/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04391309 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ic14 (Anti-Cd14) Treatment In Patients With Sars-Cov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Implicit Bioscience$|$University Of Washington } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001473-79 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An International, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase Iii Study Evaluating The Efficacy And Safety Of Dapagliflozin In Respiratory Failure In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ George Clinical (Uk) Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SGLT2, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04350593 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dapagliflozin In Respiratory Failure In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Saint Luke's Health System$|$Astrazeneca$|$George Clinical Pty Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SGLT2, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Organ Failure or Dysfunction (SOFA), Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390217 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Lb1148 For Pulmonary Dysfunction Associated With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Leading Biosciences, Inc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus Disease 2019$|$Covid19$|$Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04417257 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Of Lau-7b For The Treatment Of Covid-19 Disease In Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Laurent Pharmaceuticals Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395807 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Helmet Continuous Positive Airway Pressure Versus High-Flow Nasal Cannula In Covid-19: A Pragmatic Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lund University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;Acute Hypoxemic Respiratory Failure } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04402866 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Td-0903 For Ali Associated With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Theravance Biopharma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 159 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Lung Injury (Ali) Associated With Covid-19$|$Lung Inflammation Associated With Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04403100 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine And Lopinavir/ Ritonavir To Improve The Health Of People With Covid-19: "The Hope Coalition - 1" } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cardresearch$|$Cardresearch - Cardiologia Assistencial E De Pesquisa Ltda$|$Cytel Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ 03/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1968 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus Infection$|$Virus Disease$|$Acute Respiratory Infection$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Lopinavir/ritonavir, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04332991 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Outcomes Related To Covid-19 Treated With Hydroxychloroquine Among In-Patients With Symptomatic Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital$|$National Heart, Lung, And Blood Institute (Nhlbi) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 479 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Acute Respiratory Infection$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025704 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3, Prospective, Randomised, Open Label, Comparative, Clinical Study To Evaluate Efficacy And Safety Of Ulinastatin Plus Standard-Of-Care Compared To Standard-Of-Care In Treatment Of Acute Respiratory Distress Syndrome (ARDS) In Hospitalized Covid-19 Infection Patient } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bharat Serums And Vaccines Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: J80- Acute Respiratory Distress Syndrome
Health Condition 2: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Other + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04467840 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Opaganib, A Sphingosine Kinase-2 (Sk2) Inhibitor In Covid-19 Pneumonia: A Randomised, Double-Blind, Placebo-Controlled Phase 2/3 Study, In Adult Subjects Hospitalized With Severe Sars-Cov-2 Positive Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Redhill Biopharma Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 270 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Lung Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024773 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An International Randomised Trial Of Additional Treatments For Covid-19 In
Hospitalised Patients Who Are All Receiving The Local Standard Of Care - Solidarity Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ World Health Organization } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 7000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392531 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Assess Efficacy Of Cyclosporine Plus Standard Of Care In Hospitalized Patients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Investigación Sanitaria De La Fundación Jiménez Díaz } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Cyclosporine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Adverse Events, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, LDH, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN40580903 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Phase Ii Proof Of Principle Multi-Arm Multi-Stage Trial Designed To Guide The Selection Of Interventions For Phase Iii Trials In Hospitalised Patients With Covid-19 Infection. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Birmingham } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 588 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) In Hospitalised Patients $<$Br$>$Respiratory $<$Br$>$Covid-19 (Sars-Cov-2 Infection) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, PaO2-FiO2, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20160316027081N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison Of The Effectiveness Of Standard Treatment With Standard Treatment Plus Licorice Extract In Improving Respiratory Symptoms And Survival Rate In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Artesh University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 20/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 374 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Condition 1: Pneumonia. Condition 2: Acute Bronchitis. Condition 3: Acute Respiratory Distress Syndrome (ARDS). } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20180802040678N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effects Of Losartan In Patients With Corona Virus Disease 2019 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Disease 2019 (Covid-19). } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04393246 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Arm Therapeutic Study In Pre-ICU Patients Admitted With Covid-19 - Experimental Drugs And Mechanisms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge University Hospitals Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 03/07/2020} &
				\multicolumn{2}{l}{ 15/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1407 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SGLT2 + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, Lymphocyte Count, D-Dimer, LDH, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04373733 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Intervention In Covid-19: Favipiravir Verses Standard Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chelsea And Westminster Nhs Foundation Trust$|$Neat Id Foundation$|$Fujifilm Toyama Chemical Co., Ltd.$|$Imperial College London$|$Universitaire Ziekenhuizen Leuven } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Suspected Or Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Zinc, Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024915 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii, Open Label, Randomised Controlled Trial To Assess The Safety And Efficacy Of Convalescent Plasma To Limit Covid-19 Associated Complications } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Max Super Speciality Hospital A Unit Of Devki Devi Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/09/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04422509 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Lanadelumab For Treatment Of Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboud University$|$Takeda } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 03/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ mAB, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN85216856 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Use Of Convalescent Plasma From Patients Who Have Recovered From Covid-19 In The Management Of Ecuadorian Patients Infected With Sars-Cov-2 With Clinical Deterioration: Impact } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad Tecnológica Equinoccial } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Respiratory $<$Br$>$Covid-19 (Sars-Cov-2 Infection) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii/Iii } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029609 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Open-Label, Multiple-Center Study For The Efficacy Of Chloroquine Phosphate In Hospitalized Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Fifth Affiliated Hospital Of Sun Yat-Sen University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 205 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Lopinavir/ritonavir + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN83971151 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An International Randomised Trial Of Additional Treatments For Covid-19 In Hospitalized Patients Who Are All Receiving The Local Standard Of Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ World Health Organization } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 10000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations $<$Br$>$Covid-19 (Sars-Cov-2 Infection) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Iii } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, Lopinavir/ritonavir + Interferon, Remdesivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04327388 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Sarilumab Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanofi$|$Regeneron Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 409 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, Respiratory Rate, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452565 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Na-831, Atazanavir And Dexamethasone Combination Therapy For The Treatment Of Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Neuroactiva, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 15/08/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 525 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Severe Acute Respiratory Infection$|$Severe Acute Respiratory Syndrome Coronavirus 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antiretroviral + Dexamethasone, Other, Other + Antiretroviral, Other + Dexamethasone } & 
				\multicolumn{3}{p{4.5cm}}{ Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04427098 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Enoxaparin In Covid-19 Moderate To Severe Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliera Universitaria Di Bologna Policlinico S. Orsola Malpighi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328012 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid Med Trial - Comparison Of Therapeutics For Hospitalized Patients Infected With Sars-Cov-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bassett Healthcare } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, ARBs, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), C-Reactive Protein, D-Dimer } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200609047707N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effective Of Elman Tablet On Illness Severity And Length Of Hospital Stay In The Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Esfarayen University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 20/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients Infected With Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029496 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open Label, Parallel Controlled Trial For Evaluating The Efficacy Of Recombinant Cytokine Gene-Derived Protein Injection On Clearing Novel Coronavirus In Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Hospital Of Changsha; The Second Xiangya Hospital Of Central South University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 22/03/2020} &
				\multicolumn{2}{l}{ 29/01/2020} &
				\multicolumn{2}{l}{ 29/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Lopinavir/ritonavir + Other, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030003 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Optimization Protocal Of Integrated Traditional Chinese And Western Medicine Treatment For Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04465695 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dual Therapy With Interferon Beta-1b And Clofazimine For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Hong Kong } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 30/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antibiotics, Interferon + Antibiotics, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322344 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Escin In Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Catanzaro$|$Azienda Ospedaliera Pugliese Ciaccio$|$Azienda Ospedaliera Policlinico "Mater Domini" } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030545 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Honeysuckle Oral Liquid In The Treatment Of Novel Coronavirus Pneumonia (Covid-19): A Multicenter, Randomised, Controlled, Open Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029541 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open, Controlled Trial For Darunavir/Cobicistat Or Lopinavir/Ritonavir Combined With Thymosin A1 In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ DRV/c + Other, Lopinavir/ritonavir + Other, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030894 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Favipiravir Combined With Tocilizumab In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) - A Multicenter, Randomised, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University First Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Favipiravir + Tocilizumab, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029603 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Multi-Centre Clinical Trial Evaluating And Comparing The Safety And Efficiency Of Asc09/Ritonavir And Lopinavir/Ritonavir For Confirmed Cases Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Zhejiang University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Other } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04371406 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Azithromycin-Associated Hydroxychloroquine Therapy Given In General Practice In Early-Stage Disease In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 02/05/2020} &
				\multicolumn{2}{l}{ 02/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2770 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, Nutrition } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20170731035423N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of The Combination Of Bcc1 \& Hep-S On The Improvement Of Clinical \& Laboratory Symptoms Of Hospitalized Covid-19 Patients In A Randomised, Double-Blind, Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences, Cancer Research Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 20/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329195 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ace Inhibitors Or Arbs Discontinuation In Context Of Sars-Cov-2 Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris$|$Groupe Hospitalier Pitié-Salpêtrière } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 09/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 554 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ History Of Cardiovascular Disease Treated With Ras Blockers And With Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04394377 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Full Anticoagulation Versus Prophylaxis In Covid-19: Coalizao Action Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Brazilian Clinical Research Institute$|$Hospital Israelita Albert Einstein$|$Hospital Do Coracao$|$Hospital Sirio-Libanes$|$Hospital Moinhos De Vento$|$Hospital Alemão Oswaldo Cruz$|$Beneficência Portuguesa De São Paulo$|$Brazilian Research In Intensive Care Network } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 21/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, D-Dimer, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390594 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Evaluation Of Treatment Regimens In Adult Covid-19 Patients In Senegal } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institut Pasteur De Dakar$|$Fann Hospital, Senegal$|$Ministry Of Health, Senegal$|$Diamniadio Children Hospital, Senegal$|$Dalal Jamm Hospital, Senegal } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 258 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405921 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine, Azithromycin In The Treatment Of Covid-19 Pneumonia: A Randomised,Open-Label,Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Hôpital Universitaire Farhat Hached } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Pneumonia;Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20150716023235N15 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Use Of Sex Hormones In The Control Of Coronavirus Inflammation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 22/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severity Of Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + AZT + NSAIDs, (hydroxy)chloroquine + AZT + NSAIDs + Hormone therapy } & 
				\multicolumn{3}{p{4.5cm}}{ IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04332835 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For Patients With Covid-19: A Randomised, Open Label, Parallel, Controlled Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad Del Rosario$|$Fundación Universitaria De Ciencias De La Salud$|$Ces University$|$Instituto Distrital De Ciencia Biotecnología E Innovacion En Salud } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, Plasma based therapy + (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200517047485N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Efficacy And Side Effects Of Combination Therapy Of Kaletra And Hydroxychloroquine In Comparison With Atazanavir / Ritonavir And Hydroxychloroquine In The Treatment Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Arak University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ 20/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 108 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Atazanavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04380818 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low Dose Anti-Inflammatory Radiotherapy For The Treatment Of Pneumonia By Covid-19: Multi-Central Prospective Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Grupo De Investigación Clínica En Oncología Radioterapia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 106 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia, Viral } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir + Tocilizumab + Azithromycin + Corticosteroids + Anticoagulants + Non-invasive respiratory support, Radiation therapy + (hydroxy)chloroquine + Lopinavir/ritonavir + Tocilizumab + Azithromycin + Corticosteroids + Anticoagulants + Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000557932 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Therapies To Prevent Progression Of Covid-19, Including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 With Or Without Vitamin C, A Multi-Centre, International, Randomised Trial: The International Alliance Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aprof Dr Karin Ried } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19; $<$Br$>$Covid-19;Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Zinc + Vitamins + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04391127 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine And Ivermectin For The Treatment Of Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centenario Hospital Miguel Hidalgo } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Ivermectin, Ivermectin } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200504047298N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Atazanavir/Ritonavir Effect On Covid-19 Patients Treatment In Comparison With Lopinavir / Ritonavir } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Alborz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antiretrovirals, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, C-Reactive Protein, Platelet Count, Erythrocyte Sedimentation Rate, Blood Pressure } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04261907 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating And Comparing The Safety And Efficiency Of Asc09/Ritonavir And Lopinavir/Ritonavir For Novel Coronavirus Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ First Affiliated Hospital Of Zhejiang University$|$Ascletis Pharmaceuticals Co., Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019-Ncov } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Other } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20151227025726N15 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy And Safety Of Umifenovir (Arbidol) Administration In Comparison With Lopinavir-Ritonavir (Kaletra) In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 08/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Invasive Mechanical Ventilation or ECMO, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030946 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effects Of Different Vte Prevention Methods On The Prognosis Of Hospitalized Patients With Novel Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ 10/02/2020} &
				\multicolumn{2}{l}{ 10/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04418128 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Efficacy Of Nafamostat Mesylate For Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gyeongsang National University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ 30/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333251 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Testing Convalescent Plasma Vs Best Supportive Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Baylor Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 31/12/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 115 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia, Interstitial } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20080901001165N59 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Efficacy And Safety Of Niwasha Mouthwash In Controlling The Symptoms Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Niwasha Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 26/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029898 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy And Safety Of Hydroxychloroquine Sulfate In Comparison With Phosphate Chloroquine In Severe Patients With Novel Coronavirus Pneumonia (Covid-19): A Randomised, Open-Label, Parallel, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University Third Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025977 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised And Comparative Study To Assess Safety And Efficacy Of Supplemental Treatment Of A Herbal Formulation - Aayudh Advance Comprising Essential Oils In Patients With Corona Virus 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ms Shukla Ashar Impex Pvt Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200610047722N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparing The Efficacy Of Allicin Derivatives Capsule And Placebo As An Adjuvant For Patients With Covid-19: A Double-Blind Randomised Placebo Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hossein Nik Tale } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/06/2020} &
				\multicolumn{2}{l}{ 22/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Condition 1: Covid-19. Condition 2: Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 (Exploratory Trials) } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04385836 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Alpha One Antitrypsin Inhalation In Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Health, Saudi Arabia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04403646 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tannin Specific Natural Extract For Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital De Clinicas José De San Martín$|$Silvateam } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov 2$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030398 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Trial For Evaluation Of  The Efficacy And Safety Of Bismuth Potassium Citrate Capsules In The Treatment Of Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 340 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, SpO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04331054 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protective Role Of Inhaled Steroids For Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 436 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection;Hospitalization In Respiratory Disease Department } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321096 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Impact Of Camostat Mesilate On Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Aarhus } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 580 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030718 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Chloroquine Phosphate In The Treatment Of 2019-Ncov Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 12/03/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Cyclosporine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Serious Adverse Events, Granulocyte Stimulaiting Factor, White Blood Cell Count, Monocyte Count, Natural Killer Cell Count, Neutrophils, ALT, Albumin, Bilirubin, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328493 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Vietnam Chloroquine Treatment On Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Oxford University Clinical Research Unit, Vietnam$|$Ministry Of Health, Vietnam$|$Hospital For Tropical Diseases, Ho Chi Minh City, Vietnam$|$Cu Chi Covid Hospital, Vietnam$|$Can Gio Covid Hospital, Vietnam$|$Cho Ray Hospital$|$National Hospital For Tropical Diseases, Hanoi, Vietnam$|$Department Of Health, Ho Chi Minh City } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04456413 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma As Treatment For Subjects With Early Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hackensack Meridian Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 306 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445623 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prasugrel In The Prevention Of Severe Sars-Cov2 Pneumonia In Hospitalised Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azienda Ospedaliera Universitaria Integrata Verona } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 128 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Thrombosis } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antiplatelet, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377568 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Human Coronavirus-Immune Convalescent Plasma For The Treatment Of Covid-19 Disease In Hospitalized Children } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Hospital For Sick Children$|$C17 Council (Regulatory Sponsor) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 01/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hospitalized Children$|$Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Adverse Events, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04379492 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Hydroxycholoroquine Compared To Placebo As Treatment For People With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Memorial Sloan Kettering Cancer Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Covid19$|$Sars-Cov2$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04388410 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Convalescent Plasma Transfusion For Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran$|$Hospital San Jose Tec De Monterrey$|$Instituto Nacional De Enfermedades Respiratorias$|$Instituto Nacional De Cardiologia Ignacio Chavez$|$Hospital General Dr. Manuel Gea González$|$Instituto Nacional De Cancerologia, Columbia$|$Hospital Regional De Alta Especialidad Del Bajio } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04467151 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Administration Of Anti-Sars-Cov-2 Convalescent Plasma In Hospitalized, Non-ICU Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kashif Khan$|$University Of Southern California } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/10/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma-based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200316046792N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Formulation Of Two Natural Products (Syrup And Solution) And Evaluation Of Their Effects In Patients With Coronavirus Disease 2019 (Covid-19): A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Iran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 20/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Cough, Fever, Treatment-emergent Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200518047497N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effect Of Dinvl Medicinal Herb  On Improving Of Clinical And Paraclinical Symptoms In Patients With Covid-19 :A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zahravi Pharmaceutical Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/06/2020} &
				\multicolumn{2}{l}{ 20/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200607047675N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Randomised Controlled Trial Comparing The Effectiveness Of Traditional Medicine Combination Based On The Ferula Assa-Foetida Gum - Tragacanth With Moderate To Severe Coronavirus Disease (Covid-19) Compared To Standard Treatment } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 05/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Lymphocyte Count, Platelet Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200411047016N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating Efficacy And Safety Of Stopcivir (Zataria Multiflora Boiss+ Alium Sativum+ Heracleum Persicum+ Satureja Hortensis+ Dianthus+ Foeniculum Vulgare+ Opium) Syrup On Length Of Hospitalization In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mazandaran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ 06/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid- 19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025271 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Two Arm, Controlled Clinical Trial To Compare The Efficacy And Safety Of Mycobacterium W (Mw) Administered Along With Standard Of Care Versus Placebo Administered Along With Standard Of Care, In Adult, Covid 19 Positive Patients Hospitalized But Not Critically Ill. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cadila Pharmaceuticals Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372589 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Antithrombotic Therapy To Ameliorate Complications Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Manitoba } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 3000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029822 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Honeysuckle Decoction In The Treatment Of Patients With Novel Coronavirus (Covid-19) Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nanjing Second Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 07/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001224-33-DE }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial Of Hydroxychloroquine Versus Placebo For The Treatment Of Adult Patients With Acute Coronavirus Disease 2019 – Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universitätsklinikum Tübingen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 220 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Coronavirus Disease 2019 $<$Br$>$Meddra Version: 20.1
Level: Pt
Classification Code 10053983
Term: Corona Virus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322396 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Proactive Prophylaxis With Azithromycin And Hydroxychloroquine In Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chronic Obstructive Pulmonary Disease Trial Network, Denmark } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 226 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Virus Diseases$|$Infection Viral$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Blood Gas, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04449380 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For The Treatment With Interferon-Ss-1a (Ifnß-1a) Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Irccs San Raffaele } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 126 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20080901001165N53 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Efficacy And Safety Of Interferon Beta1a Nasal Spray In Controlling The Symptoms Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 14/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001023-14 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Double-Blind Placebo-Controlled Trial To Determine The Safety And Efficacy Of Inhaled Sng001 (Ifnß-1a For Nebulisation) For The Treatment Of Patients With Confirmed Sars-Cov-2 Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Synairgen Research Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Blood Pressure, Heart Rate, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374032 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Evaluate The Efficacy And Safety Of An Immunomodulatory Therapy For The Treatment Of Patients With Moderate To Severe Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bosnalijek D.d } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04273321 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Corticosteroids In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Chao Yang Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 15/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Novel Coronavirus Pneumonia } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04436458 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 2, Multicentre, Randomised, Double Blind, 2 Arms Placebo-Controlled Study In Adults With Moderate Covid-19 With Gastrointestinal Signs And Symptoms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ First Wave Bio, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Stool Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04401202 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nigella Sativa In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ King Abdulaziz University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Radiographic Findings, Hypoxia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04404361 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 3 Randomised, Double-Blind, Placebo-Controlled, Multicenter Study Of Pacritinib Plus Standard Of Care Versus Placebo And Standard Of Care In Hospitalized Patients With Severe Covid-19 With Or Without Cancer } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cti Biopharma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 358 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030022 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Parallel, Randomised Controlled Clinical Trial For The Efficacy And Safety Of Pediatric Huatanzhike Granules (Containing Ipecacuanha Tincture) In The Treatment Of Mild And Moderate Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ First Affiliated Hospital Of Anhui Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 22/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Lung Inflamation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04282902 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Efficacy And Safety Of Pirfenidone With Novel Coronavirus Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Huilan Zhang$|$Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 294 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia$|$Pneumonia$|$Pirfenidone } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04385043 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hyperimmune Plasma In Patients With Covid-19 Severe Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Catanzaro$|$Azienda Ospedaliera Policlinico "Mater Domini"$|$Azienda Sanitaria Provinciale Di Catanzaro$|$Annunziata Hospital, Cosenza, Italy$|$Azienda Ospedaliera Bianchi-Melacrino-Morelli } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 15/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Lymphocyte Count } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20080901001165N58 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Efficacy And Safety Of Plasmapheresis In Patients With Moderate To Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, SpO2, Shock, Hypoxemia } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04439071 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate Efficacy And Safety Of Ptc299 In Hospitalized Participants With Coronavirus (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ptc Therapeutics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 30/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 380 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia$|$Covid-19$|$Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Dyspnea, Treatment-emergent Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200508047346N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Efficacy And Safety Of Rabbit Polyclonal Antibody (Coviglobulin) In Patients With Coronavirus Covid-19 Virus Moderate To Severe } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kowsar Biotechnology Co. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 19/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 124 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Emerging Pneumonia Caused By The Covid Virus 19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Fever, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001162-12-FR }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Adaptive Phase 2/3, Randomised, Double-Blind, Placebo-Controlled, Study Assessing Efficacy And Safety Of Sarilumab For Hospitalized Patients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanofi-Aventis Recherche Et Développement } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 460 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection $<$Br$>$Meddra Version: 20.1
Level: Pt
Classification Code 10053983
Term: Corona Virus Infection
System Organ Class: 10021881 - Infections And Infestations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious or Seconday Infections, Serious Adverse Events, ALT } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200314046774N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of Vitamin A Effectiveness On Covid-19 Patients And Treatment Outcomes Referred To Health Centers Of Qom Province } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ghoum University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 13/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 94 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20170922036314N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Effects Of Self-Care Mobile Application On Psychologic Parameters Of Admitted Patients With Covid-19: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ 28/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 112 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Serious or Seconday Infections, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029763 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study On Prevention And Treatment Of Novel Coronavirus Pneumonia (Covid-19) With Traditional Chinese Medicine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China Academy Of Chinese Medical Sciences; Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 408 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, Radiographic Findings, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029438 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial Of Integrated Tcm And Western Medicine In The Treatment Of Severe Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Hospital Of Traditional Chinese Medicine; Hubei Integrated Traditional Chinese And Western Medicine Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 01/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04454307 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Tramadol In Covid-19 Egyptian Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030779 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label, Controlled Trial For The Efficacy And Safety Of  Ulinastatin Injection In The Treatment Of Patients With Severe Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Changzheng Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/03/2020} &
				\multicolumn{2}{l}{ 14/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200405046951N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Supplementation With Vitamin A On Improvement Of Symptoms Of Acute Respiratory Syndrome In Patients With Covid-19: A Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Iran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 21/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20081011001323N25 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison  Efficacy  Of  Extract  Plants Of Zingiber , Cinnamon , Zataria Multiflora With Standard Protocol In Treatment And Clinical Improvement Of Patients With Moderate To Severe Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yasouj University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 20/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029755 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open, Parallel-Controlled Clinical Trial On The Efficacy And Safety Of Jingyebaidu Granules In Treating Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital, Tongji Medical College Of Hust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030469 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Parallel Controlled Trial For Liushenwan In Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai University Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ 27/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Pneumonia or ARDS, Fever, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030001 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Triazavirin For 2019 Novel Coronary Pneumonia (Covid-19): A Multicenter, Randomised, Double Blinded, Placebo-Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Health Commission Of Heilongjiang Province } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 15/02/2020} &
				\multicolumn{2}{l}{ 28/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030254 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Favipiravir For Novel Coronavirus–Infected Pneumonia: A Multicenter, Randomised, Open, Positive, Parallel-Controlled Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongnan Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Completed w. Results } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030853 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Protective Effect Of Dexmedetomidine On Patients With Severe New Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Critical Care Medicine, The Third Affiliated Hospital Of Zunyi Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ CK-MB, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCTS031190226 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Multi-Center Open Trial To Evaluate The Safety And Efficacy Of Favipiravir In Patients Infected With Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tokue Yutaka } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients Infected With Covid-19 $<$Br$>$Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-002472-12 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Lanadelumab For Treatment Of Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboud University Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Status Unclear } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ mAb } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338906 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Efficacy And Safety Of Camostat Mesilate + Hydroxychloroquine Combination Therapy In Hospitalized Patients With Moderate Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Heinrich-Heine University, Duesseldorf } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 334 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), C-Reactive Protein, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390464 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Arm Therapeutic Study In Pre-ICU Patients Admitted With Covid-19 - Repurposed Drugs (Tactic-R) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge University Hospitals Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 07/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1167 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, mAb, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329832 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Vs. Azithromycin For Hospitalized Patients With Suspected Or Confirmed Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Intermountain Health Care, Inc.$|$University Of Utah } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed And Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025590 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Centric, Double Blind, Randomised, Comparative, Parallel-Group, Placebo-Controlled,
Phase Iii Clinical Trial To Evaluate The Efficacy And Safety Of Polyherbal Capsule
Astha-15 Used As An Add On Therapy With Standard Care Of Therapy As An Immunity Booster, Anti-Cough, Expectorant, Anti Inflammatory, Cardio-Protective, Hepato-Protective, Broncho-Protective In The Suspected And Covid-19 Diagnosed Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dalmia Centre For Research And Development } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: J00-J99- Diseases Of The Respiratory System } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04410328 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Aggrenox To Treat Acute Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rutgers, The State University Of New Jersey$|$Boehringer Ingelheim } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 132 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032456 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For The Effects Of Low-Oxygen Consumption Instruction On The Prognosis Of Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Public Health Clinical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Education + Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04380402 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Atorvastatin As Adjunctive Therapy In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mount Auburn Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Statins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Visits or Returns to Emergency Department, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025319 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Angiotensin Receptor Blocker Losartan For Prevention Of Covid 19 Complications: A Randomised Placebo Controlled Trial - Licci } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanjay Gandhi Post Graduate Institute Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 186 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Unclear } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001303-16-FR }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine, Telmisartan And Azithromycin On Survival In Elderly Hospitalized Patients With Vidoc-19 : A Randomised, Multi-Centre, Adaptive, Blinded Study - Covid-Aging } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hôpitaux Universitaires De Strasbourg } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1600 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection;Therapeutic Area: Diseases [C] - Bacterial Infections And Mycoses [C01] } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): No
Therapeutic Confirmatory - (Iii): Yes
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Alternative therapy, ARBs, Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Serious Adverse Events, C-Reactive Protein, Blood Pressure, 6-Minute Walking Distance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359095 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness And Safety Of Medical Treatment For Sars-Cov-2 (Covid-19) In Colombia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad Nacional De Colombia$|$Pontificia Universidad Javeriana$|$Clínica Universitaria Colombia$|$Hospital Universitario San Ignacio$|$Hospital Universitario Nacional De Colombia$|$Clínica Reina Sofía$|$Fundación Cardio Infantil$|$Hospital Universitario De Neiva } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 11/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1600 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362189 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Study Of Allogeneic Hb-Admscs For The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hope Biosciences$|$Advanced Diagnostics Healthcare$|$Hope Biosciences Stem Cell Research Foundation$|$United Memorial Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Azithromycin + Stem cell therapy, SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Monocyte Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Prothrombin, Electrolytes, INR, ALT, Albumin, Bilirubin, Glucose, CD4, CD8, Blood Urea Nitrogen, Blood Gas, ECG, SpO2, Bicarbonates, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200324046850N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison Of Vitamin D3 And N-Acetylcysteine Prescription In Covid19 Patients   And Their Effect On Recovery Process } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abadan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/06/2020} &
				\multicolumn{2}{l}{ 07/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC, Vitamins, Vitamins + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20130812014333N147 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Assessment Of The Efficacy And Safety Of Addon Treatment With “Sofosbuvir-Daclatasvir”, “Lithium”,And “Trifluoprazine” To “Standard Of Care In Three Groups Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kermanshah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 09/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, DAA, Lithium, Other } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20120225009124N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Different Methods Of Administeration Of Combination Regiemn Including Dexamethasone, Iv-Ig And Interferone Beta For Treatment Of Patients With Severe Covid-19: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gorgan University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 19/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 105 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, Corticosteroids + Immunoglobulins + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200318046812N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of “Hydroxychloroquine + Azithromycin + Naproxen + Prednisolone” And “Hydroxychloroquine + Azithromycin + Naproxen” Regimens In Comparison With “Hydroxychloroquine + Kaletra” On The Need For Intensive Care Unit Treatment In Patients With Covid-19; A Randomised, Multicenter, Parallel Groups, Open Label Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 11/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 906 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Corticosteroids, (hydroxy)chloroquine + Azithromycin + NSAIDs, (hydroxy)chloroquine + Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344444 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment In Patients With Suspected Or Confirmed Covid-19 With Early Moderate Or Severe Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lcmc Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 10/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04358081 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Monotherapy And In Combination With Azithromycin In Patients With Moderate And Severe Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharmaceuticals$|$Novartis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 02/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 444 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372082 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine And Diltiazem-Niclosamide Combination For The Treatment Of Non-Severe Forms Of Sars-Cov2 Infection In Patients With Co-Morbidities: Multicenter, Randomised, Open-Labeled Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Lille } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2;Sars-Cov2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, CCB + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370262 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Site Adaptive Trials For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Northwell Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 07/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 942 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355052 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open-Label Study To Compare The Efficacy, Safety, And Tolerability Of Hydroxychloroquine Combined With Azithromycin Compared To Hydroxychloroquine Combined With Camostat Mesylate And To "No Treatment" In Hospitalized Patients Suffering From A Mild Or Moderate Sars Cov 2 Virus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sheba Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid - 19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04357860 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Sarilumab In Adults Hospitalized With Covid-19 Presenting Cytokine Release Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Maimónides Biomedical Research Institute Of Córdoba } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2;Sars } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359953 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine, Telmisartan And Azithromycin On The Survival Of Hospitalized Elderly Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Strasbourg, France } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 25/04/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, ARBs, Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355026 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Bromhexine And Hydroxychloroquine For Treatment Of Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ General And Teaching Hospital Celje } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Other } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363060 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Azithromycin+Amoxicillin/Clavulanate Vs Amoxicillin/Clavulanate In Covid19 Patients With Pneumonia In Non-Intensive Unit } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nantes University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 30/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 104 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Amoxicillin/clavulanate, Azithromycin + Amoxicillin/clavulanate } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366960 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparison Of Two Doses Of Enoxaparin For Thromboprophylaxis In Hospitalized Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Niguarda Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 2712 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-6, D-Dimer, Radiographic Findings, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360824 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Associated Coagulopathy } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Iowa } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 16/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 170 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 Associated Coagulopathy } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200411047025N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Effectiveness<U+200E> Of Intravenous Vitamin C In Patients With Covid-19 Referred To Imam <U+200E>Khomeini Hospital: A Clinical Trial <U+200E> } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 19/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antiretroviral, (hydroxy)chloroquine + Antiretroviral + Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, C-Reactive Protein, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200322046833N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Efficacy And Safety Of Umifenovir In The Treatment Of Hospitalized Patients With Covid-19: A Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center For Progress And Development Of Iran } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ 20/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antiretrovirals, (hydroxy)chloroquine + Antiretrovirals + Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04367077 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multistem Administration For Covid-19 Induced ARDS (Macovia) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Athersys, Inc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 01/09/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ ARDS } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Treatment-emergent Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366089 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Oxygen-Ozone As Adjuvant Treatment In Early Control Of Covid-19 Progression And Modulation Of The Gut Microbial Flora } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Roberto Poscia Md, Phd$|$Azienda Policlinico Umberto I } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 152 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Sars-Cov 2$|$Pneumonia, Viral$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, (hydroxy)chloroquine + Azithromycin + Non-invasive respiratory support + Nutrition } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, IL-6, IL-10, Tumor Necrosis Factor (Any), CD8 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20150808023559N20 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Safety And Efficacy Of Hydroxychloroquine Plus Favipiravir Drug Regimen In Comparison With Hydroxychloroquine Plus Kaletra In  Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ardabil University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1-2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, Favipiravir + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200318046812N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Safety And Efficacy Of Hydroxychloroquine Plus Favipiravir Drug Regimen In Comparison With Hydroxychloroquine Plus Kaletra On The Need For Intensive Care Unit Treatment In Patients With Covid-19; A Randomised, Multicenter, Parallel Groups, Open Label Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bagheiat-Allah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 324 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Favipiravir, (hydroxy)chloroquine + Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20130812014333N145 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Assessment Of The Efficacy And Safety Of Add Ontreatment With “Sofosbuvir Plus Velpatasvir” To “Standard Of Care Therapeutic Regimen” In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kermanshah University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 10/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Lopinavir/ritonavir + DAA } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20180725040596N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Effect Of Arbidol Drug In The Treatment Of Hospitalized Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Iran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 22/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, (hydroxy)chloroquine + Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200420047147N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy And Safety Of Sitagliptin Administration In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 05/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia Of Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir, DPP-4i } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200317046797N3 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } To Evaluate The Effectiveness Of Intravenous Immunoglobulin (Ivig) For The Treatment Of Covid-19-Induced Cytokine Storm } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 22/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Condition 1: Covid-19. Condition 2: Coronavirus (Covid-19)-Induced Pneumonia. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Lopinavir/ritonavir + Antivirals, Immunoglobulins + (hydroxy)chloroquine + Lopinavir/ritonavir + Antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200312046749N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy Of Tumor Necrosis Factor Alpha Inhibitor In Covid-19 Outcomes: A Prospective Clinical Trial Study. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 29/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, TNF inhibitor } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20151227025726N14 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy And Safety Of Favipiravir Made By Shahid Beheshti University Of Medical Sciences In Comparison With Lopinavir-Ritonavir In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ 07/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 84 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359810 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Plasma Therapy Of Covid-19 In Critically Ill Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Max R. O'donnell$|$New York Blood Center$|$Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 105 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200415047092N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Effectiveness Of Azithromycin In Patients With Covid-19 Referred To Zeiaeian Hospital : A Clinical Trial Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 08/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 Associated Infection. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Azithromycin + Oseltamivir + Lopinavir/ritonavir + Antiretroviral + (hydroxy)chloroquine, Oseltamivir + Lopinavir/ritonavir + Antiretroviral + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04367168 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine Twice Daily During 10 Days As An Option For The Treatment Of Symptoms Induced By Inflammation In Patients With Mild And Severe Coronavirus Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 27/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 174 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Fever, Other Mild Symptoms, Ferritin, D-Dimer, Fibrinogen, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355676 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Activity And Safety Of Two Regimens Of Low Dose Oral Selinexor In Participants With Moderate Or Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Karyopharm Therapeutics Inc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, C-Reactive Protein, Ferritin, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345692 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Clinical Trial: Hydroxychloroquine For The Treatment Of Covid-19 In Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Queen's Medical Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Heart Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04357457 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Intravenous Almitrine In Reducing The Need For Mechanical Ventilation In Patients With Hypoxemic Acute Respiratory Failure Due To Covid-19-Related Pneumonia: A Randomised Controlled Double-Blind Study From The Skip-ICU Consortium } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 212 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19;Hypoxemic Respiratory Failure } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory stimulant, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364893 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Angiotensin Receptor Blockers And Angiotensin-Converting Enzyme Inhibitors And Adverse Outcomes In Patients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ D'or Institute For Research And Education$|$Brazilian Clinical Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 700 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ ARBs + ACEi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20101219005416N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of  The Effect Of Traditional Medicine Product Incorporated In The Base Of  Astragalus Gossypinus  With Food  Spice On Improvement Of Clinical Menifestation Of Covid -19 Patients With Conventional Protocol } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kerman University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 19/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, SpO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365699 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cardiovascular Effects Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Invasive Mechanical Ventilation or ECMO, Adverse Events, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190727044343N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Atorvastatin Effect In Clinical And Laboratory Findings Of Patiens With Covid-19 Admitted Razi Referral Hospital In Mazandaran State: A Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mazandaran University Of Medical Sceinces } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ 13/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19). } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2-3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Statins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360096 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inhaled Aviptadil For The Treatment Of Moderate And Severe Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Neurorx, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 288 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2$|$Covid$|$ARDS$|$Ali$|$Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)$|$Dyspnea } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Inhaled solution, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Dyspnea, PaO2-FiO2, 6-Minute Walking Distance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355637 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inhaled Corticosteroid Treatment Of Covid19 Patients With Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sara Varea$|$Fundacion Clinic Per A La Recerca Biomédica } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, LDH, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366908 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention And Treatment With Calcifediol Of Covid-19 Induced Acute Respiratory Syndrome } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Maimónides Biomedical Research Institute Of Córdoba$|$Junta De Andalucía - Consejería De Salud Y Familias$|$Dynamic Solutions$|$Faes Farma } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 28/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1008 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2$|$Covid19$|$Sars (Severe Acute Respiratory Syndrome)$|$Cytokine Release Syndrome$|$Cytokine Storm } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, Dyspnea, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355429 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Captopril In Covid-19 Patients With Severe Acute Respiratory Syndrome (Sars) Cov-2 Pneumonia (Captocovid) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 230 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia$|$Coronavirus Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ ACEi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354805 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Administration Of Chlorpromazine As A Treatment For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cairo University$|$Noha Mahmoud Nasreldin Hassan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360980 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effects Of Standard Protocol With Or Without Colchicine In Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shahid Beheshti University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 20/03/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364737 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma To Limit Covid-19 Complications In Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health$|$Albert Einstein College Of Medicine$|$Yale University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 31/01/2023} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362176 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Passive Immunity Trial Of Nashville Ii For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanderbilt University Medical Center$|$Dolly Parton } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Quality of Life, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354389 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Das181 For Stop Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ansun Biopharma, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 82 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366271 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue In Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Infantil Universitario Niño Jesús, Madrid, Spain$|$Apices Soluciones S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 106 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360876 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Targeted Steroids For ARDS Due To Covid-19 Pneumonia: A Pilot Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Colorado, Denver } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$ARDS } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Dexamethasone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, Quality of Life, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362085 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Coagulopathy Of Covid-19: A Pragmatic Randomised Controlled Trial Of Therapeutic Anticoagulation Versus Standard Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Michael's Hospital, Toronto$|$University Of Vermont Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 462 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Platelet Count, D-Dimer, Prothrombin, Fibrinogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04369742 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treating Covid-19 With Hydroxychloroquine (Teach) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health$|$State University Of New York - Downstate Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 626 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, IL-6, Platelet Count, Hemoglobin, ALT, AST, Bilirubin, Glucose, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04361318 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine And Nitazoxanide Combination Therapy For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tanta University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Ferritin, IL-6, Tumor Necrosis Factor (Any), Prothrombin, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04357613 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Non-Comparative Phase 2 Pilot Study Testing The Value Of Imatinib Mesylate As An Early Treatment Of Covid-19 Disease In Aged Hospitalized Patients. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Versailles Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 99 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars Virus } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Imatinib, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352400 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Nafamostat In Covid-19 Patients (Racona Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Padova$|$Yokohama City University$|$University Of Zurich } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 256 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365101 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Natural Killer Cell (Cynk-001) Infusions In Adults With Covid-19 (Cynk-001-Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Celularity Incorporated$|$Idri$|$Lung Biotechnology Pbc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Coronavirus Infection$|$Severe Acute Respiratory Syndrome Coronavirus 2$|$Pneumonia$|$Pneumonia, Viral$|$Lung Diseases$|$Respiratory Tract Disease$|$Respiratory Tract Infections$|$Coronaviridae Infections$|$Nidovirales Infections$|$Rna Virus Infections$|$Virus Disease$|$Immunologic Disease$|$ARDS$|$Immunologic Factors$|$Physiological Effects Of Drugs$|$Antiviral Agents$|$Anti-Infective Agents$|$Analgesics$|$Antimetabolites, Antineoplastic } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Natural Killer Cells, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370223 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ozone Auto-Hemotherapy For Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Institut D'investigació Biomèdica De Girona Dr. Josep Trueta$|$Clinica Nuestra Senora Del Rosario } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 25/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 208 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospital Discharge, Clinical Improvement Score (Any), Ferritin, Lymphocyte Count, Neutrophils } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365257 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prazosin To Prevent Covid-19 (Prevent-Covid Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Johns Hopkins University$|$Fast Grants } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 220 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359511 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Corticosteroids In Oxygen-Dependent Patients With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Tours } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 210 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366856 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Positioning In Covid-19 Oxygeno-Dependent Patients In Spontaneous Ventilation (Provid Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid;ARDS } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343963 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pyridostigmine In Patients With Severe Acute Respiratory Syndrome Secondary To Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 436 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Sars-Cov-2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366050 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ramipril For The Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of California, San Diego$|$Pfizer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 560 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ ACEi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362137 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Randomised, Double-Blind, Placebo-Controlled Multi-Center Study To Assess The Efficacy And Safety Of Ruxolitinib In Patients With Covid-19 Associated Cytokine Storm (Ruxcovid) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novartis Pharmaceuticals$|$Incyte Corporation$|$Novartis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 21/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 402 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Cytokine Storm (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ JAKi, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364763 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Effect Of Rbt-9 On Progression Of Covid-19 In High-Risk Individuals (The Prevent Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renibus Therapeutics, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 30/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 252 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Fever, Organ Failure or Dysfunction (SOFA), SpO2, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359901 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Sarilumab For Patients With Moderate Covid-19 Disease: A Randomised Controlled Trial With A Play-The-Winner Design } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Westyn Branch-Elliman } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Sarilumab, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365517 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Sitagliptin Treatment In Covid-19 Positive Diabetic Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Milan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 170 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Diabetes Mellitus, Type 2;Ckd } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ DPP-4i, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20080901001165N48 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Efficacy Of Zofa (A Herbal Medicine) In Symptom Management Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Niak Pharmaceutical Company } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363541 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Clinical Study Of Local Thermotherapy For Patients With Moderate Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Perinatologia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 298 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Thermotherapy } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372186 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Efficacy And Safety Of Tocilizumab In Hospitalized Participants With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Genentech, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 05/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 379 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, SpO2, Respiratory Rate, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04356937 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Tocilizumab To Prevent The Progression Of Hypoxemic Respiratory Failure In Hospitalized Non-Critically Ill Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 278 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04358939 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prone Position In Patients On High-Flow Nasal Oxygen Therapy For Covid-19 (High-Prone-Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Tours } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 10/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 248 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Distress Syndrome$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Patient Positioning } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04358809 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Mycobacterium W In Covid-19 Positive Patients, Hospitalized But Not Critically Ill } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cadila Pharnmaceuticals$|$Council Of Scientific And Industrial Research, India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 28/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20080901001165N46 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Efficacy And Safety Of Umifenovir In Controlling The Symptoms Of Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center For Progress And Development Of Iran } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 22/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Cough, Fever, Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001320-34-NL }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Double-Blind, Placebo-Controlled Randomised Clinical Trial With Valsartan For Prevention Of Acute Respiratory Distress Syndrome In Hospitalized Patients With Sars-Cov-2 Infection Disease (Covid-19) - Praetorian-Covid } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboudumc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 641 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200402046923N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effects Of Viroherb Capsule And Fenugreek Syrup Derived From Traditional Persian Medicine On Clinical And Paraclinical Outcomes And Survival Of Patients With Mild To Moderate Covid-19 Hospitalized In Medical Centers Of Tehran University Of Medical Sciences } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ 06/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events, ALT } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000454976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } High-Dose Intravenous Zinc (Hdivzn) As Adjunctive Therapy In Covid-19 Positive Critically Ill Patients: A Pilot Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Austin Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/09/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection;Acute Respiratory Distress Syndrome; $<$Br$>$Covid-19 Infection $<$Br$>$Acute Respiratory Distress Syndrome;Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 / 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359797 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Patient Positioning Pragmatic Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanderbilt University Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Positioning } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341584 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corimuno-Ana: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200411047030N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Adding Melatonin To Routine Treatment On Outcomes And Quality Of Sleep In Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mazandaran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 82 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Unspecified } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Melatonin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Fever, Other Mild Symptoms, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355897 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Plasma In Treatment Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Christ Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04356482 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Determination Of The Dose And Effectiveness Of Convalescent Plasma In Severely And Very Severely Ill Patients By Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Seguridad Y Servicios SOCiales De Los Trabajadores Del Estado } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Sars-Cov 2;Convalescence;Plasma;Doses } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000472976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Adapting The Decathlon Group Easybreathe® Snorkelling Face Mask For The Safer Administration Of Oxygen And/Or Continuous Positive Airway Pressure And In The Intra/Interhospital Transportation Of Patients With Proven Or Suspected Covid 19 Infection. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Simon Joosten } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Respiratory Failure.;Safe Inter- And Intra- Hospital Transfer Of Patients Suffering From Suspected Or Confirmed Covid-19; $<$Br$>$Covid-19 $<$Br$>$Respiratory Failure. $<$Br$>$Safe Inter- And Intra- Hospital Transfer Of Patients Suffering From Suspected Or Confirmed Covid-19;Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04390503 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma For Covid-19 Close Contacts } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8504 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pre-Emptive Tocilizumab In Hypoxic Covid-19 Patients, A Prospective Randomised Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Umcg, Roche } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 354 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 With Hypoxia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Anti SARS-COV-2 Titers, C-Reactive Protein, Ferritin, IL-6, IL-8, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04368156 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study Assessing Vagus Nerve Stimulation In Covid-19 Respiratory Symptoms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Carlos Tornero$|$Hospital Clínico Universitario De Valencia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Device } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370236 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Xpro1595 For The Treatment Of Pulmonary Complications From Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inmune Bio, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 366 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Deep Vein Thrombosis or Pulmonary Embolism, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04347031 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Randomised Study Of The Effectiveness Of The Drug Mefloquine, Tablets 250 Mg, Produced By Fsue Spc "Farmzashita" Of The Federal Medical Biological Agency, Fmba Of Russia (Russia) For The Treatment Of Patients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Burnasyan Federal Medical Biophysical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 320 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pneumonia, Viral;Respiratory Failure } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Other, Tocilizumab + Azithromycin + (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359277 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Trial Of Anticoagulation Strategies In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 21/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, D-Dimer, Troponin, Fibrinogen, Lung Inflamation, Hypoxemia, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345445 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Evaluate The Efficacy And Safety Of Tocilizumab Versus Corticosteroids In Hospitalised Covid-19 Patients With High Risk Of Progression } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Malaya } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 310 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, Tocilizumab } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202004801273802 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Center, Randomised, Double-Blind, Placebo-Controlled Clinical Trial Of The Efficacy And Safety Of Chloroquine Phosphate, Hydroxychloroquine Sulphate And Lopinavir/Ritonavir For The Treatment Of Covid-19 In Lagos State. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Lagos State Government } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19;Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344288 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Corticosteroids During Covid-19 Viral Pneumonia Related To Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospices Civils De Lyon } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 304 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Viral Pneumonia Human Coronavirus$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344431 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Management By Hyperbaric Oxygen Therapy Of Patients With Hypoxaemic Pneumonia With Sars-Cov-2 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Direction Centrale Du Service De Santé Des Armées } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346693 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Randomised Study Of Dalargin Effectiveness In Patients With Severe And Critical Manifestations Of Sars-Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Burnasyan Federal Medical Biophysical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 320 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Acute Respiratory Tract Infection$|$Acute Respiratory Insufficiency$|$Pneumonia$|$Septic Shock$|$Hypoxemia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Hospital Discharge, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345523 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma Therapy Vs. SOC For The Treatment Of Covid19 In Hospitalized Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cristina Avendaño Solá$|$Puerta De Hierro University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 278 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344184 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Early Infusion Of Vitamin C For Treatment Of Novel Covid-19 Acute Lung Injury (Evict-Corona-Ali) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Virginia Commonwealth University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 01/10/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Lung Injury, Acute } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345289 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Novel Treatment Options For Adults With Covid-19 Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Thomas Benfield$|$Hvidovre University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 15/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 1100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Corona Virus Infection$|$Viral Pneumonia } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342221 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Tuebingen$|$Robert Bosch Medical Center$|$Universitätsklinikum Hamburg-Eppendorf$|$Bernhard Nocht Institute For Tropical Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 220 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19, Hydroxychloroquine Sulfate } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341727 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine,Hydroxychloroquine,Azithromycin In The Treatment Of Sars Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Washington University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04340557 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Do Angiotensin Receptor Blockers Mitigate Progression To Acute Respiratory Distress Syndrome With Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sharp Healthcare } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 06/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04340232 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Baricitinib For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Colorado, Denver } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Platelet Count, Hemoglobin, Prothrombin, ALT, AST, Bilirubin, Glucose, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04343144 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Evaluating Efficacy And Safety Of Nivolumab (Optivo®) In Patients With Covid-19 Infection, Nested In The Corimmuno-19 Cohort. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Hospital } & 
				\multicolumn{2}{l}{ 92 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19- Infection With Sars-Cov-2 Virus } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025490 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Piscov Trial (Ph Based Integrated Sars Cov-2 )Immunity In Human Subjects. - Piscov } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Siddhartha Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers, Outpatient } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy, Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other + Vitamins + Alternative therapy + Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04308668 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Post-Exposure Prophylaxis / Preemptive Therapy For Sars-Coronavirus-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Minnesota$|$Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre$|$University Of Manitoba$|$University Of Alberta } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 20/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers, Outpatient } & 
				\multicolumn{2}{l}{ 1309 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Acute Respiratory Distress Syndrome$|$Sars-Cov Infection$|$Coronavirus$|$Coronavirus Infections } & 
				\multicolumn{2}{l}{ Mixed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04337541 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reduction In Covid-19 Infection Using Surgical Facial Masks Outside The Healthcare System } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rigshospitalet, Denmark$|$Nordsjaellands Hospital$|$Hvidovre University Hospital$|$Herlev Hospital$|$Technical University Of Denmark } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Outpatient } & 
				\multicolumn{2}{l}{ 6000 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04406246 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Coronavirus Disease (Covid-19) Outbreaks With Nitazoxanide } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Materno-Perinatal Hospital Of The State Of Mexico$|$Laboratorios Liomont } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Outpatient } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353037 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Patch 2\&3:Prevention \& Treatment Of Covid-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Unitedhealth Group$|$Prohealth Care Associates$|$University Of Pennsylvania Perelman School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers, Outpatient } & 
				\multicolumn{2}{l}{ 850 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363827 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protect: Study With Hydroxychloroquine For Prevention And Early Phase Treatment Of Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori$|$University Of Bologna } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Outpatient } & 
				\multicolumn{2}{l}{ 2300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Hydroxychloroquine$|$Prophylaxis$|$Treatment$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04337918 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nitric Oxide Releasing Solutions To Prevent And Treat Mild/Moderate Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanotize Research And Development Corp.$|$The Emmes Company, Llc$|$Keyrus Life Science } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025167 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Efficacy And Safety Of Thymoquinone Compared To Best Supportive Care In Patients With Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Intas Pharmaceuticals Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN13311119 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Siddha Treatment In Symptomatic Participants With Novel Coronavirus Infectious Disease (Covid-19): A Multicenter, Randomised, Open-Label, Active-Controlled Randomised Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Eminentlabs Gmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 116 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Respiratory $<$Br$>$Covid-19 (Sars-Cov-2 Infection) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04455815 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Looking At The Use Of Camostat To Reduce Progression Of Symptoms Of Coronavirus (Covid-19) In People Who Have Tested Positive But Are Able To Stay At Home } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cancer Research Uk$|$Latus Therapeutics } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 31/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 389 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed; Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Non-invasive Ventilation } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04456049 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Open Label Phase Ii Study To Evaluate The Efficacy Of Enzalutamide In High Risk Male Outpatients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ricardo Pereira Mestre$|$Oncology Institute Of Southern Switzerland$|$Institute Of Oncology Research$|$Institute For Research In Biomedicine$|$Ente Ospedaliero Cantonale, Bellinzona } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/04/024857 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Proving The Efficacy Of Homeopathic Treatment In Prevention And Cure Of Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Welling Healthcare Private Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342728 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Coronavirus 2019 (Covid-19)- Using Ascorbic Acid And Zinc Supplementation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Cleveland Clinic } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 520 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins, Vitamins + Zinc, Zinc } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425629 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety, Tolerability, And Efficacy Of Anti-Spike (S) Sars-Cov-2 Monoclonal Antibodies For The Treatment Of Ambulatory Adult Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Regeneron Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 25/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1454 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ mAB, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, Weight, Height or BMI, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04425720 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Remote Patient Monitoring (Rpm) Platform For Covid-19 Patient } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Montefiore Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Monitoring, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000033057 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Controlled Trial For Determination Of The Clinical Effect Of Internet-Assisted Pulmonary Rehabilitation On Patients With Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Hospital Of China Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Rehabilitation } & 
				\multicolumn{3}{p{4.5cm}}{ Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04418505 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vielight Rx Plus For The Treatment Of Covid-19 Respiratory Symptoms } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vielight Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 280 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351516 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial Of Hydroxychloroquine Versus Placebo In Early Ambulatory Diagnosis And Treatment Of Elderly Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Tuebingen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2;Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353284 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Camostat Mesylate In Covid-19 Outpatients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yale University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 31/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 114 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334382 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Vs. Azithromycin For Outpatients In Utah With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Intermountain Health Care, Inc.$|$University Of Utah$|$Utah Department Of Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1550 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363203 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Va Remote And Equitable Access To Covid-19 Healthcare Delivery (Va-Reach Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Salomeh Keyhani Md$|$San Francisco Va Health Care System } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04338074 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Txa And Corona Virus 2019 (Covid19) In Outpatients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Alabama At Birmingham } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/04/2020} &
				\multicolumn{2}{l}{ 12/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 15/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344457 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluate The Efficacy And Safety Of Oral Hydroxychloroquine, Indomethacin And Zithromax In Subjects With Mild Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Perseverance Research Center, Llc$|$Athena Medical Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 20/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, NSAIDs } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Cough, Fever, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342169 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } University Of Utah Covid-19 Hydrochloroquine Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Utah } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 01/04/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Coronavirus$|$Infectious Disease } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348474 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Hydroxychloroquine And Azithromycin For The Treatment Of Ambulatory Patients With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azidus Brasil } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04349241 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Favipiravir In Management Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ain Shams University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease (Covid-19) } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342689 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Role Of Resistant Starch In Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Yale University$|$University Of Michigan$|$University Of Minnesota } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04438057 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Efficacy Of Convalescent Plasma In Symptomatic Outpatients Infected With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Metro Infectious Disease Consultants } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 06/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04441398 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Nitazoxanide 600 Mg To Treat Mild Ambulatory Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azidus Brasil$|$Farmoquimica S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377711 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of The Safety And Efficacy Of Ciclesonide In The Treatment Of Non-Hospitalized Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Covis Pharma S.à.r.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 08/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Visits or Returns to Emergency Department, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04416334 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preemptive Therapy With Colchicine In Patients Older Than 70 Years With High Risk Of Severe Pneumoniae Due To Coronavirus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Investigación Marqués De Valdecilla$|$Gerencia De Atención Primaria Área 1$|$Gerencia De Atención Primaria Área 2$|$Gerencia Atencion Primaria Area 3$|$Gerencia De Atención Primaria Área 4 } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 25/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1028 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030054 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Randomised Controlled Trial For Chloroquine Phosphate And Hydroxychloroquine Sulfate In The Treatment Of Mild And Common Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhongshan Hospital Affiliated To Xiamen University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 22/02/2020} &
				\multicolumn{2}{l}{ 21/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, Heart Rate, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04400799 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Enoxaparin For Primary Thromboprophylaxis In Ambulatory Patients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Zurich$|$University Hospital Inselspital, Berne$|$University Hospital, Geneva$|$Centre Hospitalier Universitaire Vaudois$|$University Hospital, Basel, Switzerland$|$Oncology Institute Of Southern Switzerland$|$Clinica Luganese Moncucco } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ 14/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Pulmonary Embolism, Deep Vein Thrombosis } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anticoagulants, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Coagulation Test } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04446377 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Lam-002a For The Prevention Of Progression Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ai Therapeutics, Inc.$|$Yale University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 142 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04442230 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nasovax In Patients With Early Coronavirus Infectious Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Altimmune, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 96 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200508047345N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effectiveness Of Combined Extract Of 8 Medicinal Plants On The Control Of Mild To Moderate Symptoms Of Covid-19 Disease: A Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shiraz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/06/2020} &
				\multicolumn{2}{l}{ 21/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Unspecified } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04351191 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prophylaxis Of Exposed Covid-19 Individuals With Mild Symptoms Using Choloroquine Compounds } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Government Of Punjab, Specialized Healthcare And Medical Education Department$|$Mayo Hospital Lahore$|$Services Hospital, Lahore$|$Pakistan Kidney And Liver Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 30/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Symptomatic Condition$|$Covid-19 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04421664 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Preemptive Therapy For Sars-Coronavirus-2 (Covid-19 Pep Canada) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre$|$University Of Manitoba$|$University Of Alberta$|$University Of British Columbia$|$Mcmaster University$|$Lawson Health Research Institute$|$Eastern Health$|$University Of Minnesota } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Sars-Cov Infection$|$Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04404218 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Açaí Berry Covid-19 Anti-Inflammation Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Health Network, Toronto$|$University Of Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 480 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ JPRN-JRCTS031190269 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Open-Label, Randomised Controlled Trial To Evaluate The Efficacy And Safety Of Inhaled Ciclesonide For Asymptomatic And Mild Patients With Covid-19 - Racco Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sugiyama Haruhito } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 $<$Br$>$Covid-19;D000073640 } & 
				\multicolumn{2}{l}{ Yes } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04303299 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Various Combination Of Protease Inhibitors, Oseltamivir, Favipiravir, And Hydroxychloroquine For Treatment Of Covid-19 : A Randomised Control Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rajavithi Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 320 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infections$|$Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Oseltamivir, DRV/r + Favipiravir + (hydroxy)chloroquine, DRV/r + Oseltamivir, DRV/r + Oseltamivir + (hydroxy)chloroquine, Lopinavir/ritonavir + Favipiravir, Lopinavir/ritonavir + Oseltamivir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04414124 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Clinical Study To Assess The Natural History Of Covid-19 And Effects Of Kb109 And Supportive Self-Care In Outpatients With Mild-To-Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kaleido Biosciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Mild-To-Moderate Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Fever, Treatment-emergent Adverse Events, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029600 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study On Safety And Efficacy Of Favipiravir In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Third People's Hospital Of Shenzhen } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 30/01/2020} &
				\multicolumn{2}{l}{ 29/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 90 } & 
				\multicolumn{2}{l}{ Completed w. Results } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir + Interferon, Interferon, Lopinavir/ritonavir + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029387 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Effectiveness And Safety Of Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha And Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alphain In Patients With Mild To Moderate Novel Coronavirus Pneumonia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chongqing Public Health Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 108 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals + Interferon, Antivirals + Lopinavir/ritonavir + Interferon, Lopinavir/ritonavir + Interferon } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372628 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial Of Early Therapies During Non-Hospitalized Outpatient Window For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vanderbilt University Medical Center$|$Abbvie } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Other Mild Symptoms, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029741 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Chloroquine And Lopinavir/ Ritonavir In Mild/General Novel Coronavirus (Covid-19) Infections: A Prospective, Open-Label, Multicenter Randomised Controlled Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The Fifth Affiliated Hospital Sun Yat-Sen University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/02/2020} &
				\multicolumn{2}{l}{ 13/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 112 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019 Novel Coronavirus Infection (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, Myoglobin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04446429 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Anti-Androgen Treatment For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Applied Biology, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 381 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov2$|$Androgenetic Alopecia$|$Prostate Cancer$|$Benign Prostatic Hyperplasia$|$Sars (Severe Acute Respiratory Syndrome) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hormone therapy + Ivermectin + Azithromycin, Ivermectin + Azithromycin } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04462783 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Emergency Department (Ed) Self-Monitoring Pilot Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Michigan$|$Vironix Health Incorporated } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid$|$Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029899 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation The Efficacy And Safety Of Hydroxychloroquine Sulfate In Comparison With Phosphate Chloroquine In Mild And Commen Patients With Novel Coronavirus Pneumonia (Covid-19): A Randomised, Open-Label, Parallel, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Peking University Third Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 17/02/2020} &
				\multicolumn{2}{l}{ 30/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04332107 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Azithromycin For Covid-19 Treatment In Outpatients Nationwide } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Thomas M. Lietman$|$Bill And Melinda Gates Foundation$|$Pfizer$|$Stanford University$|$University Of California, San Francisco } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 2271 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Viral Load or Clearance, Household Members with CoViD-19, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04331600 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine As Antiviral Treatment In Coronavirus Infection 2020 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wroclaw Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Serious or Seconday Infections } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435795 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Inhaled Ciclesonide For Outpatients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 25/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 454 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Dyspnea, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04322682 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Colchicine Coronavirus Sars-Cov2 Trial (Colcorona) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Montreal Heart Institute$|$National Heart, Lung, And Blood Institute (Nhlbi)$|$Bill And Melinda Gates Foundation$|$The Government Of Quebec$|$Dacima Software } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 6000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Colchicine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030804 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Exocarpium Citri Grandis Relieves Symptoms Of Novel Coronavirus Pneunomia (Covid-19): A Randomised Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Maoming People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 128 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04291053 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Efficacy And Safety Of Huai Er In The Adjuvant Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 550 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04329611 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Alberta Hope Covid-19 For The Prevention Of Severe Covid19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr. Michael Hill$|$Alberta Health Services$|$University Of Alberta$|$University Of Calgary$|$Calgary Health Trust$|$Alberta Innovates Health Solutions$|$Government Of Alberta } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 20/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 148 } & 
				\multicolumn{2}{l}{ Status Unclear } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04385264 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } \#Stayhome: Early Hydroxychloroquine To Reduce Secondary Hospitalisation And Household Transmission In Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Center For Primary Care And Public Health (Unisante), University Of Lausanne, Switzerland } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04304053 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment Of Covid-19 Cases And Chemoprophylaxis Of Contacts As Prevention } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Fundacio Lluita Contra La Sida$|$Germans Trias I Pujol Hospital$|$Department Of Health, Generalitat De Catalunya$|$Laboratorios Gebro Pharma Sa$|$Laboratorios Rubió$|$Institut Catala De Salut } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 15/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 2300 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412018 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Investigation On The Effects Of Icosapent Ethyl (Vascepatm) On Inflammatory Biomarkers In Individuals With Covid-19 (Vascepa-Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Canadian Medical And Surgical Knowledge Translation Research Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Inflammatory Response } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029539 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Open-Label Study To Evaluate The Efficacy And Safety Of Lopinavir-Ritonavir In Patients With Mild Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tongji Hospital, Tongji Medical College, Huazhong University Of Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ 02/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 328 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04399356 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Niclosamide For Mild To Moderate Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tufts Medical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid (Sars-Cov-2) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04443868 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Nitric Oxide Releasing Solution To Treat And Prevent Exacerbation Of Mild Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanotize Research And Development Corp. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190406043175N3 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Diet On The Clinical Symptoms Of Covid-19 Outpatients With The Attitude Of Traditional Medicine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Mashhad University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 22/08/2020} &
				\multicolumn{2}{l}{ 23/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Disease. } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029589 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Randomised,Open, Multi-Center Clinical Trial Evaluating  The Efficiency And Safety Of Reduning Injection  In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Hospital Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ 28/06/2020} &
				\multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029439 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Combination Of Traditional Chinese Medicne And Western Medicine In The Treatment Of Common Type Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Beijing Hospital Of Traditional Chinese Medicine Affiliated To Capital Medical University/Beijing Institute Of Traditional Chinese Medhubei Integrated Traditional Chinese And Western Medicine Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334005 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Vitamin D On Prevention And Treatment Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad De Granada } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Patients Infected With Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04373460 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma To Limit Sars-Cov-2 Associated Complications } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Johns Hopkins University$|$State Of Maryland$|$Bloomberg Foundation$|$United States Department Of Defense$|$National Institute Of Allergy And Infectious Diseases (Niaid) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 03/06/2020} &
				\multicolumn{2}{l}{ 21/12/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030849 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigation On Psychological Status Of Covid-19 Rehabilitation Patients In Zhengzhou City And Research On Coping Strategies } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Zhengzhou People's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 15/03/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Psychological therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04449965 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Povidone-Iodine Rinses In The Management Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Paul's Hospital, Canada } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Hygeine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330586 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Of Ciclesonide In Adults With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Korea University Guro Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 141 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Corticosteroids, Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029601 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Community Based Prevention And Control For Chinese Medicine In The Treatment Of Novel Coronavirus Pneumonia (Covid-19) In The Isolated Population } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Provincial Hospital Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Education, Education + Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04381962 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicentre Open-Label Two-Arm Randomised Superiority Clinical Trial Of Azithromycin Versus Usual Care In Ambulatory Covid19 (Atomic2) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford$|$Pfizer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ 13/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04311177 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Losartan For Patients With Covid-19 Not Requiring Hospitalization } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Minnesota$|$The Minnesota Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/03/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 580 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Acute Respiratory Distress Syndrome$|$Sars-Cov Infection } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected Or Exposed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ ARBs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04382131 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hypertonic Saline Nasal Irrigation And Gargling With Hypertonic Saline For Suspected Or Confirmed Covid-19: Pragmatic Web-Based Bayesian Adaptive Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Edinburgh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/08/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 405 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Upper Respiratory Tract Infections;Virus;Covid;Virus Shedding;Virus Diseases } & 
				\multicolumn{2}{l}{ Confirmed, Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Clinical Improvement Score (Any), Other Mild Symptoms, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466540 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Placebo-Controlled Trial Of Hydroxychloroquine In Outpatient Cases With Coronavirus Disease 2019 (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Alemão Oswaldo Cruz$|$Ems S/A$|$Hospital Do Coracao$|$Hospital Israelita Albert Einstein$|$Hospital Sirio-Libanes$|$Hospital Moinhos De Vento$|$Brazilian Research In Intensive Care Network } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1300 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed; Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04453774 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } At Home Monitoring For Patients With Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Health Network, Toronto$|$Sunnybrook Health Sciences Centre$|$University Of Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Confirmed; Suspected } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352933 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prolific Chemoprophylaxistrial (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cambridge University Hospitals Nhs Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029435 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial For Traditional Chinese Medicine In The Prevention Of Novel Coronavirus Pneumonia (Covid-19) In High Risk Population } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Wuhan 1st Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 31/03/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, eGFR, ALT, Albumin, Bilirubin, Blood Pressure, Heart Rate, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ EUCTR2020-001740-26-GB }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multi-Centre Open-Label Two-Arm Randomised Superiority Clinical Trial Of Azithromycin Versus Usual Care In Ambulatory Covid-19 (Atomic2) - Atomic2, Version 1.0 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford, Clinical Trials And Research Governance } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 $<$Br$>$Meddra Version: 23.0
Level: Pt
Classification Code 10051905
Term: Coronavirus Infection
System Organ Class: 10021881 - Infections And Infestations
 $<$Br$>$Meddra Version: 20.0
Level: Pt
Classification Code 10070255
Term: Coronavirus Test Positive
System Organ Class: 10022891 - Investigations
;Therapeutic Area: Diseases [C] - Virus Diseases [C02] } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Human Pharmacology (I): No
Therapeutic Exploratory (Ii): Yes
Therapeutic Confirmatory - (Iii): No
Therapeutic Use (Iv): No } &
				\multicolumn{3}{p{4.5cm}}{ Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025558 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Bryonia Alba 30c In The Prevention Of Covid-19 In Quarantine Individual: Double Blind, Randomised Placebo Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Principal Aarogya Homoeopathic Medical College And Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 300 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere
Health Condition 2: B338- Other Specified Viral Diseases } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04416399 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Steroids In Covid-19 Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 24/07/2020} &
				\multicolumn{2}{l}{ 16/07/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 478 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department, Viral Load or Clearance, Fever, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001889-10 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Inhaled Corticosteroids As Treatment Of Early Covid-19 Infection To Prevent Clinical Deterioration And Hospitalisation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford, Clinical Trials And Research Governance } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 478 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Corticosteroids, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department, Viral Load or Clearance, Fever, SpO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365582 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Trial Of Efficacy And Safety Of An Early Outpatient Treatment Of Covid-19 In Patients With Risk Factor For Poor Outcome: A Strategy To Prevent Hospitalization } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Groupe Hospitalier Paris Saint Joseph } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 640 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04357990 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Kerecis Oral And Nasal Spray For Treating The Symptoms Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kerecis Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 81 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04365738 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pulmonary Rehabilitation In Post-Acute Period Of Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Istanbul Bilgi University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 11/03/2020} &
				\multicolumn{2}{l}{ 10/04/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 270 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Education, Non-invasive respiratory support } & 
				\multicolumn{3}{p{4.5cm}}{ Dyspnea, Other Mild Symptoms, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370782 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine And Zinc With Either Azithromycin Or Doxycycline For Treatment Of Covid-19 In Outpatient Setting } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Francis Hospital, New York } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 750 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin + Zinc, (hydroxy)chloroquine + Zinc + Antibiotics } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04371952 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Dynamic Study (Doxycycline Ambulatoire Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nantes University Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 330 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antibiotics, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200415047089N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Effect Of Herbal Drugs (Echinacea And Ginger) On Improvement Of Clinical Symptoms And Hospitalizations In Suspected Covid-19 Outpatient Cases } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Saveh University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/04/2020} &
				\multicolumn{2}{l}{ 09/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359329 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase Ii Clinical Trial Of Estradiol To Reduce Severity Of Covid19 Infection In Covid19+ And Presumptive Covid19+ Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sharon Nachman } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 110 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Estrogen steroid hormone, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346628 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Oral Favipiravir Compared To Placebo In Subjects With Mild Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stanford University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 12/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Other Mild Symptoms, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342663 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Double-Blind, Placebo-Controlled Clinical Trial Of Fluvoxamine For Symptomatic Individuals With Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Washington University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/04/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 152 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19$|$Coronavirus } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, SSRIs } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04355767 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Convalescent Plasma In Outpatients With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Stanford University$|$National Heart, Lung, And Blood Institute (Nhlbi)$|$Strategies To Innovate Emergency Care Clinical Trials Network (Siren) - Network } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Clinical Improvement Score (Any), Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04356495 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatments To Decrease The Risk Of Hospitalization Or Death In Elderly Outpatients With Symptomatic Sars-Cov-2 Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Bordeaux$|$University Of Bordeaux } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 29/07/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 634 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Antihypertensive, Favipiravir, Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, Creatinine Phosphokinase, Procalcitonin, Prothrombin, ALT, LDH, Bicarbonates, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354428 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Treatment For Covid-19 In High-Risk Adult Outpatients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Washington$|$Bill And Melinda Gates Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 01/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 630 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360759 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Centre Randomised Controlled Trial Of Chloroquine/Hydroxychloroquine Versus Standard Of Care For Treatment Of Mild Covid-19 In Hiv-Positive Outpatients In South Africa } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Cape Town } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 560 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Hiv } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04345991 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Convalescent Plasma To Treat Covid-19 Patients, A Nested Trial In The Corimuno-19 Cohort } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris$|$Etablissement Français Du Sang } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 15/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Plasma based therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, Albumin, LDH, Urine Sample, PaO2-FiO2, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04340544 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine For The Treatment Of Mild Covid-19 Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital Tuebingen$|$Robert Bosch Medical Center$|$Universitätsklinikum Hamburg-Eppendorf$|$Bernhard Nocht Institute For Tropical Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/04/2020} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 30/11/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Outpatient } & 
				\multicolumn{2}{l}{ 2700 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000707965 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Multicenter, Phase Iii, Double-Blind, Randomised, Placebo-Controlled Study To Evaluate The Efficacy Of The Recombinant Bcg Vpm1002 On The Incidence Or Disease Severity Of Sars-Cov-2/Covid-19 Among High-Risk Participants In Australia } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Accelagen Pty Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 3468 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19; $<$Br$>$Covid-19;Infection - Studies Of Infection And Infectious Agents;Infection - Other Infectious Diseases } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025298 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Non-Randomised Open  Label Controlled Interventional Study On 
The E Ffe Ct Of Siddha Intervention As A Prophylactic Measure Among High Risk 
Population (Health Care Workers/ 
Containment Zone Population) Exposed  To Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Siddha } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 21500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04438837 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Post-Exposure Prophylaxis For Coronavirus Disease (Covid-19) Among Health-Care Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rambam Health Care Campus } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 23/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/06/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 582 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19)$|$Post-Exposure Prophylaxis } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025491 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Double Blind, Placebo Controlled, Multi-Centric,
Cluster Randomised Study To Evaluate The Efficacy Of Homeopathic Medicines In
The Prevention Of Covid-19 In Quarantined Or Exposed Individuals } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Life Force Foundation Trust } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04384549 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Controlled Trial Evaluating The Efficacy Of Vaccination With Bacillus Calmette And Guérin (Bcg) In The Prevention Of Covid-19 Via The Strengthening Of Innate Immunity In Health Care Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infection;Viral, Agent As Cause Of Disease Classified Elsewhere } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04456595 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial Of Efficacy And Safety Of Sinovac's Adsorbed Covid-19 (Inactivated) Vaccine In Healthcare Professionals } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Butantan Institute$|$Sinovac Life Sciences Co., Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 21/07/2020} &
				\multicolumn{2}{l}{ 01/09/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 8870 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04387409 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Iii, Double-Blind, Randomised, Placebo-Controlled Multicentre Clinical Trial To Assess The Efficacy And Safety Of Vpm1002 In Reducing Healthcare Professionals' Absenteeism In The Sars-Cov-2 Pandemic By Modulating The Immune System } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vakzine Projekt Management Gmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infection, Respiratory Tract } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04443270 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine Phosphate Prophylactic Use In Health Personnel Exposed To Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cmn "20 De Noviembre" } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 31/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025484 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Non-Randomised Open Labeled Controlled Interventional Study On The Effect Of Chyavanprash Lehyam As A Prophylactic Measure Among High Risk Population (Health Care Workers/Containment Zone Population) Exposed To Covid-19 - Cpc } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ccrasniimh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025485 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Non-Randomised Open Labeled Controlled Interventional Study On The Effect Of Guduchi (Tinospora Cordifolia) As A Prophylactic Measure Among High Risk Population (Health Care Workers/Containment Zone Population) Exposed To Covid-19 - Gpc } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ccrasniimh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04437693 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Post Exposure Prophylaxis In Healthcare Workers Exposed To Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hamad Medical Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 30/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435808 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine Prophylaxis For Health Care Workers At High Risk For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of New Mexico } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 14/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04460651 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prepare-It. Prevention Of Covid19 With Epa In Healthcare Providers At Risk - Intervention Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Estudios Clínicos Latino América$|$Amarin Pharma Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Triglycerides } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025769 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prophylactic Interventional Study To Determine The Possible Protective Effect Of Siddha Polyherbal Formulation Kabasura Kudineer / Nilavembu Kudineer Against The Covid 19 On
Intermittent, Month-Long Consumption By Highrisk Population And Frontline Workers In Tamil Nadu, India } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Siddha  Ministry Of Ayush } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/09/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452643 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Bacmune (Mv130) In The Prevention Of Disease Due To Covid-19 Infection In Healthcare Personnel } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inmunotek S.l.$|$Bioclever 2005 S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/11/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 3312 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04446065 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protection Of Health Workers Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Melisa Institute Genomics \& Proteomics Research Spa$|$Universidad Austral } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 30/07/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 524 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04372017 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine As Post-Exposure Prophylaxis Against Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sanford Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 20/04/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 1739 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20130306012728N8 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prospective Post-Exposure Hydroxycloroquine Prophylaxis For Covid 19 (Prosclorocov 19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tabriz University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. $<$Br$>$U07.1;U07.1 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200401046909N2 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating Preventive Effects Of Oral 25-Hydroxyvitamin D3 On Covid-19 In Adults: A  Randomised, Controlled Double-Blind Clinical Trial. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tehran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed, Healthcare Workers } & 
				\multicolumn{2}{l}{ 540 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334928 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Clinical Trial For The Prevention Of Sars-Cov-2 Infection (Covid-19) In Healthcare Personnel } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Plan Nacional Sobre El Sida (Pns)$|$Effice Servicios Para La Investigacion S.l. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + NRTIs, NRTIs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334148 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Healthcare Worker Exposure Response And Outcomes Of Hydroxychloroquine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Adrian Hernandez$|$Patient-Centered Outcomes Research Institute$|$Duke University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04336748 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low-Dose Hydroxychloroquine For Primary Prophylaxis Against Sars-Cov-2 In Health-Care Workers - A Randomised, Double-Blind, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Medical University Of Vienna } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 440 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2;Infection Viral;Healthcare Worker;Prophylaxis } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344379 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Sars-Cov-2 In Hospital Workers S Exposed To The Virus } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Assistance Publique - Hôpitaux De Paris } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04349371 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Saved From Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348370 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bcg Vaccine For Health Care Workers As Defense Against Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Texas A\&M University$|$Baylor College Of Medicine$|$M.d. Anderson Cancer Center$|$Cedars-Sinai Medical Center$|$Harvard University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus$|$Coronavirus Infection$|$Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04350931 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Application Of Bcg Vaccine For Immune-Prophylaxis Among Egyptian Healthcare Workers During The Pandemic Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ain Shams University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease (Covid-19) } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04348435 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Clinical Trial To Determine The Safety And Efficacy Of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (Hb-Admscs) To Provide Protection Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hope Biosciences$|$Hope Biosciences Stem Cell Research Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Stem cell therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Labor Absenteeism, IL-6, IL-10, Tumor Necrosis Factor (Any), Monocyte Count, Neutrophils, Platelet Count, Hemoglobin, Prothrombin, INR, Albumin, Bilirubin, Glucose, Blood Urea Nitrogen } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04349228 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Assessment Of The Efficacy And Safety Of Hydroxychloroquine (Hcq) Administered As A Prophylaxis For Health Professionals Exposed To Covid19 And Working In Medical Intensive Care Units, In Tunisia. Multicentric Randomised Comparative Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Abderrahmane Mami Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 530 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19;Sars-Cov2;Hydroxychloroquine;Prophylaxis;Healthcare Worker;Covid19;Sars-Cov2;Hydroxychloroquine;Prophylaxis;Healthcare Worker } & 
				\multicolumn{2}{l}{ No } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Renal Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04335084 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Hydroxychloroquine, Vitamin C, Vitamin D, And Zinc For The Prevention Of Covid-19 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Progenabiome$|$Dscs Cro } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 20/07/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Coronavirus Infection$|$Sars-Cov2$|$Corona Virus Infection$|$Covid$|$Coronavirus$|$Coronavirus-19$|$Coronavirus 19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Vitamins + Zinc, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001441-39 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chloroquine/ Hydroxychloroquine Prevention Of Coronavirus Disease (Covid-19) In The Healthcare Setting; A Randomised, Placebo-Controlled Prophylaxis Study (Copcov) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 40000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030432 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Application Of Rehabilitation And Lung Eight-Segment Exercise In Front-Line Nurses In The Prevention Of Novel Coronavirus Pneumonia (Covid-19) Epidemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Fujian Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 02/03/2020} &
				\multicolumn{2}{l}{ 27/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 80 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333225 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine In The Prevention Of Covid-19 Infection In Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Baylor Research Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 30/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 228 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Exposed } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04333732 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Crown Coronation: Chloroquine Repurposing To Healthworkers For Novel Coronavirus Mitigation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Washington University School Of Medicine$|$Bill And Melinda Gates Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 55000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328467 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pre-Exposure Prophylaxis For Sars-Coronavirus-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Minnesota } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection$|$ARDS$|$Acute Respiratory Distress Syndrome } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04320238 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Experimental Trial Of Rhifna Nasal Drops To Prevent 2019-Ncov In Medical Staff } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Jiao Tong University School Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 21/01/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 2944 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ 2019 Novel Coronavirus Infection } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, Interferon + Other } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04318015 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Chemoprophylaxis In Healthcare Personnel In Contact With Covid-19 Patients (Phydra Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Respiratory Diseases, Mexico$|$Sanofi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Severe Acute Respiratory Syndrome } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04312243 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } No Prevention Of Covid-19 For Healthcare Providers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Massachusetts General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 07/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 470 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections$|$Healthcare Associated Infection } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030013 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study On The Efficacy And Safety Of Recombinant Human Interferon Alpha 1b Spray In Preventing Novel Coronavirus (Covid-19) Infection In Highly Exposed Medical Staffs. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chinese Pla General Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04327206 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bcg Vaccination To Protect Healthcare Workers Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Murdoch Childrens Research Institute$|$Royal Children's Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ 30/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 10078 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19)$|$Respiratory Illness$|$Corona Virus Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000417987 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Multi-Site, Randomised, Open-Label, Parallel-Group, Placebo-Controlled Study To Assess The Chemoprophylactic Efficacy Of Chloroquine Against Sars-Cov-2/Covid-19 In Healthcare Workers At High-Risk Of Exposure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Australian Defence Force Malaria And Infectious Disease Institute } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 680 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection; $<$Br$>$Covid-19 Infection;Infection - Other Infectious Diseases } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04331834 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Pre-Exposure Prophylaxis With Hydroxychloroquine For High-Risk Healthcare Workers During The Covid-19 Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Barcelona Institute For Global Health$|$Hospital Clinic Of Barcelona$|$Laboratorios Rubió$|$Fundació Institut De Recerca De L'hospital De La Santa Creu I Sant Pau$|$Hospital Plató$|$Hospital De Granollers } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/04/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 03/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 440 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Negative } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04406532 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Home-Based Covid-19 Rehabilitation Program } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Albert Einstein College Of Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Confirmed Or Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Visits or Returns to Emergency Department, Depression, Anxiety } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04386252 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase Ib-Ii Trial Of Dendritic Cell Vaccine To Prevent Covid-19 In Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Aivita Biomedical, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN99916292 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An International, Multi-Site, Bayesian Platform Adaptive, Randomised, Placebo-Controlled Trial Assessing The Effectiveness Of Varied Doses Of Oral Chloroquine In Preventing Or Reducing The Severity Of Covid-19 Disease In Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University College London } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 30000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Iii } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328285 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Chemoprophylaxis Of Sars-Cov-2 Infection (Covid-19) In Exposed Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Centre Hospitalier Universitaire De Saint Etienne$|$Institut Pasteur } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 14/04/2020} &
				\multicolumn{2}{l}{ 30/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04461379 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention, Efficacy And Safety Of Bcg Vaccine In Covid-19 Among Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Universitario Dr. Jose E. Gonzalez } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 06/07/2020} &
				\multicolumn{2}{l}{ 01/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 908 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Bcg$|$Covid-19$|$Sars-Cov2$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04379336 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bcg Vaccination For Healthcare Workers In Covid-19 Pandemic } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Task Applied Science } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 07/05/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 28/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328441 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reducing Health Care Workers Absenteeism In Covid-19 Pandemic Through Bcg Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Umc Utrecht$|$Radboud University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 25/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Labor Absenteeism, Fever, Other Mild Symptoms, Anti SARS-COV-2 Titers, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04373291 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Using Bcg Vaccine To Enhance Non-Specific Protection Of Health Care Workers During The Covid-19 Pandemic. A Randomised Controlled Multi-Center Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bandim Health Project } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/01/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Non-Specific Effects Of Vaccines;Morbidity;Absenteeism;Heterologous Immunity;Covid-19;Non-Specific Effects Of Vaccines;Morbidity;Absenteeism;Heterologous Immunity } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Labor Absenteeism, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405999 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Infection And Incidence Of Covid-19 In Medical Personnel Assisting Patients With New Coronavirus Disease } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, Of The Ministry Of Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 20/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Increased Risk Of Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025275 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Protective Potential Of An Ayurvedic Rasayan (Chyawanprash) In The Prevention Of Covid-19 Among Health Care Personnel Â?? An Open Label, Prospective Randomised Controlled Parallel Group Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ccras New Delhi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405271 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Taf/Ftc For Pre-Exposure Prophylaxis Of Covid-19 In Healthcare Workers (Coviprep Study) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Italiano De Buenos Aires$|$SOCiedad Argentina De Infectología (Sadi) (Argentine SOCiety Of Infectious Diseases) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 28/07/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1378 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Healthcare Workers$|$Covid-19$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ NRTIs, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04408183 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy, Safety, And Tolerability Of Gls-1200 Topical Nasal Spray In The Prevention Of Incident Confirmed, Symptomatic Sars-Cov-2 Infection In Healthcare Personnel } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Geneone Life Science, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 225 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov 2;Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04384458 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Heart Rate, ECG } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000501943 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Prophylactic Hydroxychloroquine On Incidence Of Covid-19 Infection In Front-Line Health And Allied Health Care Workers: The Covid-Shield Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Walter And Eliza Hall Institute Of Medical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 2250 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection; $<$Br$>$Covid-19 Infection;Infection - Other Infectious Diseases;Respiratory - Other Respiratory Disorders / Diseases } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 / 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04452773 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Evaluate The Efficacy Of Food Supplement Manremyc® Against Sars- Cov-2 Infection (Covid-19) In Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Reig Jofre Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 315 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04453488 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Double-Blind, Randomised, Placebo-Controlled Clinical Trial To Evaluate The Efficacy Of The Ruti® Vaccine To Prevent Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Pere-Joan Cardona } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 315 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Sars-Cov2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025242 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Population Pharmacokinetics Of Hydroxychloroquine Sulphate In Healthcare Workers Given For Prophylaxis Against Corona Virus Disease 2019 (Covid 19) Pandemic In India } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Indian Council Of Medical Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04427865 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Utility Of Lactoferrin As A Preventive Agent For Healthcare Workers Exposed To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cairo University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 11/06/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04421391 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Quadramune(Tm) For Prevention Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Therapeutic Solutions International } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 08/06/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Coronavirus$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition } & 
				\multicolumn{3}{p{4.5cm}}{ Labor Absenteeism, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200411047019N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Investigating The Effect Of Bcg Vaccine On Preventing Covid-19 Infection In Healthcare Staff Exposed To Sars-Cov-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Professor Alborzi Clinical Microbiology Research Center, Shiraz University Of Mdical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 05/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease 2019 (Covid-19). } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04360122 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Levamisole And Isoprinosine In Immune-Prophylaxis Of Egyptian Healthcare Workers Facing Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ain Shams University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 01/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Disease (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04362124 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Performance Evaluation Of Bcg Vaccination In Healthcare Personnel To Reduce The Severity Of Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad De Antioquia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/06/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Viral Load or Clearance, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04374942 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Does Hydroxychloroquine Before \& During Patient Exposure Protect Healthcare Workers From Coronavirus? } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Megan Landes$|$University Health Network, Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 27/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 988 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Pre-Exposure Prophylaxis$|$Coronavirus$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Other Mild Symptoms, Adverse Events, Quality of Life, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364815 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The University Of The Philippines Hydroxychloroquine Pep Against Covid-19 Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of The Philippines } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 960 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04371523 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine To Prevent Covid-19 Disease Amongst Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ St. Joseph's Healthcare Hamilton } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1100 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Corona Virus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04363450 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine As Prophylaxis For Covid-19 In Healthcare Workers (Hcqprep) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Louisiana State University Health Sciences Center In New Orleans$|$Lafayette General Health$|$University Of Louisiana At Lafayette } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 06/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1700 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection$|$Wuhan Coronavirus$|$Prophylaxis$|$Healthcare Worker$|$Sars-Cov2$|$Hydroxychloroquine } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Labor Absenteeism } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354870 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Prep Hcw Hcq Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nyu Langone Health } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 350 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04346329 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Immune Monitoring Of Prophylactic Effect Of Hydroxychloroquine In Healthcare Providers Highly Exposed To Sars-Cov-2 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad Nacional De Colombia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 86 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352946 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Protecting Health Care Workers From Covid-19 With Hydroxychloroquine Pre-Exposure Prophylaxis: A Randomised, Placebo-Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Geosentinel Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 374 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Prophylaxis;Covid-19;Health Care Worker;Hydroxychloroquine } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Adverse Events, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04370015 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Hydroxychloroquine In Primary Prophylaxis Of Sars-Cov-2 Infection In Healthcare Workers At Risk Of Exposure: Randomised Control Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Services Institute Of Medical Sciences, Pakistan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 374 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2;Healthcare Workers } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Labor Absenteeism, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04354597 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine And Azithromycin As Prophylaxis For Healthcare Workers Dealing With Covid19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ King Hussein Cancer Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 15/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Azithromycin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353128 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Melatonin In The Prophylaxis Of Coronavirus Disease 2019 (Covid-19) Among Healthcare Workers. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto De Investigación Hospital Universitario La Paz } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 450 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19$|$Sars-Cov 2$|$Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ Melatonin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202004693933092 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Measles Vaccine In Health Care Professionals During Covid-19 Outbreak (Randomised Controlled Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Misr University For Science And Technology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/12/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19;Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ACTRN12620000473965 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reducing Acute Severe Respiratory Events In Health Care Workers During The Covid-19 Pandemic With Om85 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Queensland } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Lower Respiratory Illness;Covid-19; $<$Br$>$Severe Lower Respiratory Illness $<$Br$>$Covid-19;Respiratory - Other Respiratory Disorders / Diseases;Infection - Other Infectious Diseases } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04366180 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Probiotic Lactobacillus Coryniformis K8 On Covid-19 Prevention In Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biosearch S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 01/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 314 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Pneumonia or ARDS, Cough, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359537 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Various Doses Of Hydroxychloroquine In Pre-Exposure Prophylaxis For Covid 19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shaheed Zulfiqar Ali Bhutto Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 01/05/2020} &
				\multicolumn{2}{l}{ 25/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Other Mild Symptoms, Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04359680 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Trial To Evaluate The Efficacy And Safety Of Nitazoxanide (Ntz) For Post Exposure Prophylaxis Of Covid-19 And Other Viral Respiratory Illnesses (Vri) In Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Romark Laboratories L.c. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ 31/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Viral Respiratory Illnesses } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341441 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Will Hydroxychloroquine Impede Or Prevent Covid-19: Whip Covid-19 Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Henry Ford Health System } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 3000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Coronavirus;Coronavirus Infections;Sars-Cov 2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Adverse Events, Serious Adverse Events, IgG, IgM or IgA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04340349 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Low-Dose Hydroxychloroquine And Bromhexine: A Novel Regimen For Covid-19 Prophylaxis In Healthcare Professionals (Elevate Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Instituto Nacional De Rehabilitacion } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 11/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthcare Workers } & 
				\multicolumn{2}{l}{ 140 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hydroxychloroquine;Antimalarials;Enzyme Inhibitors;Antirheumatic Agents } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ NA } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04460690 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Rapid, Onsite Covid-19 Detection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Wisconsin, Madison$|$National Institutes Of Health (Nih)$|$Wisconsin Alumni Research Fund$|$Aids Vaccine Research Lab } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 22/07/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed, Healthy Exposed } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov2 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ SLCTR/2020/011 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine For Post-Exposure Prophylaxis Of Covid-19 Among Naval Personnel: A Placebo-Controlled, Randomised, Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Department Of Medicine, Faculty Of Medicine, University Of Kelaniya } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Post-Exposure Prophylaxis For Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Cough, Fever, Dyspnea, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030386 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For Moxibustion In The Preventing Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hu'nan University Of Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/02/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Child } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed Or Unexposed) } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000030033 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study For The Intervention Of Xiangxue Antiviral Oral Solution And Wu-Zhi-Fang-Guan-Fang On Close Contacts Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The First Affiliated Hospital Of Guangzhou Medical University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 21/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 30/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 828 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ New Treatment Measure Clinical Study } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Household Members with CoViD-19 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04328961 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine For Covid-19 Post-Exposure Prophylaxis (Pep) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Washington$|$Bill And Melinda Gates Foundation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 14/05/2020} &
				\multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection$|$Sars (Severe Acute Respiratory Syndrome)$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Vitamins } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04318444 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Hydroxychloroquine Post Exposure Prophylaxis For Coronavirus Disease (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Columbia University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/03/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 29/03/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Corona Virus Infection } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321174 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 Ring-Based Prevention Trial With Lopinavir/Ritonavir } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Darrell Tan$|$St. Michael's Hospital, Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ 31/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1220 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infections$|$Post-Exposure Prophylaxis } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Lopinavir/ritonavir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04395976 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Ayurveda As Prophylaxis For Suspected Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ British Ayurvedic Medical Council$|$All Party Parliamentary Group - Indian Traditional Sciences$|$University Of Warwick } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ 10/06/2020} &
				\multicolumn{2}{l}{ 10/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/024986 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Arsenicum Album 30c In Prevention Of Covid-19 In Individuals Residing In Hospots Of Red Zones In Delhiâ?? A  Prospective Cohort Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Homoeopathy } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 10000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Suspected } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032459 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Safety And Immunogenicity Of Inactivated Novel Coronavirus (2019-Cov) Vaccine (Vero Cells) In Healthy Population Aged 3 Years And Above: A Randomised, Double-Blind, Placebo Parallel-Controlled Phase I/Ii Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Henan Provincial Center For Disease Control And Prevention } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 288 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 02-Jan } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025385 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Non-Randomised Open Label Controlled Interventional Study On The Effect Of Guduchi Ghan Vati/ Sudarshan Ghan Vati As A Prophylactic Measure Among Containment Zone Population Exposed To Covid 19" } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Ayurvedic Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 40000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025272 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Homoeopathic Prophylactic Intervention On Covid-19 Pandemic-A Double Blind Randomised Controlled Trial
 - Hpcov-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Nil } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 800 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025205 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Arsenicum Album 30c In Prevention Of Covid-19 In Individuals Residing In Hot Spots Of Red Zonesâ?? A Multicentric, Randomised, Cluster Level, Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Homoeopathy } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 33000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04448119 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Control Of Covid-19 Outbreaks In Long Term Care } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Appili Therapeutics Inc.$|$Mount Sinai Hospital$|$Applied Health Research Centre$|$Sunnybrook Health Sciences Centre$|$University Health Network, Toronto$|$University Of Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 760 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Favipiravir, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025277 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Two Arm, Placebo Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Mycobacterium W In Preventing Covid-19 In Subjects At Risk Of Getting Infected With Covid-19. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cadila Pharmaceuticals Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20200513047426N1 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } The Prophylactic Effect Of Oral Hydroxy-Chloroquine In Close Contacts Of Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Boushehr University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 21/06/2020} &
				\multicolumn{2}{l}{ 22/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 500 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19. } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04399252 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised Trial Of The Effect Of Lactobacillus On The Microbiome Of Household Contacts Exposed To Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Duke University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Microbiome } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Nutrition, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435314 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Nitazoxanide For Post Exposure Prophylaxis Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Azidus Brasil$|$Farmoquimica S.a. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Treatment-emergent Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04409327 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase 3 Study To Determine If Rtb101 Reduces The Severity Of Covid-19 In Older Adults Residing In Nursing Homes } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Restorbio Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 31/07/2020} &
				\multicolumn{2}{l}{ 11/07/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 550 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025254 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Population Based Prospective Study On Effectiveness And Outcomes Of Unani Medicine Prophylactic Interventions On Population At Risk Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Unani Medicine Ccrum New Delhi } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 40000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04369794 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19: Bcg As Therapeutic Vaccine, Transmission Limitation, And Immunoglobulin Enhancement } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Campinas, Brazil } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19;Therapeutic Vaccine;Bcg;Sars-Cov 2;Transmission } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025222 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of Clinical Efficacy Of Aoim Â?? Z Tablets For Prevention Of Covid Â?? 19 Pandemic In High Risk Healthy Police Personnel Â?? Single Arm, Open Labelled, Prospective Exploratory Interventional Clinical Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shree Dhootapapeshwar Limited } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/01/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 275 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025429 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Non-Randomised Open Labeled Controlled Interventional Study On The Effect Of Ashwagandha (Withania Somnifera) As A Prophylactic Measure Among High Risk Population (Health Care Workers/Containment Zone Population) Exposed To Covid-19 - Apc } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ccrasniimh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/10/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 5000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025650 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective Cohort Interventional Study Assessing The Safety And Outcome Of Unani Medicine As A Prophylaxis In Population At Risk Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ministry Of Ayush Government Of India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Health Condition 1: B972- Coronavirus As The Cause Of Diseases Classified Elsewhere } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025213 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Impact Of Ayurvedic Intervention (Guduchighan Vati)In Prevention Of Covid-19 Infection In Containment Areas Of Himachal Pradesh-A Community Based Study } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Central Council For Research In Ayurvedic Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 23/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025928 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Povidone Iodine Gargle And Intranasal Application: A Quasi-Experimental Study To Reduce The Spread Of Coronavirus Infection In Community With Covid-19 Positive Clusters. } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dr Sumita Shankar } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 204 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Hygiene } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029803 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Prospective, Randomised, Open-Label, Controlled Clinical Study To Evaluate The Preventive Effect Of Hydroxychloroquine On Close Contacts After Exposure To The Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Renmin Hospital Of Wuhan University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 14/02/2020} &
				\multicolumn{2}{l}{ 24/02/2020} &
				\multicolumn{2}{l}{ 20/02/2020} &
				\multicolumn{2}{l}{ 20/02/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 320 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia  (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Umifenovir } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Serious Adverse Events, C-Reactive Protein, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029602 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study For Community Based Prevention And Control Strategy Of Novel Coronavirus Pneumonia (Covid-19) In The Isolate Suspected And Confirmed Population } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hubei Provincial Hospital Of Tcm } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/02/2020} &
				\multicolumn{2}{l}{ 12/02/2020} &
				\multicolumn{2}{l}{ 01/02/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 0 } &
				\multicolumn{3}{p{4.5cm}}{ Education + Monitoring + Traditional Chinese Medicine, Psychological therapy } & 
				\multicolumn{3}{p{4.5cm}}{ Clinical Improvement Score (Any), Viral Load or Clearance, Fever } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330144 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Hydroxychloroquine As Post Exposure Prophylaxis For Sars-Cov-2(Hope Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Gangnam Severance Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 2486 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Contact Person From Covid-19 Confirmed Patient } & 
				\multicolumn{2}{l}{ Healthy (Exposed) } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04368988 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluation Of The Safety And Immunogenicity Of A Sars-Cov-2 Rs (Covid-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Novavax } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 27/05/2020} &
				\multicolumn{2}{l}{ 25/05/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 131 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364022 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Pragmatic Same-Day Covid-19 Ring Prophylaxis For Adult Individuals Exposed To Sars-Cov-2 In Switzerland } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Calmy Alexandra$|$University Hospital, Geneva } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 420 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Prevention Of Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, Lopinavir/ritonavir } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031944 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Chinese Herbal Tea In The Prevention Of Novel Coronavirus Pneumonia (Covid-19) For Returning Workers In Wuhan: A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ China Academy Of Chinese Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 31/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ IRCT20190122042450N4 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Prevention Of Covid-19 Disease After Contact With An Infected Patient With Coronavirus After Taking Hydroxychloroquine In The Community } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Iran University Of Medical Sciences } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 20/06/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19. } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Radiographic Findings } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04342156 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Efficacy Of Hydroxychloroquine For At Risk Population (Sharp) Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Tan Tock Seng Hospital$|$National Center For Infectious Diseases$|$Singapore Clinical Research Institute$|$Singapore Eye Research Institute$|$Saw Swee Hock School Of Public Health$|$Duke-Nus Graduate Medical School$|$Netherlands: Ministry Of Health, Welfare And Sports } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 1200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Hydroxychloroquine Adverse Reaction } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ TCTR20200404004 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Comparative Effectiveness Of Chloroquine And Vitamin C Prophylaxis In Household Contacts Of Confirmed Covid-19 Patients } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Health Systems Research Institute (Hsri) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Household Members Of Newly Diagnosed Covid-19 Patients $<$Br$>$Household Members$<$Br$>$Covid-19$<$Br$>$Prophylaxis;Household Members$<$Br$>$Covid-19$<$Br$>$Prophylaxis } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Hospitalization, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04344600 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Peginterferon Lambda-1a For The Prevention And Treatment Of Sars-Cov-2 Infection } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Johns Hopkins University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/10/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Exposed } & 
				\multicolumn{2}{l}{ 164 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Interferon, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04336410 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety, Tolerability And Immunogenicity Of Ino-4800 For Covid-19 In Healthy Volunteers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Inovio Pharmaceuticals$|$Coalition For Epidemic Preparedness Innovations (Cepi) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 07/04/2020} &
				\multicolumn{2}{l}{ 07/07/2020} &
				\multicolumn{2}{l}{ 03/04/2020} &
				\multicolumn{2}{l}{ 01/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04449276 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of Vaccine Cvncov In Healthy Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Curevac Ag$|$Coalition For Epidemic Preparedness Innovations (Cepi) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ 01/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 168 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Severe Acute Respiratory Syndrome$|$Coronavirus$|$Sars-Cov-2$|$Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04447781 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety, Tolerability And Immunogenicity Of Ino-4800 Followed By Electroporation In Healthy Volunteers For Covid19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ International Vaccine Institute$|$Coalition For Epidemic Preparedness Innovations$|$Inovio Pharmaceuticals } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ 22/02/2022} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 160 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection$|$Sars-Cov 2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Device, Vaccine + Device } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN90906759 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii/Iii Study To Determine The Efficacy, Safety And Immunogenicity Of The Candidate Coronavirus Disease (Covid-19) Vaccine Chadox1 Ncov-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/07/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 05/11/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 10560 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Ii/Iii } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04398147 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase I/Ii Clinical Trial Of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) In Canada } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cansino Biologics Inc.$|$Beijing Institute Of Biotechnology$|$Canadian Center For Vaccinology } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/05/2020} &
				\multicolumn{2}{l}{ 02/07/2020} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ 20/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 696 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, IL-2, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/024981 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Â??Clinical Evaluation Of Dabur Chyawanprash (Dcp) As A Preventive Remedy In Pandemic Of Covid-19 Â?? An Open Label, Multi Centric, Randomised, Comparative, Prospective, Interventional Community Based Clinical Study On Healthy Individuals.â?? - Nil } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Dabur India Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/02/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ PACTR202005681895696 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ib/Ii Single-Blinded, Randomised, Controlled Study To Determine Safety, Immunogenicity And Efficacy Of The Candidate Coronavirus Disease (Covid-19) Vaccine Chadox1 Ncov-19 In Adults In Kenya } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 400 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ $<$Br$>$Covid-19 Disease;Covid-19 Disease } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Phase-1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04334980 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Evaluating The Safety, Tolerability And Immunogenicity Of Bactrl-Spike Vaccine For Prevention Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Symvivo Corporation } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ 29/06/2020} &
				\multicolumn{2}{l}{ 01/07/2020} &
				\multicolumn{2}{l}{ 31/08/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 112 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Stool Sample, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04324606 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of A Candidate Covid-19 Vaccine (Cov001) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 27/03/2020} &
				\multicolumn{2}{l}{ 08/07/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1090 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04326114 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness And Safety Of Respiratory Training Devices In The Prevention And Severity Of Covid-19: A Randomised Controlled Clinical Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Universidad Complutense De Madrid } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Disease, Infectious;Respiratory Disease;Safety Issues;Effectiveness } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Non-invasive respiratory support, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04313127 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Phase I Clinical Trial Of A Covid-19 Vaccine In 18-60 Healthy Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cansino Biologics Inc.$|$Institute Of Biotechnology, Academy Of Military Medical Sciences. Pla Of China$|$Jiangsu Province Centers For Disease Control And Prevention$|$Hubei Provincial Center For Disease Control And Prevention$|$Tongji Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/03/2020} &
				\multicolumn{2}{l}{ 19/05/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 30/12/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 108 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04357028 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness Of Measles Vaccine In Health Care Professionals During Covid-19 Outbreak (Randomised Controlled Trial) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Kasr El Aini Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04321928 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Personalized Health Education Against The Health Damage Of Novel Coronavirus (Covid-19) Outbreak In Hungary } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Pecs } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/03/2020} &
				\multicolumn{2}{l}{ 09/06/2020} &
				\multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 21/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 7576 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2$|$Coronavirus$|$Covid-19$|$2019-Ncov$|$2019ncov } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Education, Psychological therapy } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000029479 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Use Of Herbal Medicines To Reduce Risk Of The Common Cold During Covid-19 Pandemic: A Large Randomised Clinical Trial Among Community-Dwelling Residents } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hospital Of Chengdu University Of Traditional Chinese Medicine } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/02/2020} &
				\multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ 30/01/2020} &
				\multicolumn{2}{l}{ 01/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 20000 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Common Cold } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Traditional Chinese Medicine } & 
				\multicolumn{3}{p{4.5cm}}{ Pneumonia or ARDS } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04283461 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Study Of 2019-Ncov Vaccine (Mrna-1273) For Prophylaxis Of Sars-Cov-2 Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Allergy And Infectious Diseases (Niaid) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 25/02/2020} &
				\multicolumn{2}{l}{ 17/07/2020} &
				\multicolumn{2}{l}{ 16/03/2020} &
				\multicolumn{2}{l}{ 22/11/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Covid-19 Immunisation } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2 } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN15281137 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase I/Ii Study To Determine Efficacy, Safety And Immunogenicity Of The Candidate Coronavirus Disease (Covid-19) Vaccine Chadox1 Ncov-19 In Uk Healthy Adult Volunteers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1112 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ I/Ii } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04412538 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Study Of An Inactivated Sars-Cov-2 Vaccine For Preventing Against Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Chinese Academy Of Medical Sciences$|$West China Second University Hospital$|$Yunnan Center For Disease Control And Prevention } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 02/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 15/05/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 942 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466085 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Study Of Recombinant Novel Coronavirus Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 27/07/2020} &
				\multicolumn{2}{l}{ 12/07/2020} &
				\multicolumn{2}{l}{ 15/09/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, IL-2, IL-4, IL-6, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04436276 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Phase 1/2a Study To Evaluate The Safety, Reactogenicity, And Immunogenicity Of Ad26covs1 In Adults Aged 18 To 55 Years Inclusive And Adults Aged 65 Years And Older } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Janssen Vaccines \& Prevention B.v. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1045 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Healthy } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04495933 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study On The Safety, Tolerability And Immune Response Of Sars-Cov-2 Sclamp (Covid-19) Vaccine In Healthy Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ The University Of Queensland$|$Syneos Health$|$Coalition Of Epidemic Preparedness Innovations (Cepi) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 03/08/2020} &
				\multicolumn{2}{l}{ 13/07/2020} &
				\multicolumn{2}{l}{ 01/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 120 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04383574 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Study Of Inactivated Vaccine For Prevention Of Sars-Cov-2 Infection(Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sinovac Research And Development Co., Ltd.$|$Sinovac Biotech Co., Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ 30/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 422 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001228-32 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2/3 Study To Determine The Efficacy, Safety And Immunogenicity Of The Candidate Coronavirus Disease (Covid-19) Vaccine Chadox1 Ncov-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ctrg } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 21/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 12330 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Stool Sample } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04466280 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Mucoadhesive Sustained Release, Mucodentol, In Comparison With Hydroxychloroquine To Prevent Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Baqiyatallah Medical Sciences University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 10/07/2020} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ 15/11/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 180 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine + Other, Other } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405908 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Scb-2019 As Covid-19 Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Clover Biopharmaceuticals Aus Pty Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 28/05/2020} &
				\multicolumn{2}{l}{ 23/06/2020} &
				\multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ 20/10/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 150 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, ACE, ACE-II, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445389 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 1/2a, Multi-Center, Randomised, Double-Blind, Placebo-Controlled Study To Investigate The Safety, Tolerability, And Immunogenicity Of Gx-19, A Covid-19 Preventive Dna Vaccine In Healthy Subjects } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Genexine, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 17/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 190 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1/2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04377646 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Study Of Hydroxychloroquine And Zinc In The Prevention Of Covid-19 Infection In Military Healthcare Workers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Military Hospital Of Tunis$|$Ur17dn02 : Autoimmune Diseases Research Unit$|$Dacima Consulting } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 06/05/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 24/05/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 660 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov2$|$Covid19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, (hydroxy)chloroquine + Zinc, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000034112 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase I Clinical Trial To Evaluate The Safety, Tolerance And Preliminary Immunogenicity Of Different Doses Of A Sars-Cov-2 Mrna Vaccine In Population Aged 18-59 Years And 60 Years And Above } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shulan (Hangzhou) Hospital; Center For Disease Control And Prevention Of Guangxi Zhuang Autonomous Region } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 24/06/2020} &
				\multicolumn{2}{l}{ 09/07/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 31/12/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 168 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Pneumonia } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04330300 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Coronavirus (Covid-19) Acei/Arb Investigation } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National University Of Ireland, Galway, Ireland } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 01/04/2020} &
				\multicolumn{2}{l}{ 30/06/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 31/07/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 2414 } & 
				\multicolumn{2}{l}{ Suspended } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Hypertension$|$Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Antihypertensive } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Troponin } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ ISRCTN89951424 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Iii Randomised Controlled Trial To Determine Safety, Efficacy, And Immunogenicity Of The Non-Replicating Chadox1 Ncov-19 Vaccine } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/11/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 (Sars-Cov-2 Infection) $<$Br$>$Infections And Infestations } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Iii } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04405076 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase 2a, Randomised, Observer-Blind, Placebo Controlled, Dose-Confirmation Study To Evaluate The Safety, Reactogenicity, And Immunogenicity Of Mrna-1273 Sars-Cov-2 Vaccine In Adults Aged 18 Years And Older } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Modernatx, Inc. } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 13/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 600 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies, Blood Pressure, Respiratory Rate } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04414267 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Bacillus Calmette-Guérin Vaccination To Prevent Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Hellenic Institute For The Study Of Sepsis } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 14/07/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 25/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 900 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19$|$Virus Diseases$|$Corona Virus Infection$|$Coronary Heart Disease$|$Chronic Obstructive Pulmonary Disease } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ IgG, IgM or IgA, Radiographic Findings, Cardiac Outcome (Unspecified) } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NL8547 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reducing Hospital Admission Of Elderly In Sars-Cov-2 Pandemic Via The Induction Of Trained Immunity By Bacillus Calmette-Guérin Vaccination, A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboudumc } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1600 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04439045 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study: Efficacy And Safety Of Vpm1002 In Reducing Sars-Cov-2 Infection Rate And Covid-19 Severity } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Health Network, Toronto } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 14/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 3626 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04435379 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Iii, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Clinical Trial To Assess The Efficacy And Safety Of Vpm1002 In Reducing Hospital Admissions And/Or Severe Respiratory Infectious Diseases In Elderly In The Sars-Cov-2 Pandemic By Modulating The Immune System } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Vakzine Projekt Management Gmbh } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 16/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 18/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 2038 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infection, Respiratory Tract } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392219 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Covid-19 First In Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of Eidd-2801 In Healthy Volunteers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Ridgeback Biotherapeutics, Lp } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 25/06/2020} &
				\multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 08/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 130 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1 } &
				\multicolumn{3}{p{4.5cm}}{ Antivirals, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04408456 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Hydroxychloroquine (Hcq) As Post Exposure Prophylaxis (Pep) For Prevention Of Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Postgraduate Institute Of Medical Education And Research } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/05/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 01/03/2020} &
				\multicolumn{2}{l}{ 31/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 325 } & 
				\multicolumn{2}{l}{ Completed } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000031174 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Effectiveness And Safety Of Hydroxychloroquine Sulfate In The Preventive Treatment Of Novel Coronavirus Pneumonia (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Public Health Clinical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 04/05/2020} &
				\multicolumn{2}{l}{ 23/03/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Novel Coronavirus Pneumonia (Covid-19) } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Single-Arm } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04442048 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Cov-Immuno: A Randomised, Phase Iii Trial Of Immunization With Imm-101 Versus Observation For The Prevention Of Severe Respiratory And Covid-19 Related Infections In Cancer Patients At Increased Risk Of Exposure } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Canadian Cancer Trials Group } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 01/08/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1500 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Cancer;Covid-19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/06/025613 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Melatonin For Covid 19 Pre Exposure Prophylaxis In High Risk  Population  . (Melatonin Immune Boost Covid 19 Study ) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Rohit Walia } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 06/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/06/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ Melatonin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ C-Reactive Protein } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ RPCEC00000314 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Population Impact Of Intervention Based On The Administration Of A Single Dose Of The Outer Membrane Vesicle (Omv) Complex Contained In Va-Mengoc-Bc To Stimulate The Innate Response Against Sars-Cov-2 (Covid-19) - Vme-Corona } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Finlay Vaccine Institute (Ifv) } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 24/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 115000 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid 19 } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Unspecified } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04445428 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Oral Polio Vaccine As Potential Protection Against Covid-19: A Cluster-Randomised Trial In Guinea-Bissau } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Bandim Health Project } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 22/06/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/07/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 3400 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Poliovirus Vaccine, Oral;Covid;Mortality;Morbidity;Non-Specific Effects Of Vaccines } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CTRI/2020/05/025488 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } An Open Label, Multi Centric, Randomised, Comparative, Prospective, Interventional Community Based Clinical Study To Evaluate Safety And Efficacy Of Guduchi Ghana Vati As A Preventive Remedy On Healthy Individuals In Pandemic Of Covid-19 - Ggvc19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ National Institute Of Ayurveda } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 31/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 06/03/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 12000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ NA } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ NA } & 
				\multicolumn{2}{l}{ Healthy } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2/ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Alternative therapy } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04368728 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study To Describe The Safety, Tolerability, Immunogenicity, And Efficacy Of Rna Vaccine Candidates Against Covid-19 In Healthy Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biontech Se$|$Pfizer } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 16/04/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 29481 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Sars-Cov-2 Infection$|$Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Triple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2$|$3 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Serious Adverse Events, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04380701 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Trial Investigating The Safety And Effects Of Four Bnt162 Vaccines Against Covid-2019 In Healthy Adults } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Biontech Rna Pharmaceuticals Gmbh$|$Biontech Se } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 08/05/2020} &
				\multicolumn{2}{l}{ 12/05/2020} &
				\multicolumn{2}{l}{ 23/04/2020} &
				\multicolumn{2}{l}{ 01/08/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Infections, Respiratory$|$Virus Diseases$|$Infection Viral$|$Vaccine Adverse Reaction$|$Rna Virus Infections } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Non-Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Adverse Events, Treatment-emergent Adverse Events, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ 2020-001072-15 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase I/Ii Study To Determine Efficacy, Safety And Immunogenicity Of The Candidate Coronavirus Disease (Covid-19) Vaccine Chadox1 Ncov-19 In Uk Healthy Adult Volunteers } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Of Oxford } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 19/03/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 1112 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Coronavirus Infection } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Anti SARS-COV-2 Titers } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04417335 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Reducing Covid-19 Related Hospital Admission In Elderly By Bcg Vaccination } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Radboud University } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 04/06/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 01/05/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 2014 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Single } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Secondary CoViD-19 Re-infection, Fever, Other Mild Symptoms } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ CHICTR2000032487 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Study For Using Sulfate In The Prevention And Control Of Novel Coronavirus Pneumonia (Covid-19) In High And Low Prevalence Communities } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Shanghai Public Health Clinical Center } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 29/04/2020} &
				\multicolumn{2}{l}{ 26/03/2020} &
				\multicolumn{2}{l}{ 30/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 2000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Unspecified } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 4 } &
				\multicolumn{3}{p{4.5cm}}{ (hydroxy)chloroquine, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04353518 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Clinical Trial To Evaluate Mycobacterium W In Preventing Covid-19 In Subjects At Risk Of Getting Infected With Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Cadila Pharnmaceuticals$|$Council Of Scientific And Industrial Research, India } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 22/04/2020} &
				\multicolumn{2}{l}{ 30/04/2020} &
				\multicolumn{2}{l}{ 30/03/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 4000 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Other } & 
				\multicolumn{3}{p{4.5cm}}{ Serious or Seconday Infections, Adverse Events, Serious Adverse Events } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04341389 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } A Phase Ii Clinical Trial To Evaluate The Recombinant Vaccine For Covid-19 (Adenovirus Vector) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Insitute Of Biotechnology, Academy Of Military Medical Sciences, Pla Of China$|$Cansino Biologics Inc.$|$Jiangsu Province Centers For Disease Control And Prevention$|$Hubei Provincial Center For Disease Control And Prevention$|$Zhongnan Hospital } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 10/04/2020} &
				\multicolumn{2}{l}{ 18/05/2020} &
				\multicolumn{2}{l}{ 12/04/2020} &
				\multicolumn{2}{l}{ 31/01/2021} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 508 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Double } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Viral Load or Clearance, Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Interferon (Any), IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04352608 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Safety And Immunogenicity Study Of Inactivated Vaccine For Prophylaxis Of Sars Cov-2 Infection (Covid-19) } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Sinovac Research And Development Co., Ltd.$|$Sinovac Biotech Co., Ltd } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 20/04/2020} &
				\multicolumn{2}{l}{ 04/08/2020} &
				\multicolumn{2}{l}{ 16/04/2020} &
				\multicolumn{2}{l}{ 10/07/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ Healthy Unexposed } & 
				\multicolumn{2}{l}{ 744 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 1$|$2 } &
				\multicolumn{3}{p{4.5cm}}{ SOC, Vaccine } & 
				\multicolumn{3}{p{4.5cm}}{ Visits or Returns to Emergency Department, Serious Adverse Events, Platelet Count, Hemoglobin, Creatinine Phosphokinase, ALT, AST, Bilirubin, Urine Sample, IgG, IgM or IgA, Antibodies } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04364009 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy And Safety Of Anakinra During Adult " Covid-19 " With Aggravating Respiratory Symptoms: A Multicenter Open-Label Controlled Randomised Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ University Hospital, Tours } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 17/04/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 27/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ 240 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 Infection;Anakinra Treatment;Optimized Standard Of Care (Osoc) } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 3 } &
				\multicolumn{3}{p{4.5cm}}{ Anakinra, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, White Blood Cell Count, D-Dimer, Fibrinogen, LDH, PaO2-FiO2, Respiratory Rate, Quality of Life } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04392713 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Efficacy Of Ivermectin In Covid-19 : A Randomised Controlled Trial } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Combined Military Hospital, Pakistan } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 05/05/2020} &
				\multicolumn{2}{l}{ N/A} &
				\multicolumn{2}{l}{ 15/04/2020} &
				\multicolumn{2}{l}{ N/A} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ 100 } & 
				\multicolumn{2}{l}{ Recruiting } & 
				\multicolumn{2}{l}{ Child, Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid } & 
				\multicolumn{2}{l}{ Confirmed } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Open-Label } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ Nr } &
				\multicolumn{3}{p{4.5cm}}{ Ivermectin, SOC } & 
				\multicolumn{3}{p{4.5cm}}{ NA } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
				
			
		
			\toprule
			\multicolumn{9}{l}{\textbf{ NCT04400890 }} \\
			& \multicolumn{8}{p{12cm}}{\textbf{Title: } Randomised Proof-Of-Concept Trial To Evaluate The Safety And Explore The Effectiveness Of Resveratrol For Covid-19 } \\
			\midrule
			& \multicolumn{4}{l}{\textbf{Institution}} & \multicolumn{4}{l}{\textbf{URL}} \\
			& \multicolumn{4}{p{6cm}}{ Marvin Mccreary, Md$|$Mount Carmel Health System } & 
				\multicolumn{4}{p{6cm}}{ \url{  }} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Date Registered}} & \multicolumn{2}{l}{\textbf{Date Updated}} & \multicolumn{2}{l}{\textbf{Trial Start Date}} & \multicolumn{2}{l}{\textbf{Primary Completion}} \\
			& \multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 26/05/2020} &
				\multicolumn{2}{l}{ 01/06/2020} &
				\multicolumn{2}{l}{ 01/09/2020} \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Patient Setting}} & \multicolumn{2}{l}{\textbf{Expected No. of Patients}} & \multicolumn{2}{l}{\textbf{Recruitment Status}} & \multicolumn{2}{l}{\textbf{Patient Age}} \\
			& \multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ 200 } & 
				\multicolumn{2}{l}{ Not Recruiting } & 
				\multicolumn{2}{l}{ Adult, Senior } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Therapy Target}} & \multicolumn{2}{l}{\textbf{Covid-19 Status}} & \multicolumn{2}{l}{\textbf{Study Design}} & \multicolumn{2}{l}{\textbf{Blinding}} \\
			& \multicolumn{2}{p{3cm}}{ Covid-19 } & 
				\multicolumn{2}{l}{ NA } & 
				\multicolumn{2}{l}{ Randomised } &
				\multicolumn{2}{l}{ Quadruple } \\
			\midrule
			& \multicolumn{2}{l}{\textbf{Phase}} & \multicolumn{3}{l}{\textbf{Treatments}} & \multicolumn{3}{l}{\textbf{Outcomes}}\\
			& \multicolumn{2}{p{3cm}}{ 2 } &
				\multicolumn{3}{p{4.5cm}}{ Vitamins, Vitamins + Polyphenols } & 
				\multicolumn{3}{p{4.5cm}}{ ICU Admission, Hospitalization } \\
			\bottomrule
			\rowcolor{white}
			\multicolumn{9}{c}{\setcounter{rownum}{0}} \\
		
		
		
	\end{supertabular}

\end{document}
